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Ovarian cancer (OC) is the leading cause of death in women from gynaecological 
malignancies. Late stage diagnosis occurs in most women due to the benign nature of 
disease symptoms. Cytoreductive surgery and chemotherapy remains the standard of 
care for patients. Chemotherapy resistance is the biggest challenge faced in the clinic, 
with over 80% of women experiencing disease recurrence. As such, it is vital to 
identify and target the mechanisms which drive resistance in order to improve patient 
outcomes.  
We have evaluated a panel of ovarian cancer cell lines for their response to two 
clinically relevant chemotherapies, paclitaxel and carboplatin. From our analysis, two 
subgroups of cells with differential drug responses emerged. The cell lines which were 
most sensitive to both drugs (OVCAR-3 and -4) displayed the highest levels of active 
caspase-3, a marker of apoptosis, while the most resistant cells (ID8-luc2, OVCAR-5 
and -8) displayed the lowest levels of active caspase-3. OC patients receive their 
treatment in cycles, with treatment free intervals between doses. To mimic this, the 
cell lines with the highest drug-induced apoptosis levels were recovered for 7 days 
after treatment and were then re-challenged with paclitaxel. Following this re-
challenge, apoptosis levels were found to be significantly decreased compared to the 
initial toxicity, while clonogenic recovery was significantly increased, providing a 
novel insight into one of the ways OC cells may become resistant to treatment.  
We then evaluated the autophagy competency of the OC cell line panel. All of the cell 
lines were found to express the key autophagy proteins Beclin 1, LC3 and the Atg5/12 
conjugate, although to different levels. To assess basal autophagy, chloroquine (CQ) 
was used to prevent autophagosome turnover. Each of the cell lines demonstrated the 
ability to undertake basal autophagy, although to varying levels. We then assessed the 
 
 xv 
effect of paclitaxel and carboplatin on autophagy induction. Interestingly, the cell lines 
could again be sub-grouped based on their autophagy induction. Reflecting the same 
groups as the apoptosis data, the OVCAR-3 and -4 cells displayed the lowest levels of 
autophagy induction, while the ID8-luc2, OVCAR-5 and -8 cells had the highest 
autophagy induction. It is notable that the OVCAR-8 cells were found to have the 
highest autophagy levels but expressed the lowest levels of Beclin 1 and Atg5/12. This 
data has particular relevance in clinical biomarker studies as it suggests that autophagy 
protein expression levels do not correlate with OC cells ability to undergo autophagy. 
Autophagy has been implicated in OC chemoresistance, and it is emerging as an 
attractive therapeutic target. We therefore examined the effect of two autophagy 
modulators, CQ and lithium, on the chemosensitivity of the OC cell lines. 
Interestingly, both CQ and lithium exerted significant chemosensitising effects, but 
only in the cell lines which displayed high levels of autophagy (ID8-luc2, OVCAR-5 
and -8). In the OVCAR-3 and -4 cells, the addition of CQ provided either no effect or 
a protective effect following treatment. These data suggest that the use of such 
modulators will only benefit a subset of patients, but in these patients, they could have 
significant therapeutic benefit. Brefeldin A, which inhibits transport from the Golgi, 
has been reported to inhibit the non-canonical Atg5/Atg7-independent autophagy 
pathway. Following treatment with CQ, the addition of brefeldin A significantly 
reduced autophagosome accumulation. Similarly, the addition of brefeldin A 
following paclitaxel treatment significantly reduced autophagosome accumulation. 
These data suggest that Atg5/Atg7-independent autophagy may be present in OC cells 
both basally and in response to treatment.  
The contribution of autophagy to chemoresistance in OC cells was then assessed in 
the cell lines that displayed high levels of autophagy. We have shown that knockdown 
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of BECN1 and ATG5 by siRNA significantly reduces the recovery of ID8-luc2 and 
OVCAR-8 cells following paclitaxel treatment. To assess a role for Atg5/Atg7-
independent autophagy in paclitaxel response, the non-canonical gene Rab9 was 
knocked down using siRNA along with BECN1. Knockdown of these genes 
significantly reduced clonogenic recovery in OVCAR-8 cells following paclitaxel 
treatment. These data suggest that both the canonical and non-canonical autophagy 
pathways may contribute to chemoresistance in OC cells.  
We have also shown that OC cells can recover their DNA profile following recovery 
from paclitaxel treatment. Importantly, inhibition of autophagy with CQ could impede 
this recovery in ID8-luc2 cells. Furthermore, siRNA knockdown of BECN1 and 
ATG5 in OVCAR-8 cells could also impede the recovery of the DNA profile. 
Additionally, we observed the localisation of the autophagy markers LC3 and LAMP1 
with fragmented nuclear material after paclitaxel treatment. Taken together, these data 
support the possibility that a selective type of autophagy, termed nucleophagy, may 
be active in OC cells and contribute to recovery following paclitaxel treatment.  
Here, we have made potentially clinically relevant observations. We have highlighted 
reduced apoptosis competency following drug re-challenge and shown that autophagy 
modulators are effective only in a subgroup of cell lines with high autophagy levels. 
We have provided a novel insight into a role for canonical and non-canonical 
autophagy in OC chemoresistance, and demonstrated for the first time a potential role 
for nucleophagy in OC cell recovery. It is hoped that autophagy inhibitors, along with 
appropriate biomarkers, may be incorporated into treatment strategies to overcome 
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1.1 Ovarian Carcinoma 
1.1.1 Incidence of ovarian carcinoma 
Ovarian cancer (OC) is the seventh most common gynaecological malignancy among 
women worldwide, with epidemiological data indicating that the highest age adjusted 
occurrences are found in developed regions of the world, namely north America and 
Europe (C. Wang et al., 2017)(Reid, Permuth and Sellers, 2017). In Ireland, ovarian 
cancer was the fourth most commonly diagnosed cancer among women between 2015 
and 2017 (National Cancer Registry Ireland). Ovarian cancer is prevalent among older 
women, with over one third of all invasive cancers diagnosed in women aged between 
60 and 74 years. The mortality rate has remained largely unchanged, with 5-year 
survival remaining less than 40% (National Cancer Registry Ireland). A better 
understanding of the molecular mechanisms underlying the various subtypes of OC is 
imperative in order to aid the discovery and development of new treatments to improve 
patient outcomes. 
 
1.1.2 Screening and diagnosis 
The introduction of prophylactic screening in ‘at risk’ populations has contributed to 
the early detection and increased survival rates among people with cervical cancer. 
Prophylactic screening has also proven to be a critical factor in the improved survival 
rates observed in other solid malignancies such as breast cancer, while Bowel Screen 
has recently been implemented for the early detection of colorectal cancer in Ireland. 
However, there are currently no reliable markers for the early detection of OC. 
Ovarian cancer is often dubbed the ‘silent killer’ due to the vague and non-specific 
symptomatic nature of the disease. Despite this, symptoms of ovarian cancer are 
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present during the early stages of disease, on average 3 to 6 months prior to consulting 
a physician (Goff, 2012). The most common symptoms reported include abdominal 
discomfort, such as bloating and nausea, which can often be mistaken for 
gastrointestinal ailments. Due to the benign nature of the symptoms, the majority of 
ovarian cancers are diagnosed at an advanced stage (III or IV), resulting in poor 
survival rates.  
Women who experience symptoms typically consult with their physician for an initial 
examination. This includes a physical examination, to determine the presence of a 
pelvic mass or ascites, or signs of shallowed breathing, an indicator of pleural effusion 
which is a common symptom of OC. A referral to a specialised gynaecologist is the 
next step, where trans-vaginal ultrasound (TVUS) and blood CA125 levels may be 
assessed. Serum CA125 levels above 35 UI/ml are considered abnormal. The risk 
malignancy index (RMI) is utilised in order to distinguish benign from malignant 
masses, which incorporates CA125 levels, menopausal status and ultrasound features. 
Premenopausal women are assigned a score of 1, while post-menopausal women 
receive a score of 3 (Karimi-Zarchi et al., 2015). The study by Karimi-Zarchi et al. 
(2015) highlighted the relatively high specificity of using RMI to distinguish patients 
with malignant masses at an initial stage for further interventions.  
A number of studies have also been undertaken to assess the potential utility of TVUS 
as an early detection method. The University of Kentucky Markey Cancer Centre’s 
ovarian cancer screening program conducted TVUS on over 45,000 women. The study 
found that regular TVUS examinations were proficient at detecting early stage 
cancers. In addition, women whose cancer was detected at an early stage and 
underwent treatment were found to have a better outcome (van Nagell et al., 2011). 
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However, due to economic reasons it is unlikely that TVUS would be utilised as a 
screening tool in the general ‘low risk’ population.  
The prostate lung colorectal and ovarian screening trial (PLCO) assessed the impact 
of annual CA125 and TVUS screening on OC mortality. When compared to a control 
cohort of women, who received standard care and were not offered screening, no 
reduction in OC mortality was found (Buys et al., 2011). In 2017, extended patient 
follow-up by a further 6 years, corroborated the initial study findings, reporting no 
benefit of CA125 and TVUS screening on mortality rates (Pinsky et al., 2016). 
Another large study was conducted to assess the impact of screening on OC related 
deaths. The United Kingdom Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) study recruited over 200,000 postmenopausal women from England, 
Northern Ireland, and Wales (Jacobs et al., 2016). Prevalent cases, classed as women 
diagnosed with OC before screening commenced, were excluded. Women were 
randomised into one of three groups – multimodal screening (MMS), whereby CA125 
screening in combination with the risk of OC calculation was used, annual transvaginal 
ultrasound screening (USS), or no screening. Ovarian cancer death was the primary 
outcome, while death by OC and primary peritoneal cancer was the secondary 
outcome. The primary results from the study revealed no significant reduction in 
mortality in the screened groups. However, following the exclusion of prevalent cases 
a significant reduction in mortality was found in the MMS group, revealing a 28% 
reduction in mortality following 7 years of screening. While this result was 
encouraging, the authors concluded that further follow up of patients would be 
required to accurately assess both the cost and efficacy of screening for OC patients.  
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In Ireland, in 2016 new referral guidelines were introduced by the National Cancer 
Control Program to help GP’s identify and prioritise women with suspected ovarian 
cancer. These are included in Appendix 1. The aim is to facilitate earlier detection by 
highlighting symptoms that may be suggestive of ovarian cancer. It provides GPs with 
a step-wise algorithm for assessing worrisome symptoms. 
 
 
1.1.3 Histological subtypes of Ovarian Cancer  
Ovarian cancer is a broad term, which describes a range of distinct histological 
subtypes. Identifying the subtype is important in terms of both treatment and patient 
outcome. Ovarian cancer can be broadly separated into four subtypes: epithelial, germ 
cell, sex cord stromal, and metastatic tumours, as illustrated in Figure 1.1. While some 
OC tumours originate from cells within the ovary itself, such as germ cell tumours, 
other tumours, such as epithelial tumours, including high grade serous cancers 
(HGSOC), are proposed to originate from the fallopian tubes (Venkatesan, 
2017)(Xiang, L, et al., 2018). Elucidating the cellular origin and subsequent 




























1.1.3.1 Epithelial Tumours 
Epithelial tumours comprise the vast majority of ovarian cancers diagnosed, of which 
serous tumours are most prevalent. Ovarian carcinomas of epithelial origin include 
serous, intestinal mucinous, endometrioid and clear cell (Soslow, 2008). Serous 
cancers can be defined as low or high grade, with high grade serous ovarian 
Figure 1.1: The above image describes the four histological subtypes of ovarian cancer, 
along with their incidence. From: Soslow, R. A. (2008) ‘Histologic Subtypes of Ovarian 




carcinomas most commonly diagnosed. Both low and high grade serous tumours tend 
to present at a late stage (III or IV) and can be distinguished from one another by their 
varied genetic alterations and route of pathogenesis (McCluggage, 2011). HGSOC 
often originate as serous tubal intraepithelial carcinomas (SITC) in the fimbria of the 
fallopian tube (Karnezis et al., 2016). Supporting the theory of a fallopian tube origin 
for HGSOC, precursor lesions were identified in high risk patients undergoing 
prophylactic salpingo-oophorectomies  (Medeiros et al., 2006; Callahan et al., 2007).  
Endometrioid tumours remain the second most commonly diagnosed tumours, with 
many arising due to a state of chronic inflammation associated with endometriosis. 
They typically present at an early stage (I) and are usually well differentiated  
(McCluggage, 2011). Mucinous tumours, often described as intestinal, are very rare, 
originating from mucinous cystadenomas, progressing in a sequential manner. The 
vast majority are unilateral, involving only one ovary, and diagnosed at an early stage 
(I) (McCluggage, 2011). Clear cell carcinomas have a poor prognosis compared to 
other epithelial subtypes when diagnosed at an advanced stage and are known to be 
more resistant to first line platinum therapies (Mabuchi, Sugiyama and Kimura, 2016). 
Interestingly, the incidence of clear cell carcinomas varies according to ethnicity, with 
approximately 4% in Caucasians, 3.1% in black people and 11.1% among Asian 
populations, although a reason for this has not been elucidated (Anglesio et al., 2011). 
 
 
1.1.3.2 Germ Cell tumours 
Germ cell tumours are rare tumours which arise from oocytes within the ovaries. 
Histological subtypes include dysgerminoma, yolk sac tumour, choriocarcinoma and 
immature teratoma (Low, Ilancheran and Ng, 2012). Dysgerminoma is the most 
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common germ cell tumour, accounting for 2% of cases. These tumours are prevalent 
in younger women of reproductive age, typically under the age of 30. Germ cell 
tumours almost always present unilaterally and are exceptionally chemosensitive. 
Fertility preserving surgery is recommended, even with the presence of metastatic 
disease. Unilateral salpingo-oophorectomy and preservation of the contralateral ovary 
and uterus is recommended (Gershenson, 2007). Adjuvant chemotherapy is 
administered to women with stage IA disease or later (Low, Ilancheran and Ng, 2012). 
The BEP (bleomycin, etoposide, cisplatin) regimen is widely used, with overall 
survival ranging from 87 to 98% (Dimopoulos et al., 2004) (Williams et al., 1994). 
 
1.1.3.3 Sex Cord Stromal Tumours 
Sex cord stromal tumours are rare neoplasms, representing 7% of ovarian tumours 
diagnosed. Such tumours arise from a heterogeneous mix of either sex cord or stromal 
cells. Sex cord cells include granulosa and sertoli cells, while examples of stromal 
cells include fibroblasts, theca and leydig cells (Horta and Cunha, 2015). Sex cord 
stromal tumours are diagnosed across a broad age spectrum but tend to present in 
younger women. Stage 1 disease is commonly diagnosed and treated with primary 
surgery, resulting in favourable outcomes for patients. Platinum chemotherapy can be 
administered to patients with advanced stage or recurrent disease, with response rates 




1.1.4 Ovarian cancer risk factors 
1.1.4.1 Age  
As with most cancers, the risk of developing OC increases with age. Although OC is 
diagnosed in younger women, the majority of cases are diagnosed in postmenopausal 
women over the age of 50. In Ireland, during the period 2005-2015, the median age 
group at diagnosis was 65-69 years (National Cancer Registry Ireland).  
 
1.1.4.2 Family History  
Arguably the most significant risk factor for the development of OC is a family history 
of the disease. Approximately 10% of all ovarian cancers diagnosed arise due to a 
hereditary genetic predisposition. While several syndromes are linked to hereditary 
ovarian cancer - Li-Fraumani, Cowden and Peutz-Jeghers, it is hereditary non-
polyposis colorectal carcinoma (HNPCC), also known as Lynch Syndrome, and 
hereditary breast and ovarian cancer syndrome (HBOC) which are the most tightly 
linked (Lindor et al., 2008). As would be expected, women with HBOC syndrome 
have a family history of breast and/or ovarian cancers, passed through successive 
generations in an autosomal dominant manner. Studies into the genetic causation of 
hereditary ovarian cancers have predominantly focused on the BRCA1 and BRCA2 
genes. BRCA genes are involved in homologous recombination DNA repair, a high-
fidelity pathway used to repair double strand breaks. Women who carry mutations in 
these genes, namely BRCA1, have a significantly increased lifetime risk of developing 
ovarian cancer; 25-65% when compared to the general populations risk of only 1.5% 
(Lindor et al., 2008). Germ line mutations in the BRCA1 or BRCA2 genes, which are 
involved in DNA repair, account for 90% of hereditary cases. The remaining 10% are 
 
 10 
attributable to mutations in mismatch repair genes, namely hMLH1 and hMSH2, 
which are associated with HNPCC (Prat, Ribe and Gallardo, 2005). Cumulative 
lifetime risks of developing OC are 40% for BRCA1 carriers and 18% for BRCA2 
carriers (Chen and Parmigiani, 2007). Ovarian cancers driven by BRCA mutations 
tend to present earlier, with serous cancers being the predominant subtype. Numerous 
studies have indicated that the presence of a germline BRCA mutation is associated 
with better prognosis, including a study by Ben-David et al.(2002) reporting BRCA 
mutation to be an independent prognostic factor (Rubin et al., 1996)(David et al., 
2002). However, there are a small proportion of patients with a strong family history 
of OC who do not carry a BRCA mutation. The advent of next generation sequencing 
has allowed large scale screening of entire genomes, revealing multiple mutations 
which may also contribute to OC risk. Among 466 women tested in a recent study, the 
most significant alterations were found in genes involved in the homologous repair 
pathway, highlighting its significance in ovarian cancer pathogenesis. BRIP1, a 
member of the Homologous Recombination repair pathway which interacts with 
BRCA, was found to be the most prevalent mutation among the cohort (Chen and 
Parmigiani, 2007). Further studies have uncovered mutations in several other 
important DNA repair proteins, including RAD51C and RAD51D, with RAD51C 
mutations detected in 2.9% of highly penetrant ovarian cancer families (Kroeger and 
Drapkin, 2017) (Lilyquist et al., 2017). Mutations in the lower fidelity mismatch repair 
pathway, including MLH1, MSH2 and MSH6, are known to underpin Lynch 
syndrome, which also carries an increased risk of developing OC at 6-8% (Lu and 
Daniels, 2013). Such mutations in multiple DNA repair pathways provides a rationale 
for the efficacy of the FDA approved PARP inhibitor Olaparib as a maintenance 
therapy in women regardless of BRCA status. 
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1.1.4.3 Environmental risk factors  
Reproductive risks have been widely reported to contribute to OC development. In 
1971, Fathalla put forward the ‘incessant ovulation’ hypothesis, that repeated cycles 
of ovulation from menarche to menopause during a woman’s lifetime increases the 
risk of developing OC. It was suggested that repeated cycles of damage and 
subsequent repair at the ovarian surface epithelium predisposes to genetic instability 
and thus malignant transformation. Supporting this idea is the finding that women on 
the oral contraceptive pill have a reduced risk for OC development (Beral et al., 2008). 
Similarly, parity has also been shown to reduce the risk of developing OC, reportedly 
due to the decrease in the number of ovulatory cycles (Fathalla, 2013). Parity describes 
the number of pregnancies carried to 20 weeks in the United States, and 24 weeks in 
the United Kingdom (Opara and Zaidi, 2007). 
In recent years, the role of obesity in promoting and propagating cancer has come to 
the forefront and is particularly relevant in hormone driven cancers. Cancer has often 
been described as a wound that does not heal, in a constant state of systemic 
inflammation. Adipose cells can themselves be described as hormones and contribute 
to providing a microenvironment in which cancer cells can thrive. This is particularly 
pertinent when describing OC, due to the proximity of the omentum, which is a 
common site of metastasis. While there are conflicting theories in the literature, the 
consensus appears to be that increased obesity and BMI (body mass index) are 
associated with an increased risk of OC only in pre-menopausal women (Z. Liu et al., 
2015) (Kuper, Cramer and Titus-Ernstoff, 2002). 
Talcum powder was first suggested to be a carcinogen, due to its chemically similar 
structure to asbestos, which is a carcinogen linked to OC development following work 
place exposure (Acheson et al., 1982). Results are conflicting, and while some studies 
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have suggested a link between perineal talc exposure and increased risk for OC, no 
biological basis for this has been shown (Muscat and Huncharek, 2008).  
 
1.1.5 Staging of ovarian cancer  
The staging of ovarian cancer is based on the International Federation of Gynecology 
and Obstetrics (FIGO) surgical system, in conjunction with corresponding Tumour 
Node Metastasis (TNM) classifications devised by the American Joint Committee on 
Cancer (AJCC), as outlined in table 1.1. FIGO broadly classifies four stages of disease 
(I-IV), with further sub classifications based on the extent of disease spread. In 2014 
FIGO updated its classifications, eliminating sections believed to be redundant. Stage 
I describes disease confined to one or both ovaries or fallopian tubes. Stage II classifies 
disease which has extended to extra-ovarian pelvic organs, such as the bowl or bladder. 
Cancer cells may also be present in the fluid of the abdomen. Subsequent to FIGO 
classification revisions in 2014, stage IIB is no longer sub classified, while stage IIC 
has been removed completely (Prat et al., 2015). Stage III cancers comprise the vast 
majority of cancers diagnosed, with high grade serous carcinomas being the most 
prevalent. These tumours are typified by spreading along the abdominal and pelvic 
peritoneum. Although a rare occurrence, FIGO revisions provide for a new 
classification, IIIA1, defining disease present in retroperitoneal lymph nodes with the 
absence of intraperitoneal dissemination (Prat et al., 2015). Stage IV describes distant 
metastasis, such as the presence of pleural effusion or parenchymal liver metastasis 





Tumour Extension TNM 
classification 
I Tumour limited to the ovaries or fallopian tubes T1 
IA Tumour limited to one ovary; capsule intact, no tumour 
on ovarian surface; no malignant cells in ascites or 
peritoneal washings 
T1a 
IB Tumour limited to both ovaries; capsule intact, no 
tumour on ovarian surface; no malignant cells in ascites 
or peritoneal washings 
T1b 
IC Tumour limited to one or both ovaries with any of the 
following:  
IC1: surgical spill intraoperatively  
IC2: capsule ruptured before surgery or tumour on 
ovarian surface 
IC3: malignant cells present in ascites or peritoneal 
washings 
T1C 
II Tumour involves one or both ovaries or fallopian tubes 
with pelvic extension (below pelvic brim)  
T2 
IIA Extension and/or implants in the uterus and/or fallopian 
tubes and/or ovaries 
T2a 
IIB Extension and/or implants in other pelvic 
intraperitoneal tissues 
T2b 
III Tumour involves one or both ovaries, or fallopian tubes, 
with cytologically or histologically confirmed spread to 
the peritoneum outside the pelvis and/or metastasis to 
the retroperitoneal lymph nodes 
T3 
IIIA Metastasis to the retroperitoneal lymph nodes with or 
without microscopic peritoneal involvement beyond the 
pelvis 
T1, T2, T3aN1 
IIIA1 Positive retroperitoneal lymph nodes only 
(cytologically or histologically proven) 
T3a 
IIIA(i) Metastasis of ≤ 10mm in greatest dimension (tumour 





Table 1.1: Details of the TNM (tumour node metastasis) staging system and the 
International federation of gynaecology and obstetrics (FIGO) classifications are 








IIIA (ii) Metastasis of > 10mm in greatest dimension  
IIIA2 Microscopic, extra pelvic peritoneal involvement 
(above the brim) with or without involvement of 
retroperitoneal lymph nodes 
T3a/T3aN1 
IIIB Macroscopic, extra pelvic, peritoneal metastasis ≤ 2cm 
in greatest dimension with or without involvement of 
retroperitoneal lymph nodes 
T3b/T3bN1 
IIIC Macroscopic, extra pelvic, peritoneal metastasis > 2cm 
in greatest dimension with or without involvement of 
retroperitoneal lymph nodes (includes extension to 
capsule of liver or spleen) 
T3c/T3cN1 
IV Distant metastasis excluding peritoneal metastasis  
IVA Pleural effusion with positive cytology Any T, Any N 
IVB Metastasis to extra abdominal organs including 
parenchymal metastasis, inguinal lymph nodes and 




1.1.6 Management of ovarian cancer 
1.1.6.1 Surgical management 
Clinical management of ovarian cancer is unique, given that regardless of stage or 
histological classification, surgery is indicated first. A primary debulking surgery 
(PDS) is usually performed on women with a suspected ovarian cancer. This surgery 
is important to not only effectively resect tumour, but also to determine the cancer 
stage. This can be done by performing peritoneal washings and scrapings, and by 
visual evidence of cancer spread beyond the ovaries. A number of studies have 
identified optimal debulking as a primary prognostic factor, thus it is recommended 
such surgeries are performed by those with specialist training, such as gynaecology 
oncologists.  
 
1.1.6.2 Chemotherapeutics and targeted therapies 
1.1.6.2.1 Chemotherapy  
The earliest regimen of chemotherapeutics used in the treatment of advanced ovarian 
cancer consisted of intravenous administration of doxorubicin (an anthracycline) 
coupled with cyclophosphamide (a DNA cross linker). In the 1980’s, the platinum 
drug cisplatin was added to this regime. Following subsequent clinical trials, cisplatin 
and cyclophosphamide became the standard of care for first line treatment of ovarian 
cancer.  
Current recommendations state that surgery alone is indicated for early stage IA or B 
tumours. Patients with stage III and IV disease receive adjuvant chemotherapy 
following PDS. The current standard of care involves the administration of a platinum 
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compound, such as cisplatin or carboplatin, in conjunction with a taxane agent, such 
as paclitaxel. Carboplatin and paclitaxel are the preferred combination due to their 
combined lower toxicity profile.  
A major challenge in the clinical management of OC is the high rate of disease 
recurrence. Approximately 80% of women that exhibit an excellent response to first 
line therapy present with recurrent disease. In this instance, second line treatment 
depends upon the length of time until recurrence. Recurrent ovarian cancer can be 
classified as platinum sensitive or platinum resistant. Platinum sensitive patients 
generally receive a second round of platinum agents. Platinum resistant patients are 
offered alternative drugs, such as liposomal doxorubicin, gemcitabine or etoposide. 
However, response to these second line therapies remains poor, highlighting the need 
for targeted therapies. 
While PDS is important in the management of OC, not all women are eligible for PDS, 
due to the existence of precluding comorbidities, poor performance criteria or old age. 
The nutrition status of the patient is an important factor to assess pre-surgery. Low 
prealbumin levels are associated with malnutrition and postoperative complications 
and morbidity in OC patients (Geisler et al., 2007). Neoadjuvant chemotherapy allows 
such patients to improve their nutritional status before debulking surgery. A number 
of clinical indicators may also identify patients where optimal debulking is unlikely, 
and who should receive neoadjuvant chemotherapy. Such indicators include 
extraperitoneal disease spread (such as lung metastasis), diaphragmatic or liver disease 
greater than 2cm, bowel adhesions or thickening and the detection of ascites in a 
minimum of two-thirds of CT scan slices (Nelson, Rosenfield and Schwartz, 1993) 
(Wright et al., 2016). In these instances, neoadjuvant chemotherapy is administered to 
reduce the tumour burden, after which, interval debulking surgery can be performed. 
 
 17 
A comprehensive review of guidelines surrounding neoadjuvant chemotherapy and 
interval debulking for advanced OC patients was conducted by (Wright et al., 2016).  
Given that the peritoneal cavity is the primary site of disease spread, intraperitoneal 
(IP) administration of chemotherapy drugs was developed as a means to deliver 
targeted and more concentrated doses to tackle disseminated disease. A number of 
large scale trials were designed to assess any benefits of IP chemotherapy. Results 
from the GOG-172 study revealed significant improvements in both progression-free 
survival (PFS) and overall survival (OS) when cisplatin and paclitaxel were 
administered IP as opposed to IV (Armstrong et al., 2006). IP administration however 
proved toxic, with less than half of patients completing the planned number of therapy 
cycles. Further analysis of the GOG-172 study also revealed that in patients with 
aberrant expression of BRCA1, IP cisplatin increased survival to 84 months, up from 
47 months in patients receiving IV cisplatin (Lesnock et al., 2013). Following a meta-
analysis of IP chemotherapy trials by the National Cancer Institute (NCI), it 
recommended the use of IP cisplatin for optimally debulked stage III OC patients. 
Despite this recommendation, IP administration has yet to be widely adopted. Further 
trials were conducted which compared IP to IV administered carboplatin, which is 
more clinically relevant. The GOG-252 study of women with newly diagnosed 
advanced OC revealed no survival benefit of IP chemotherapy compared to IV 
carboplatin administration (Walker et al., 2019). It has been hypothesised however, 
that the concurrent administration of bevacizumab in this trial may have adversely 
impacted the efficacy of IP chemotherapy. The Intraperitoneal Therapy for Ovarian 
Cancer with Carboplatin (iPOCC) trial compared the efficacy and safety of IP versus 
IV carboplatin with weekly IV paclitaxel, without bevacizumab, and thus may give a 
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more accurate comparison of IV versus IP carboplatin (Fujiwara et al., 2011). Survival 
analysis is expected to be competed in 2020.  
As mentioned at the start of this section, paclitaxel and carboplatin are the preferred 
chemotherapy doublet used in the clinic. Paclitaxel functions in the cell as a 
microtubule stabiliser. It binds to the β tubulin subunit of the microtubule and reduces 
the threshold amount of purified tubulin subunits required for polymerisation into 
microtubules. It also enhances the number the tubulin subunits which assemble, 
stabilising the microtubule (Schiff, Fant and Horwitz, 1979). Cancer cells treated with 
paclitaxel undergo mitotic arrest, due to the activation of the spindle assembly 
checkpoint. Carboplatin causes the formation of intra and interchain DNA adducts by 
covalently binding to purine bases. The formation of such adducts impedes DNA 
replication and transcription (Todd and Lippard, 2009). 
 
1.1.6.2.2 PARP inhibitors  
Currently, Olaparib is FDA approved for use in a select cohort of patients with 
recurrent OC. Only those who carry a BRCA mutation and have received three prior 
chemotherapeutic options are eligible to receive Olaparib (Bixel and Hays, 2015). 
However, as will be discussed later in this review, PARP inhibitors have also shown 
to be beneficial in women without BRCA mutations, but with defects in other DNA 
repair genes. PARP inhibitors such as Olaparib exploit the synthetic lethality model, 
whereby a combination of gene mutations results in cell death, as shown in figure 1.2. 
Women with BRCA mutations have defective DNA repair pathways used to mend 
double strand breaks, such as homologous recombination and non-homologous end 
joining. BRCA defect alone is not enough to elicit a lethal phenotype, as single strand 
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break repair pathways such as nucleotide excision repair (NER), base excision repair 
(BER) and mismatch repair still function to repair damage. PARP is a key enzyme 
involved in such single strand repair pathways, whose inhibition via Olaparib renders 
the cell unable to repair DNA damage, resulting in cell death. The administration of 
Olaparib was shown to extend the time to recurrence from 4.3 months to 11.2 months 
compared to the placebo group (Ledermann et al., 2014). The SOLO1 trial evaluated 
the use of olaparib as a maintenance therapy in newly diagnosed patients with 
advanced (stage III or IV) HGSOC or endometrioid cancer, with a BRCA1 or 2 
mutation, or both (Moore et al., 2018). Women in the trial had either a complete or a 
partial response to platinum chemotherapy. Compared to patients who received a 
placebo, a significant improvement in PFS was observed in patients who received 
Olaparib as a maintenance therapy. The authors reported a 70% reduction in the risk 
of disease progression or death following Olaparib treatment. While the advent of such 
treatments has been proven to successfully improve PFS, they have not been shown to 
improve the patient’s OS. Recent studies suggest that patients with mutations in other 
DNA repair genes will also have a good response to PARP inhibitors. The recent 
approval of PARP inhibitors including olaparib, rucaparib and niraparib by the FDA 
and European Medicines Agency (EMA) for use in all platinum sensitive patients 
regardless of BRCA mutation status supports this. The phase III NOVA trial found 
that the addition of niraparib as maintenance therapy, in platinum sensitive patients 
could improve PFS, regardless of BRCA mutation status (NCT01847274). In the 
absence of PARP, DNA damage is repaired via homologous recombination repair 
(HRR). Defects in HRR related genes, including ATM, CHEK2 and RAD51C 
represent a small portion of HGSOC patients, but may have clinical utility in 
identifying those patients with BRCA mutation who will benefit from PARP inhibition 
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(Matsumoto et al., 2019).  Through research and a deeper understanding of the 
molecular pathogenesis of OC, it is hoped that treatments will serve not only to extend 












Figure 1.2: The use of PARP inhibitors is predicated on BRCA mutation resulting in defective 
homologous recombination repair. Cells use various pathways to repair DNA damage. (A) 
PARP inhibition in cells with functional homologous recombination can still repair damage 
via this pathway. (B) Inhibiting PARP in BRCA-mutated, homologous recombination- 
defective cells, means the cell has no pathway to repair DNA damage. (Adapted with 
permission from JD Iglehart and DP Silver. (2009) NEJM 361:189–191, copyright 
Massachusetts Medical Society.)  
 
1.1.6.2.3 Anti-angiogenic agents 
Angiogenesis, the process of forming new blood vessels, plays an integral role in 
tumour growth and metastasis. In ovarian cancer, it also has a role in the development 
of malignant ascites (Graybill et al., 2015). The anti-VEGF monoclonal antibody 
Bevacizumab is the most widely studied anti-angiogenic, which has shown efficacy in 
other solid malignancies including colorectal and breast cancer. Bevacizumab has 
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approval for use in women as a first line therapy, and in women with stage III or IV 
cancer with residual disease following surgery. It is also approved for use in the 
recurrent setting, for women with either platinum sensitive or platinum resistant 
disease. Two large phase III trials conducted, GOG-218 and ICON7, demonstrated 
improved PFS in poor prognosis women following administration of Bevacizumab in 
conjunction with carboplatin and paclitaxel in the first line setting (Burger et al., 2011; 
Perren et al., 2011). Despite this, the final OS results revealed that the addition of 
Bevacizumab to platinum chemotherapy provided no OS benefit in the study 
population (Oza et al., 2015). Additionally, further trials have evidenced significant 
improvement in PFS with the addition of Bevacizumab in the recurrent setting. The 
addition of Bevacizumab to carboplatin or gemcitabine in platinum-sensitive and 
platinum-resistant relapsed disease significantly improved PFS for these women 
(Aghajanian et al., 2012; Pujade-Lauraine et al., 2014). However, following 
publication of the final analysis of OS from the GOG-218 study, no survival benefit 
was observed in patients receiving bevacizumab with their chemotherapy (Tewari et 
al., 2019). A meta-analysis assessed the efficacy of anti-angiogenic agents in the 
recurrent ovarian cancer setting and associated toxicities. The addition of VEGF 
antagonists was found to provide an OS benefit to platinum sensitive patients, but not 
to platinum resistant cohorts, and also resulted in enhanced toxicities (Yi et al., 2017). 
Due to the unwarranted toxicities arising from anti-angiogenic therapies, elucidating 
clinically relevant markers to identify patients who will respond to treatment is 
necessary. An ongoing phase IV trial MITO16/MANGO-2 aims to assess clinical 
factors and biological markers to aid in the identification of patients which will benefit 
from the addition of Bevacizumab to first line chemotherapy (NCT01462890).  
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1.1.6.2.4 Immunotherapies in ovarian cancer 
Dendritic cells (DCs) are the most potent antigen presenting cells, displaying antigen 
for the activation of T cells. In the cancer setting, their numbers are usually quite low. 
DC therapy involves harvesting the patients DCs, growing them and exposing them to 
tumour antigen before reinfusing high numbers back into the patient. Natural killer 
(NK) cells are key players in the innate immune response, unique in the fact that they 
do not require antigens or MHC to elicit their effects. Thus, they can elicit a rapid 
response to virus-infected cells or importantly, tumour antigens, whilst sparing healthy 
cells that express MHC class 1 molecules (Pampena and Levy, 2015). The addition of 
NK cells to DC therapy was introduced following evidence that NK cells can eliminate 
immature DCs whilst selecting for a highly immunogenic subset of activated  DCs 
(Ferlazzo et al., 2002). A case study reported in 2017 has highlighted the potential of 
DC/NK cell therapy in enhancing chemotherapeutic efficacy and inducing a durable 
remission. A 74 year - old woman presented with severe ascites and large masses on 
the left ovary. A diagnosis of serous carcinoma with metastasis to the omentum and 
peritoneum was made. During the implementation of a chemotherapy regimen, 
comprising docetaxel and paclitaxel, the patient also received infusions of monocyte 
derived DCs, which had been exposed to tumour antigens, CA-125, WT1, NY-EOS1 
and telomerase, along with NK cells. These antigens were selected based on the 
patient’s human leukocyte antigen (HLA) type. Three months following initiation of 
the DC/NK cell therapy, there was no evidence of ascites, while the peritoneal mass 
had shrunk in size enabling laparoscopic debulking. In this case the patient went into 
remission and was still cancer free 13 months on (Sasada, Abe and Abe, 2017).  
Similar to DCs, NK cells present in ascites have been found to be malfunctioning. As 
part of their function, NK cells release cytokines such as TNF-α and IFN. In a bid to 
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enhance NK cell activity from ovarian ascites, a study by Geller et al. (2017) combined 
a novel IL-15 super agonist and the PD-L1 antagonist Pembrolizumab. Expression of 
TNF- α and IFN was found to be enhanced following this combination treatment, 
resulting in a significant decrease in tumour burden in a mouse model of ovarian 
cancer (Geller et al., 2017). IL-15 stimulates NK cell growth and expansion, as well 
as aiding their cytolytic capabilities (Rautela and Huntington 2017). While 
immunotherapies have been trialled and shown to have efficacy, particularly in 
melanomas, clinical trials of immune therapies for ovarian cancer is a recent 
occurrence. Tumour-associated macrophages are the most abundant immune cells 
which infiltrate the ovarian microenvironment, eliciting an anti-inflammatory effect. 
Colony stimulating factor, also referred to as CSF-1, is essential for proliferation and 
survival of macrophages. The use of an anti-CSF-1 mAB in mice models effectively 
depleted tumour associated macrophages, while simultaneously increasing the 
numbers of CD4+ and CD8+ cytotoxic T cells (Krishnan et al 2017). This paved the 
way for a clinical trial with a humanised anti-CSF-1 antibody developed by Roche in 
2011. Early results from this trial (NCT01494688) indicate the antibody is well 
tolerated and can deplete tumour associated macrophages. T cells, such as CD4+ and 
CD8+ cytotoxic T cells, are key effector cells in mounting an immune response. 
CTLA-4 is a negative regulator of T cell activity, resulting in what is known as T cell 
anergy. In an immune supressed tumour microenvironment, blocking CTLA-4 results 
in the activation of CD4+ and CD8+ T cells. The anti-CTLA-4 monoclonal antibody 
Ipilimumab (Yervoy, Bristol Meyers Squibb) has had efficacy in melanoma patients 
and was FDA approved in 2011. A phase II study is currently underway assessing the 
efficacy of Ipilimumab as a monotherapy in platinum sensitive ovarian cancer 
(NCT01611558). Another trial to study the efficacy of immune checkpoint blockade 
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was the phase II KEYNOTE-100 study (NCT02674061). KEYNOTE-100 is the 
largest study to date to assess the safety and efficacy of the monotherapy 
Pembrolizumab, an anti-PD-1 antibody, in patients with recurrent OC. The objective 
response rate (ORR), although durable (≥ 6 months), was modest at just 8%. 
Importantly, higher PD-L1 expression corresponded to a better response, highlighting 
its potential role as a clinical maker to predict response. 
The Javelin solid tumour trial assessed the safety and efficacy of Avelumab, a PD-L1 
inhibitor, in advanced OC patients, with recurrent and/or resistant disease who 
previously received platinum chemotherapy. Monotherapy Avelumab showed anti-
tumour efficacy and acceptable safety (Disis et al., 2019). The Javelin Ovarian 100 
trial aimed to assess the efficacy of Avelumab in combination with or following 
carboplatin/paclitaxel in OC patients with advanced disease (stage III or IV), who were 
treatment naïve (NCT02718417). Interim analysis indicated no benefit to PFS in 
patients receiving Avelumab over chemotherapy alone, resulting in the termination of 
the trial. The Javelin Ovarian PARP 100 trial was designed to assess the efficacy of 
combining Avelumab with chemotherapy, followed by a maintenance therapy of 
Avelumab with the PARP inhibitor talazoparib in women with stage III or IV disease 
(Eskander et al., 2019). However, results from the Javelin Ovarian 100 trial prompted 
investigators to discontinue the trial. Finally, the Javelin 200 trial evaluated the 
efficacy of Avelumab in combination with pegylated-liposomal doxorubicin (PLD) 
versus PLD alone in platinum resistant/refractory patients (Pujade-Lauraine et al., 
2019). No survival benefit was found when avelumab was administered with PLD 




































































































































































































































































































































































1.1.7 Molecular pathogenesis of ovarian carcinoma 
1.1.7.1 Genomic landscape of ovarian cancer 
1.1.7.1.2 Sporadic ovarian cancer 
New classifications have broadly divided OC tumours into two categories, Type I and 
Type II tumours. Recent large scale genomic studies have validated this subdivision 
and have further expanded the grouping of ovarian tumours according to their genetic 
features (see Table 1.2). Type I tumours, including low grade serous OC tumours 
(LGSOC) and clear cell tumours, are typically described as indolent and follow a less 
aggressive clinical course, with disease commonly confined to one ovary. Mutations 
in genes such as KRAS, PIK3CA, ARID1A and PTEN are frequently found (Y. K. 
Wang et al., 2017). Conversely, Type II tumours, including high grade serous 
carcinomas (the most common subtype), follow an aggressive course and typically 
spread beyond the ovaries. Type II tumours almost universally harbour p53 mutations 
which are rarely found in Type I tumours. Mutations in genes involved in homologous 
recombination repair are common in Type II tumours, as are mutations in genes such 
as FOXM1, RB1 and NOTCH 3 (Testa et al., 2018). In addition, type II tumours 
display chromosomal instability, while Type I are relatively stable. While this broad 
classification may be suited to Type II tumours, as molecular and cell of origin studies 
advance, it is becoming clear that Type I tumours are too heterogenous to group 
together. Going forward, Type I tumours should be classified as distinct diseases and 
not automatically considered to be indolent. This is evidenced by the fact that 
mucinous OC (classified as Type I) can be clinically aggressive and have high 
proliferation rates (Kobel et al., 2008). Of all the histological subtypes, LGSOC and 




Several studies on high grade serous ovarian cancers suggest that they are relatively 
unique in that they are driven not by repeated point mutations, but rather by copy 
number alterations. Copy number alterations manifest themselves as structural 
changes to the genome, including chromosomal deletions or gains, which can vary 
considerably in size. To elucidate potential therapeutic targets, the cancer genome 
atlas undertook a comprehensive analysis of 489 high grade serous ovarian cancer 
patient samples. Matched ‘normal’ DNA was also obtained and analysed for each 
patient. Mutation analysis, via the Illumina GAIIx and ABI SOLid 3 platforms, 
revealed significant mutations in six genes: RB1, NF1, FAT3, CSMD3, GABRA6 and 
CDK1 (The Cancer Genome Atlas, 2011). High grade serous cancers were found to 
have strikingly high levels of somatic copy number alterations (SCNAs). One of the 
most prominent copy number alterations in ovarian cancer occurs at the 19q12 locus, 
found to be driven by the CCNE1 gene. This regulates the cell cycle and can cause 
unwarranted DNA replication and centrosome amplification, thus leading to 
chromosomal instability (Kroeger and Drapkin, 2017). CCNE1 amplification has been 
heralded as the leading chromosomal aberration associated with disease relapse 
following first line chemotherapy (Etemadmoghadam et al., 2009; Naomi et al., 2010).  
A recent study was able to identify an amplification in the GAB2 gene, involved in 
MAPK and PI3K signalling, as being responsible for the transformation of 
immortalised ovarian and fallopian tube epithelial cells (Dunn et al., 2014). 
Investigating the functional relevance of such SCNAs is important in understanding 
the genetic drivers of ovarian cancer development.  
A study by Sakai et al. (2017), utilised next generation sequencing on formalin-fixed 
paraffin-embedded (FFPE) tissue from 24 patients to detect mutations in several 
tumour suppressor genes, including TP53 (53% of samples) and FBXW7 (8.3% of 
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samples). P53 mutations are present in more than 95% of high grade serous tumours 
and data suggests that early p53 mutation is necessary for tumour initiation; while 
BRCA1/2 mutations were detected in 40-50% of high grade serous cancers (Sakai et 
al., 2017). Given that these genes play integral roles in maintaining genomic stability, 
it provides a rationale for the chaotic chromosomal rearrangements found in high 




Table 1.2: Summary of ovarian tumour subtypes, cells of origin and defining genetic mutations from 
a review by (Testa et al., 2018) . 
































KRAS, TP53, CDKN2A, 
BRAF, RNF43 
Unknown 
Brenner tumour I Transitional-like 










I Fallopian tube 






KRAS, NRAS, BRAF, 
EIF1AX, USP9X, 




I Same as for 
endometrioid, low-
grade serous and 
mucinous  


















TP53, BRCA1, BRCA2, 
CNAs of CCNE1 
amplification, PTEN, 











II Unknown Unknown TP53, PI3KCA, 
PPP2R1A, KRAS, PTEN, 
CHD4, BCOR, histone 






Sex cord stromal 
cells (or granlosa 
cells) 
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Small cell carcinoma 
of the ovary, 
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N/A Rare resident 
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1.1.7.2 Epigenetic drivers 
1.1.7.2.1 MicroRNA 
MicroRNA are small non-coding RNA molecules which function to post-
transcriptionally regulate gene expression. miRNA regulate a large and diverse array 
of cellular processes and have been previously reported to be aberrantly expressed 
among various cancer types. DROSHA is an RNase II, which recognises primary-
microRNAs (Pri-mRNA) and generates a precursor micro-RNA (pre-miRNA). The 
pre-miRNA is then transported to the cytoplasm where it is processed by DICER, 
resulting in two mature single-stranded microRNA molecules which can then be 
loaded onto the RISC complex and suppress gene expression (Shukla, Singh and 
Barik, 2011). Low expression of DICER was found to be associated with reduced 
median survival and advanced disease stage in serous tumours (Merritt et al., 2008). 
Similarly, low levels of DROSHA was associated with reduced median survival along 
with ‘suboptimal cytoreduction’. The combined reduction in both DICER and 
DROSHA was found to be a predictor of death from OC, while an increase in both 
was associated with increased median survival (Wang, Ivan and Hawkins, 2017). 
Given that low levels of expression of the miRNA machinery correlates with poor 
prognosis, a meta-analysis has suggested that it is the ‘global loss of miRNA’ which 
contributes to the poor prognosis in epithelial ovarian cancer (EOC), with the loss of 
DICER effectively equating to a loss of a tumour-suppressor.  
In the cancer setting, miRNAs are known to play either oncogenic or tumour 
suppressor roles. miR-133a is a prominent tumour suppressor miRNA, found to be 
markedly downregulated in all 70 EOC tissue samples analysed. This downregulation 
of miR-133a was associated with ‘advanced clinical stages, poor histological 
differentiation and lymph node metastasis’(LUO et al., 2014). In line with this, an 
 
 31 
analysis of 164 ovarian cancer tissue samples revealed that miR-129-5p was 
significantly decreased when compared to non-cancerous ovarian samples. This 
correlated with a higher FIGO stage, histological differentiation and pelvic metastasis 
(Tan et al., 2015). Expression of miR-181a correlated with a reduced progression free 
and overall survival. This miR was reported to modulate TGF-β signalling and induce 
epithelial-mesenchymal-transition (EMT) (Parikh et al., 2014). A common aberration 
found in ovarian cancers is the downregulation of the Let-7 microRNA. One of its 
targets, HMGA2, a DNA binding factor important for the regulation of cell growth, 
differentiation and apoptosis, is consequently over expressed (Testa et al., 2018). 
HGMA2 overexpression is found in 65% of ovarian cancers, with the highest 
prevalence in high grade serous cancers  (Mayr, Hemann and Bartel, 2007). Let-
7/HGMA2 dysregulation provides a molecular marker to enable the distinction of 
Type I and Type II tumours, with Let-7 downregulated tumours being less 
differentiated (Shell et al., 2007). Low Let-7 expression also results in the increased 
expression of BRCA1 and RAD51, key players in the repair of double strand DNA 
breaks. High BRCA1 and RAD51 expression coupled with low Let-7 expression was 
found in chemoresistant EOC compared to the sensitive group (Xiao et al., 2017). 
Chemosensitivity could be improved by over expressing Let-7 with an antagomir, 
demonstrating a role for this miR in chemoresistance.  
Various miRNA’s have been found to differentiate clear-cell from serous tumours, 
including miR-132, miR-9, miR-126, miR-34s and miR-21 (Wang, Ivan and Hawkins, 
2017). In CD44+/CD133+ clear cell ovarian tumours, miR 134-3p was found to be 
downregulated. The down-regulation of this miR is believed to play a pathogenic role, 
given it directly targets RAB27A, which plays a role in the downregulation of stem 
cell markers and adhesion proteins (Chang et al., 2017).  
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A role for miRNA’s in explaining the heterogeneity observed in EOC has recently 
been proposed and it involves the inappropriate activation of the HoxA genes, which 
are involved in regulating body formation during development. The HOX genes 
responsible for the differentiation of EOC subtype are primarily found in the 3’-region 
of the HoxA genes. HOXA7 is expressed in endometrial and endocervical epithelia but 
not ovarian surface epithelium cells (OSE) and is targeted by miR-196. This miR 
controls the degree of EOC differentiation and promotes a low-grade phenotype. 
Using a model of in-vitro transformed OSE cells, induction of stable HOXA7 
expression resulted in the formation of low-grade phenotype tumours which also had 
stable expression of E-cadherin (Mezzanzanica et al., 2010). In a study comparing 
EOC versus immortalised ovarian surface epithelium cells (IOSE), of the 35 miRNA 
which were differentially expressed, only 4 were found to be up-regulated. A 
comparison of late vs early stage and high vs low-grade EOC, found there was a total 
down-regulation of these miRNAs. It was found that in advanced EOC, genomic copy 
number losses and epigenetic silencing may account for 15-36 % of this miRNA 
down-regulation, respectively. It was also found that of these down-regulated 
miRNA’s in late stage EOC, 25% were clustered across chromosomes 14, 19 and X 
(Mezzanzanica et al., 2010).  
 
1.1.7.2.2 Long non-coding RNAS 
Long non-coding RNAs (lncRNAS) are non-coding RNAs which can regulate gene 
transcription via the recruitment of chromatin modifying enzymes. One of the most 
widely studied lncRNA’s in cancer is H19. This LncRNA plays an oncogenic role in 
OC, and overexpression of H19 is associated with metastasis in OC cells (Matouk et 
al., 2014). Overexpressing histone h1.3, which represses H19, in OVCAR-3 cells, 
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decreased their growth rate and colony formation (Liu et al., 2013). Human OC-
specific transcript 2 (HOST2) is highly expressed in the 4 major ‘clinico-pathological’ 
subtypes of OC. It is believed that this lncRNA plays a pathogenic role in OC by acting 
as an oncogene. HOST2 acts a molecular sponge which controls the availability of 
miR-let-7b, which is a potential tumour suppressor gene, thereby inducing 
proliferation, invasion and tumour cell migration (Gao et al., 2015). Urothelial 
carcinoma associated 1 (UCA1) could act as both a biomarker and therapeutic target 
for OC. Its overexpression was found to be associated with lymph node metastasis, 
chemoresistance and poor overall survival in OC patients (Zhang et al., 2016). It could 
also serve as a therapeutic target given that knockdown of UCA1 reduced the cells 
ability to migrate and invade. Other lncRNA’s have been shown to play a role in OC, 
such as Hox transcript antisense intergenic RNA (HOTAIR) and PVT1. HOTAIR was 
found to be expressed in OC tissues which were benign and late-stage versus early 
stage tumours (Wang et al, 2015). The over-expression of PVT1, due to amplification 
of 8q24, was recently found to induce cisplatin, or carboplatin + docetaxel resistance 
through the regulation of apoptotic pathways. The downregulation of PVT1 in OC cell 
lines inhibited proliferation and induced a strong apoptotic response (Ma et al, 2016). 
 
1.1.7.3 Tumour microenvironment in ovarian cancer pathogenesis 
In order to fully elucidate and understand cancer biology, it is imperative to study not 
only the cancer cells themselves, but also the tumour microenvironment. The ovarian 
tumour microenvironment comprises a milieu of cells, including various immune 
cells, fibroblasts, and adipocytes. In addition, malignant ascites, a build-up of 
peritoneal fluid, also contains a host of cytokines, chemokines and growth factors 
which can aid tumour progression, metastasis, and drug resistance. Understanding the 
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complex interactions of microenvironment components with cancer cells will enable 
improved therapeutic targeting.  
1.1.7.3.1 Adipocytes  
Among the milieu of cells residing in the tumour microenvironment, a role for 
adipocytes in promoting tumour growth and chemoresistance has emerged. 
Traditionally adipocytes are cells which synthesize and store fat. However, recent 
studies have demonstrated their ability to secrete chemokines, hormones and growth 
factors into the tumour microenvironment to facilitate and support tumour growth and 
spread. A study by Niemann et al. (2011) illustrated that omentum-associated 
adipocytes could drive preferential migration of ovarian cancer cells to the omentum 
in a mouse model. This effect was elicited through the secretion of adipokines such as 
IL-6, IL-8 and CCL2 (Nieman et al., 2011). Visceral adipocytes in the ovarian 
microenvironment can promote tumour growth and metastasis by supplying fatty 
acids. Ovarian cancer cells which had been co-cultured with patient adipocytes derived 
from the omentum had high levels of the fatty acid receptor CD36. The use of an anti-
CD36 monoclonal antibody effectively reduced tumour burden in a xenograft model. 
Moreover, when compared to matched controls, metastatic tissue expressed higher 
levels of CD36 (Ladanyi et al., 2018). Thus, targeting adipocyte-induced CD36 
expression could attenuate tumour metastasis. Intriguingly, a novel role for adipocytes 
in altering apoptotic protein expression has been identified. Adipocytes in epithelial 
ovarian cancer could upregulate BCLXL expression and this was correlated with 
chemoresistance (Cardenas et al, 2017).  
1.1.7.3.2 T cells  
T cells play a central role in cell-mediated immunity, recognising antigens from virus 
infected or tumour cells presented to them other immune cells, for example dendritic 
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cells. T cells function not only to drive an immune response, via cytotoxic T cells, but 
also to repress it, via suppressor T cells. Accumulation of cytotoxic CD8+ T cells 
within the tumour microenvironment has consistently been associated with improved 
outcomes for ovarian cancer patients (Hwang et al., 2012; Hermans et al., 2014). A 
subset of T cells, known as Tregs, serve as suppressors of immune cells to maintain 
tolerance to self-antigens and thus prevent autoimmune disease. The ovarian tumour 
microenvironment favours the induction and maturation of Tregs via upregulating the 
CCL2/CCL17 axis, which traffics Tregs to tumours. When compared to non-
cancerous ovaries, ovarian tumours and ascites were found to have higher CCL2 
mRNA levels. A study conducted with 104 ovarian cancer patients revealed that 
CCL2- mediated accumulation of Tregs in ovarian tumours was associated with 
reduced survival and increased risk of mortality (Curiel et al., 2004).  
 
1.1.7.3.3 Macrophages 
Macrophages are a subset of white blood cells which engulf and digest foreign bodies 
via phagocytosis. They can be broadly classified into two subgroups, M1 and M2. M1 
macrophages are classically activated, usually by IFN-γ and eliminate viruses and 
bacteria from the body. In contrast, M2 macrophages are activated by cytokines such 
as IL-10 and IL-4 and function in wound healing and repair. M1 macrophages which 
infiltrate tumours can be polarised to an M2 phenotype, enhancing tissue restoration 
and dampening local immune response (Martinez and Gordon, 2014). The ability of 
ovarian cancer cells to polarise M1 macrophages to the M2 phenotype has been 
documented (Hagemann et al., 2006). Co-culture experiments have revealed the 
crosstalk between ovarian cancer cells and macrophages to support tumour 
progression. Macrophages co-cultured with ovarian cancer cells developed a 
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phenotype which resembles macrophages isolated from human tumours. A significant 
increase in the expression of genes such as CCL2, CCL22, TNF-α and VEGF was 
observed following co-culture with ovarian cancer cells (Hagemann et al., 2006). 
Importantly, this effect was not recapitulated by co-culturing with healthy ovarian 
surface epithelial cells. The importance of tumour associated macrophages (TAMs), 
believed to have a phenotype resembling M2 macrophages, in aiding ovarian cancer 
metastasis was evidenced by Yin and colleagues (Yin et al., 2016). To enable 
migration to distant sites, cancer cells need to be able to survive anoikis, a type of cell 
death elicited when cells no longer have ECM support. Small clusters of free moving 
cells known as spheroids were detected in the peritoneal fluid of 128 ovarian cancer 
patients. High numbers of macrophages within spheroids were correlated with poor 
overall survival. By secreting EGF, TAMs active EGF signalling in the cancer cells, 
leading to an upregulation of the VEGF-C/VEGFR-3 autocrine signalling axis. As a 
result, ICAM-1 is upregulated, and provides a means by which spheroids can attach to 
macrophages via integrins (Yin et al., 2016). In addition to macrophages, ovarian 
tumours also have infiltration of dendritic cells (Krempski et al., 2011).  
 
1.1.7.3.4 The role of Ascites in metastasis and chemoresistance  
Ovarian cancer can be defined as a peritoneal malignancy, meaning transcoelomic 
spread of cancer cells is the primary route through which cancer cells adhere to the 
omentum and serous linings of other organs in the peritoneal cavity. The peritoneal 
environment is formed from effusions which accumulate within the abdominal cavity, 
commonly known as ascites. This has its own unique molecular profile, which may 
aid cancer metastasis and chemoresistance. OC accounts for 38% of all malignant 
ascites diagnosed in women (Parsons, Lang and Steele, 1996).  
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A study by Matte et al. (2012) conducted on 10 ovarian cancer patients identified 
several cytokines significantly upregulated in the ascites, including adiponectin, 
angiogenin, ICAM-1, IL-6, PDGF-BB and RANTES (Matte et al., 2012). Cytokines 
present in ascites such as IL-6 can induce STAT3 signalling, a pathway influential in 
mediating chemoresistance via inhibiting pro-apoptotic signalling (Pogg Von 
Strandmann et al., 2017). A recent study by Mikula-Pietrasik et al. (2017) has 
evidenced a pro-angiogenic role for ovarian malignant ascites. This study was 
conducted with 48 ovarian cancer patients with different subtypes and grades of 
disease. Half of the cohort studied had tumours without ascites, while ascites was 
collected for the remaining 24 patients. Control samples were obtained from women 
undergoing surgery for the removal of non-cancerous lesions. Antigens against CD31 
and CD34, markers of endothelial cells, were used on paraffin fixed tumour 
specimens. Interestingly, tumours which formed in the presence of ascites displayed 
higher expression of both antigens when compared to tumours formed in the absence 
of ascites. Furthermore, analysis of the gap junction protein Connexin-43 was found 
to be exceptionally high in vascular smooth cells of tumours formed in the presence 
of ascites (Mikula-Pietrasik et al., 2017). Connexins play a role in angiogenesis 
through branch formation and their loss has been shown to impair the angiogenic 
process (C. Gartner et al., 2012). These studies illustrate that malignant ascites is 




1.1.8 Mutation signatures and biomarkers for ovarian cancer  
1.1.8.1 Utilisation of mutation signatures in the clinic 
Advances in next generation sequencing has enabled a wealth of genetic data to be 
collected from tumours of cancer patients. Large databases exist, including TCGA (The 
Cancer Genome Atlas), COSMIC (Catalogue of Somatic Mutations in Cancer) and 
cBioportal to name but a few. However, these databases have yet to be successfully 
implemented into clinically useful tools. Discovery of the BRCA gene epitomises the 
potential of translating genetic analysis of tumours to the clinic. As discussed earlier, 
patients with a BRCA mutation are particularly responsive to PARP inhibitors such as 
Olaparib.  
There is also potential for mutation signatures to be used in diagnosis and prognosis. The 
HPRT locus is important for mismatch repair (MMR), with defects in this repair pathway 
leading to chemoresistance. A recent study identified gene expression changes in HGSOC 
patients pre- and post-neoadjuvant chemotherapy. Significant changes in expression 
(greater than 2-fold change) were noted for a total of 86 genes. A BRCA1/2 mutational 
signature identified was found to have prognostic significance in relation to survival and 
overall survival rates. Patients with the mutational signature had a progression free 
survival of 55.2 months, and an overall survival of 46.3 months. In stark contrast, patients 
lacking the mutational signature had a survival of 38 months, with an overall survival of 
23.6 months (Arend et al., 2018). The TCGA (The Cancer Genome Atlas) was also 
utilised to derive a signature prognostic of lymphatic invasion, a factor known to confer 
disease aggression and patient survival (Paik et al., 2018). Looking forward there is an 
urgent need to re-evaluate and assess the genetic data already gathered to try and elucidate 
potential clinical value. It is clear there are fantastic resources of information available 
which are being severely under-utilised.  
 
 39 
1.1.8.2 Prognostic implications of the C1-C5 classification of high-grade serous 
tumours 
Targeted cancer therapy, whereby mutation profiles and immune signatures are used to 
deliver a highly personalised, effective and less toxic treatment, have revolutionised 
cancer treatment. As alluded to earlier, ovarian cancer is a highly heterogenous disease, 
displaying both inter- and intra-patient variability, making it particularly susceptible to 
targeted therapies. Tothill et al. (2008) were able to identify molecular subtypes of high 
grade serous ovarian carcinoma and use these to infer chemo-response and patient 
prognosis. Four predominant subtypes emerged from this study to describe high grade 
serous tumours, named C1, C2, C4 and C5, as described in Table 1.3 below (C. Wang et 
al., 2017). These subtypes are predictive of prognosis and may be useful in designing 
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Table 1.3: Summary of C1-C5 classification:  immune signatures, corresponding gene 






1.1.8.3 Diagnostic and prognostic biomarkers for ovarian cancer  
Cancer antigen 125 (CA125) is a protein expressed by epithelial tissues, currently 
approved by the FDA for use a surveillance aid in women diagnosed with OC. A CA125 
value above 35 UI/ml is considered above normal. While 85% of women with metastatic 
OC display elevated CA125 levels, there are limitations which reduce both the specificity 
and sensitivity of this protein. Approximately fifty percent of women with stage I disease 
display normal levels of CA125 pre-operatively. In addition, a number of benign ovarian 
conditions have been shown to elevate CA125 levels, including endometriosis, uterine 
fibroids, and menstruation (Nowak et al., 2015). As such, research has aimed at 
elucidating other biomarkers. Human epididymis protein 4 (HE4), while absent from 
ovarian surface epithelium, is found in the epithelium of fallopian tubes and the 
endometrium. This protein was found to be more sensitive than CA125, with elevated 
HE4 expression detected in OC patients with normal CA125 levels. Unlike CA125, HE4 
expression is unaffected by benign conditions such as endometriosis and during 
menstruation (Hallamaa et al., 2012). The examination of HE4 alongside CA125, 
factoring in menopausal status, led to the development of the Risk Of Malignancy 
Algorithm (ROMA). The FDA approved ROMA as a diagnostic aid in women presenting 
with a pelvic mass (Moore et al., 2009). In 2009, a 5-protein panel of biomarkers, termed 
OVA-1 (consisting of β-2 microglobulin, transferrin, apolipoprotein A-1, transthyretin 
and CA125), was FDA approved to aid in the presurgical evaluation of ovarian masses. 
Following on from this, in 2016 an OVA-1 panel with higher specificity, called OVERA, 
was approved. Despite this progress, research is ongoing to elucidate less invasive 
biomarkers with higher specificity and sensitivity which can detect OC in the early stages 




1.1.9 Molecular mechanisms of chemoresistance in ovarian cancer 
The poor survival rates associated with ovarian cancer are attributable to several 
factors, predominantly the late stage of disease at diagnosis. As discussed earlier, the 
treatment of ovarian cancer has remained largely unchanged, with surgery and 
chemotherapy still the mainstays of treatment. While clinical trials with targeted 
agents are slowly getting underway, bringing a treatment from bench to beside is a 
costly and slow process. While the vast majority of patients exhibit an excellent 
response to first line chemotherapy, a substantial number of women will experience 
recurrent refractory disease. Once the disease has relapsed, subsequent regimens tend 
to be aimed at prolonging and improving the quality of life for patients. Thus, 
elucidating the molecular mechanisms which beget chemoresistance is imperative in 
improving patient outcomes. A complex array of mechanisms have been implicated in 
OC chemoresistance, including altered expression of drug efflux pumps, survival 
signalling pathways and DNA damage responses. 
 
1.1.9.1 Alterations in drug transport and metabolism  
Multidrug resistance remains the biggest challenge faced in the management of OC. 
The overexpression of drug efflux transporters is a key resistance mechanism utilised 
by cancer cells. These pumps function by reducing the amount of chemotherapy drug 
which accumulates within a cell, reducing or abolishing the drugs activity. 
Permeability-glycoprotein (P-gp), a member of the ATP cassette binding (ABC) 
family of transporters, is one of the best studied efflux pumps, encoded by the MDR1 
gene. It can effectively expel a wide range of chemotherapy agents, including taxanes 
and platinum drugs (Leonard, Fojo and Bates, 2003). Increased expression of P-gp has 
been shown to negatively impact survival in OC patients (Sedlakova et al., 2015). 
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Copper exporters, such as ATP7A have also been demonstrated to play a role in 
platinum resistance. ATP7A sequesters platinum drugs into intracellular 
compartments thus inhibiting its interaction with nuclear DNA (Samimi et al., 2004). 
ATP7A is overexpressed in cisplatin resistant OC cell lines, and it’s overexpression in 
OC patients is associated with reduced survival (Samimi et al., 2003).  
Altered metabolism of chemotherapeutic in drugs in cancer cells can also contribute 
to resistance. Members of the cytochrome p450 family of haemoproteins, involved in 
phase one drug metabolism, catalyses the oxidation of xenobiotics, including 
chemotherapy drugs, leading to their degradation. One such member, CYP1B1 was 
found to be overexpressed in malignant versus benign tissue obtained from patients 
(Zhu et al., 2015). The same study also demonstrated that CYP1B1 expression was 
associated with paclitaxel resistance in OC cell lines, and its inhibition (using α-
naphthoflavone) sensitised the cells to paclitaxel (Zhu et al., 2015). 
 
1.1.9.2 DNA repair pathways in resistance 
Given that the primary cytotoxic agents used to treat ovarian tumours are DNA 
damaging agents, it is little surprise that DNA repair pathways play an important role 
in resistance. Of the low fidelity repair pathways, nucleotide excision repair (NER) 
and mismatch repair (MMR) have been implicated in platinum resistance. Platinum 
agents such as carboplatin and cisplatin cause inter- and intra-strand adducts to form 
on DNA. Typically, this results in a cell cycle arrest where the damage is rectified, or 
the cell undergoes apoptosis. NER uses a plethora of proteins to identify, remove and 
replace damaged nucleotides. Enhanced NER has been correlated with platinum 
resistance, specifically expression of the protein ERCC1, which complexes with XPF 
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to excise 5’ adducts (Dabholkar et al., 1994; Selvakumaran et al., 2003). MMR 
recognises and replaces mismatched or unmatched bases. As mentioned earlier, 
ovarian cancers are deficient in several MMR genes, including MLH1, which enables 
a cell to continue proliferating in the presence of a platinum agent while evading 
apoptosis (Strathdee et al., 1999)(Zeller et al., 2012).  
 
1.1.9.3 Survival Pathways and resistance  
1.1.9.3.1 PIK3/AKT and STAT3 
PIK3 is a serine/threonine protein kinase which regulates several cellular processes 
including proliferation, metabolism and growth. Aberrant activation of this pathway 
is frequent in Type 1 ovarian tumours (as described earlier) and has been shown to 
play a role in chemoresistance (Carden, 2012). Amplification of PIK3CA is evident in 
up to 40% of ovarian cancers (Huang et al., 2011). Interestingly, P53 has emerged as 
an important player in PIK3C-mediated chemoresistance. In addition to AKT, P53 
inhibits PI3K by binding to the promoter of the PIK3CA gene, thus preventing its 
transcription. In OC, wild-type P53 is found to be involved in chemoresistance through 
PI3K/AKT and XIAP. In order to combat this resistance through inhibition of 
components of the PI3K/AKT pathway, the presence of wild-type P53 is necessary 
(Abraham and O’Neill, 2014). The role of AKTs in OC has been well characterised. 
Activation of the PI3K/AKT pathway in OC cells stimulates proliferation, migration 
and invasion, and inhibits both apoptosis and autophagy. Inhibition of AKT sensitizes 
chemoresistant OC cells to cisplatin by disrupting the cell cycle, causing S and G2/M 
phase arrest (Zhang et al., 2016). Other studies have also suggested a role for AKT in 
resistance to platinum agents. Exposure to platinum induced an AKT-dependent, pro-
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survival, DNA damage response in platinum-resistant, but not platinum-sensitive 
cells. AKT translocates to the nucleus in platinum resistant cells where it is 
phosphorylated by DNA-PK. This activation of AKT inhibits platinum-mediated 
apoptosis (Stronach et al., 2011). 
Signal transducer and activator of transcription-3 (STAT3) is a transcription factor 
involved in cytokine and growth factor signalling. A study by Gyoung Jung and 
colleagues identified increased STAT3 signalling in cells resistant to platinum agents 
compared to their sensitive parental counterparts. Furthermore, a transcriptional 
regulator of STAT3 activity in ovarian cancer cells, PBX1, was identified. PBX1 is 
highly expressed in ovarian cancer and is a known effector in the NOTCH3 pathway, 
which serves to maintain stemness and promote platinum resistance. Importantly, 
PBX1 was found to be upregulated in tissue obtained from patients with recurrent 
disease when compared to primary cancerous tissues and predicted a worse outcome 
for patients following platinum treatment. Targeting the PBX1/STAT3 axis 
significantly reduced tumour growth in vivo (Jung et al., 2016). A study by Chen et 
al. (2017) has found STAT3 to be enriched in ovarian cancer stem cells, where it can 
activate WNT/β-catenin signalling through targeting of miR-92a. Combining STAT3 
inhibition with paclitaxel treatment could effectively abrogate peritoneal seeding and 
prolong survival in a mouse model of ovarian cancer (Chen et al., 2017). This signifies 
STAT3 as a potentially valuable therapeutic target, particularly as disease recurrence 
is the major clinical challenge faced when treating ovarian cancer. Targeting the 
cancer stem cell population via STAT3 inhibition could prove to be an effective 




1.1.9.3.2 Autophagy and chemo-resistance 
Autophagy is an evolutionally conserved process, which is upregulated in response to 
various types of stressful stimuli. By upregulating this process, cells can adapt to and 
recover from a multitude of cellular insults including nutrient depletion, accumulation 
of protein aggregates, endoplasmic reticulum stress and DNA damage. This has 
important implications when discussing chemoresistance. Previous studies have 
implicated a role for autophagy in enabling cancer cells to recover from 
chemotherapeutic insult (Wang and Wu, 2014; Pagotto et al., 2017). In fact, the DNA 
damage response can directly induce autophagy. Ataxia-telangiectasia mutated 
(ATM) and ATM and Rad3-related (ATR) have been shown to activate TSC2 via the 
LKB1/AMPK pathway and inhibit mTOR1 (Tripathi et al., 2013). This inhibition of 
mTOR leads to the activation of the autophagy pathway. The cisplatin resistant ovarian 
cancer cell line A2780cp was found to have elevated levels of autophagy compared to 
its sensitive counterpart, and blockade of autophagy via the chemical inhibitor 3-MA 
or Beclin-1 knockdown could effectively re-sensitise the cells to cisplatin (Bao et al., 
2015). Cancer stem cells (CSCs) are at the forefront of studies into treatment resistance 
across a broad spectrum of cancers. A key hallmark of CSCs is their chemoresistance, 
which makes them extremely difficult to eliminate. Thus, it has been suggested that 
this subpopulation of cells are responsible for tumour regrowth and clinical relapse. 
An interesting study by Pagotto et al. (2017) isolated a CD44+ CD117+ positive 
putative cancer stem cell subpopulation from epithelial ovarian cancer ascites. This 
subpopulation of CSCs was found to have higher levels of basal autophagy when 
compared to its non-stem cell counterparts. CSCs have a unique ability to form 
spheroids in-vitro. The spheroid forming capacity of the CD44+ CD117+ positive 
CSCs was greatly reduced following treatment with carboplatin plus chloroquine, an 
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autophagy inhibitor (Pagotto et al., 2017). This effect was not recapitulated with either 
compound alone, implying a role for autophagy in CSC carboplatin resistance.  
 
1.2 Cell death mechanisms in cancer  
1.2.1 Apoptosis 
The term ‘apoptosis’ was first coined by Kerr et al. (1972) to describe a process by 
which cells trigger their own destruction in response to certain stimuli (Kerr, Wyllie 
and Currie, 1972). Since its discovery it has been become one of the most studied 
biological processes, with functions ranging from embryonic development, immune 
system maintenance and normal cell homeostasis. Conversely, its deregulation has 
been implicated in a number of pathological conditions including autoimmune disease 
and cancer (Singh, Letai and Sarosiek, 2019). 
Several morphological features enable the identification of cells undergoing apoptosis. 
First, cells shrink, and the chromatin condenses. The cell membrane begins to bulge 
and bleb, before the cell finally breaks into apoptotic bodies, which can then be cleared 
via phagocytosis.  
Apoptosis is elicited via two main pathways, the intrinsic pathway, stimulated by 
intracellular stimuli including DNA damage and nutrient depravation, and the 
extrinsic pathway triggered via extracellular stimuli such as signals from cytotoxic T 
cells. Both pathways converge with the activation of executioner caspases. The 
intrinsic pathway is mediated via the mitochondria. Apoptotic stimuli result in the 
activation of BH-3 only proteins, which in turn activate BAX and BAK. BAX and 
BAK become oligomerised within the mitochondrial outer membrane, leading to 
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mitochondrial outer membrane permeabilization (MOMP) (Lopez and Tait, 2015). 
The release of mitochondrial proteins, notably cytochrome c, second mitochondria-
derived activator of caspase (SMAC) and Omi, serve to activate caspases. Cytochrome 
c is an integral component of the apoptosome, formed in conjunction with pro-caspase 
9, dATP and APAF-1 (apoptotic protease-activating factor-1). This complex converts 
pro-caspase-9 to the active caspase-9, which in turn activates the executioner caspases-
3 and -7 (Hassan et al., 2014)(Green and Llambi, 2015). 
The extrinsic pathway is triggered via the binding of a cell death ligand to the tumour 
necrosis factor (TNF) family of death receptors. Well characterised ligand-receptor 
pairs include TNF (Tumour Necrosis Factor) which binds the TNFR1 (TNF-Receptor 
1), FasL (Fas Ligand or CD95) which binds the Fas receptor (FasR or Apo1) and 
TRAIL (TNF-related apoptosis-inducing ligand) which binds DR4 (Death Receptor 
4) or DR5 (Death Receptor 5). Following receptor stimulation, an adaptor protein, 
such as Fas-associated death domain (FADD) or TNF receptor-associated death 
domain (TRADD) is recruited, followed by pro-caspase-8 and -10 forming the death-
inducing signaling complex (DISC). The pro-caspases-8 and -10 are activated by the 
DISC, leading to the subsequent activation of the effector caspases -3 and -7 (Pfeffer 
and Singh, 2018). The extrinsic pathway can activate the intrinsic mitochondrial 
pathway via the BH3-only protein Bid. Bid is cleaved by caspase-8 activated at the 
DISC to form tBid, which translocates to the mitochondrial membrane leading to its 

























1.2.2 Necrosis and Necroptosis  
Necrosis is derived from the Greek expression ‘the stage of dying, the act of killing’. 
Necrotic cells can be distinguished morphologically by early rupturing of the plasma 
membrane, dilation of cytoplasmic organelles and visible swelling of the cells 
(Golstein and Kroemer, 2007). Necrosis was thought to be an uncontrolled process; 
however evidence suggests that its occurrence and progression may be tightly 
regulated. It has also been shown that inhibition of certain proteins involved in 
apoptosis and autophagy can induce necrotic cell death (Golstein and Kroemer, 2007).  
Figure 1.4: Schematic illustration of the apoptosis pathways. Representative 
image of the intrinsic and extrinsic apoptosis pathways, which converge with the 
activation of the executioner caspases -3 and -7. 
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Necroptosis is a form of regulated cell death (RCD), triggered in response to intra- and 
extra-cellular stress stimuli, and sensed via death receptors, including FAS and 
TNFR1, pathogen recognition receptors (PRRs) including TLR3,TLR4 and Z-DNA 
binding protein 1 (ZBP1) - also known as DNA activator of Interferon (DAI) (Dhuriya 
and Sharma, 2018) (Galluzzi et al., 2014). In the presence of caspase-8, RIPK1 and 
RIPK3 are inactivated, leading to apoptosis. In the absence of caspase, RIPK1 and 
RIPK3 remain active and form a complex called ‘the necrosome’ (Seifert and Miller, 
2017). Following receptor stimulation, RIPK3 is activated by RIPK1, which in turn 
phosphorylates MLKL (Mixed Lineage Kinase-domain Like), generating MLKL 
oligomers which translocate to the plasma membrane and trigger its permeabilization 
(Quarato et al., 2016). 
 
1.2.3 Mitotic Catastrophe 
Mitotic catastrophe is a regulated mechanism that functions to attenuate the survival 
of cells that are unable to complete mitosis. Failure to complete mitosis can be due to 
a number of factors, including DNA damage, failures in mitotic machinery or 
defective mitotic checkpoints (Vitale et al., 2011). According to the Nomenclature 
Committee on Cell Death (NCCD), mitotic catastrophe itself is not a form of regulated 
cell death per se. The term mitotic death, a specific from of cell death, eliciting an 
intrinsic apoptotic process driven by mitotic catastrophe, should be used (Galluzzi et 
al., 2018). Mitotic catastrophe can be identified morphologically by marked nuclear 
changes, including micronucleation and/or multinucleation, both consequences of 
aberrant chromosomal segregation (Vitale et al., 2011). 
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1.2.4 Immunogenic Cell Death 
Each day, millions of cells are turned over, primarily via apoptosis, to maintain whole 
body homeostasis. To avoid detection by the immune system and avoid a catastrophic 
autoimmune response, this process is confined within membranous bodies which are 
then rapidly cleared via phagocytosis (Serrano-del Valle et al., 2019). In comparison 
to necrosis, typically considered to be immunogenic, apoptosis has long been thought 
to be a poorly immunogenic process. The term immunogenic cell death (ICD) is used 
to describe a cell death process resulting in the release of DAMPS (damage associated 
molecular patterns). ICD has the ability to transform dying or dead cells into 
‘vaccines’, enabling an immune response to be mounted in response to cancer-derived 
neo-epitopes (Galluzzi et al., 2017). To date, a small number of anti-cancer therapies 
including the chemotherapy oxaliplatin, along with radiotherapy, are bona fide ICD 
inducers (Garg et al., 2017) (Adkins et al., 2014). Such inducers trigger stress 
responses, including ER stress, ROS generation, autophagy, and unfolded protein 
response (UPR), critical for the trafficking and release of DAMPS. During ICD, dying 
cells expose ‘find me signals’ such as the heat shock proteins (HSP) 70 and 90, and 
calreticulin (CRT), recognised by CD91 macrophage receptors facilitating the 
engulfment of dying cells (Spisek et al., 2007) (Krysko, Ravichandran and 
Vandenabeele, 2018). Dying cells also release several DAMPs. The secretion of 
adenosine triphosphate (ATP) attracts monocytes via binding the P2Ys purinoceptor 
(Martins et al., 2009). During late apoptosis, high mobility group box 1 (HMGB1) is 
released which binds TLR2 and TLR4 to promote DC pro-inflammatory cytokine 
production and assists in antigen presentation to cytotoxic T cells (Saenz et al., 




1.3 Molecular regulation of Autophagy 
1.3.1 What is autophagy? 
Autophagy is an evolutionarily-conserved process, used to preserve cell homeostasis 
in response to stressful stimuli such as nutrient deprivation or damage to organelles. 
Derived from the Greek for self (auto) and eat (phagein), autophagy directly translates 
to ‘eat oneself’. The process involves the generation of a double membrane bound 
vesicle, termed an autophagosome, which engulfs cargo and fuses with a lysosome to 
degrade it’s intravesicular cargo. Years of research into autophagy have revealed it to 
be a regulated, context-dependent process, with biological roles beyond those of 
survival and homeostasis. Autophagy has been shown to play a key role in 
neurodegenerative diseases such as Alzheimer’s, in immune responses and cancer. 
The role of autophagy as a key biological process with implications in human health 
and disease was highlighted with the awarding of the 2016 Nobel prize in physiology 
or medicine to Yoshinori Ohsumi for his work on autophagy mechanisms in yeast.  
 
1.3.2 Types of autophagy 
Different types of autophagy exist, varying in how they uptake cargo, but all of which 
cumulate in lysosomal degradation. The most well characterised form of autophagy is 
termed macro-autophagy. In the literature, macro-autophagy is termed autophagy 
unless otherwise stated. This involves the de-novo generation of an autophagosome 
which sequesters its cargo for transport to the lysosome. In contrast to macro-
autophagy, micro-autophagy circumvents the need for an autophagosome by directly 
sequestering cargo into the lysosome for degradation. This type of autophagy is 
generally non-selective, although there are some exceptions. Chaperone-mediated 
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autophagy (CMA) is highly selective, whereby cargo labelled with a unique 
pentapeptide motif (KFERQ) are recognised by HSP70 and transported to the 
lysosome. Here, HSP70 interacts with the lysosomal membrane protein LAMP-2A to 
translocate cargo into the lysosome for hydrolytic degradation (Cuervo and Wong, 
2013). 
 
1.3.3 Autophagic vesicle formation and trafficking 
1.3.3.1 Formation of the autophagosome  
In mammalian cells, autophagosome formation, initiated by a stimulus such as nutrient 
deprivation, is generally accepted to occur on the endoplasmic reticulum membrane 
via the formation of an Omegasome. Phagophore formation begins when the ULK1/2 
kinase complex (consisting of ULK1, ULK2, ATG13, FIP200 and ATG101) becomes 
activated. Activation of the ULK1/2 complex results in its translocation to the ER, at 
a site denoted by ATG9 (Yu, Chen and Tooze, 2017). Next, the class III 
phosphatidylinositol 3-kinase (PtdIns3-kinase) complex is recruited, resulting in the 
generation of ER domains or the Omegasome, containing PtdIns3P. These ER 
domains are highly curved areas, favouring the recruitment of the PtdIns3K complex 
I, facilitating changes to the lipid structure to form the phagophore. This curved shape 
also serves to aid the clustering of PtdIns3P,  allowing the recruitment of WIPI2B and 
in turn the recruitment of the ATG12–ATG5-ATG16L1 E3-like complex (Dooley et 
al., 2014). Besides the endoplasmic reticulum, organelle membranes, such as the 
mitochondrial membrane, have been shown to play a role in autophagosome 
formation, where ATG components such as ATG14 and the Q-snare protein STX17 
accumulate. The Golgi is also a purported site of origin for autophagosomes during 
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non-canonical autophagy (see later). The so called ATG9 compartment, an 
evolutionarily conserved cluster of vesicles, can be mobilised under stressful 
conditions and fuse with the growing phagophore (Mari et al., 2010). 
 
1.3.3.2 Autophagosome elongation  
Following exposure to a stressful stimulus, ULK proteins are phosphorylated and 
undergo a  conformational change to phosphorylate Atg13 and FIP200 (Chan, Longatti 
et al., 2009; Jung, Jun et al., 2009). Activation of the class III PI3K complex 
(composed of vps34, vps15, beclin-1 and Atg14) then occurs following 
phosphorylation of AMBRA1 by the ULK/Atg1 complex. The PI3K complex controls 
vesicle elongation via recruiting two essential ubiquitin-like conjugation systems to 
the phagophore in a sequential manner. Firstly, the Atg12-Atg5 complex is formed 
when Atg12, activated by Atg7 (E1-like activating enzyme), is conjugated to Atg5 by 
Atg10 (E2-like conjugating enzyme). This complex interacts with Atg16 to form a 
tetrameric Atg12-Atg5-Atg16 complex. This structure then attaches to the 
phagophore, resulting in its expansion around target substrates (Geng and Klionsky, 
2008).  
The Atg8-PE conjugation system is the second ubiquitin-like mechanism required for 
autophagosome formation. Atg8 is a homologue of mammalian LC3 (microtubule-
associated protein 1 light chain 3), which resides in the cytosol under normal 
conditions and is recruited to the phagophore in response to stressful stimuli. The c-
terminus of LC3 I is cleaved by Atg4 to expose a glycine residue, which is 
subsequently conjugated to phosphatidylethanolamine (PE) in the autophagosome 
membrane bilayer to form LC3II (Glick, Barth and Macleod, 2010). The presence of 
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LC3II on the mature double membraned autophagosome is considered one of the most 
reliable markers of autophagy. LC3II is reported to play roles in membrane tethering 

















Figure 1.5: Schematic depiction of the autophagy ubiquitin-like conjugation 
systems, the Atg8 system and the Atg12 system. During the Atg8 system, Atg8 is 
cleaved by Atg4, transferred on to Atg7(E1) and Atg3(E2) and binds with is 
substrate phosphatidylethanolamine (PE). The Atg8-PE conjugate functions in the 
autophagosome membrane. Atg8-PE can then be deconjugated by Atg4, and Atg8 
is recycled. Atg12 is activated by Atg7 (E1) and conjugated to Atg5 by Atg10(E2). 
The Atg5-12 complex interacts with Atg16 to form the Atg12-Atg5-Atg16 
complex, which aids phagophore expansion.  
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1.3.3.3 Autophagosome/Lysosome tethering and fusion  
To enable the mature autophagosome to fuse with a lysosome, they need to be in close 
proximity. Stressful stimuli, such as starvation, results in a clustering of lysosomes in 
the perinuclear region of the cell. Microtubules, particularly the microtubule motor 
dynein, facilitate the transport of autophagosomes to perinuclear lysosomes. The 
HOPs complex, consisting of vacuolar protein sorting 11 (VPS11), Vps16, VPS18, 
Vps33A, VPS39, and Vps41, play a core role in tethering (Seals et al., 
2000)(Wurmser, Sato and Emr, 2000). Additionally, RAB proteins, particularly Rab7, 
are small GTPases which interact with the HOPS complex and bind to other membrane 
anchored proteins, thus allowing the fusion of opposing membranes. Another key 
aspect to autophagosome/lysosome fusion is the generation of a SNARE complex. The 
force necessary to facilitate adjacent membranes fusing is driven by the assembly of 
an R-SNARE and a Q-SNARE protein into a trans-snare complex. In mammalian 
cells, the Q-SNARE protein STX17 interacts with the R-SNARE VAMP8 to mediate 








Figure 1.6: Illustration of the autophagic pathway, from generation of the 
phagophore, elongation and completion of the autophagosome, to fusion with the 




1.3.4 Signalling pathways regulating autophagy  
1.3.4.1 PI3K/AKT/mTOR signalling 
When is a cell is not under nutritive stress and has a plentiful supply of nutrients and 
amino acids, inducible autophagy is supressed via activation of the class I 
PI3K/AKT/mTOR pathway. In contrast, under conditions of nutrient depravation, the 
PI3K/AKT/mTOR pathway is deactivated, resulting in autophagy activation. 
The mechanistic target of rapamycin (mTOR) is an evolutionarily conserved 
serine/threonine protein kinase, belonging to the PI3K-related kinase family (PIKK). 
mTOR responds to extracellular and intracellular stimuli, including growth factors, 
nutrients, energy status and cellular stress. mTOR and its associated proteins form two 
distinct complexes, mTORC1 and mTORC2. The two complexes differ in their 
composition, activation and also in their sensitivity to rapamycin. While mTOR in 
both complexes interacts with DEPTOR and mLST8, only mTORC1 interacts with 
RAPTOR and PRAS40, while mTORC2 interacts with rapamycin-insensitive 
companion of mTOR (RICTOR) and mSIN1 (H. Yang et al., 2013)(P. Liu et al., 
2015).  
mTORC1 activation involves the guanosine triphosphatases (GTPases) RAG and 
RHEB (Ras homolog enriched in brain). RAG exists as a heterodimer attached to the 
lysosome membrane and is activated in the presence of nutrients (Bar-Peled et al., 
2012). Following RAG activation, mTORC1 is recruited to the lysosome membrane 
where it meets RHEB. RHEB activation is negatively controlled by tuberous sclerosis 
1 and 2 (TSC1/2). The phosphorylation of TSC1/2 is a key regulatory step dictating 
mTOR activation in response to upstream signals. Growth factor induced PI3K/AKT 
signalling activates TSC2 via S939/T1462 phosphorylation, resulting in RHEB 
activation and thus mTORC1 activation. In contrast, nutrient deprivation activates 
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adenosine monophosphate protein kinase (AMPK), leading to TSC2 phosphorylation 




AMP-activated protein kinase (AMPK) is a metabolic sensor which plays a key role 
in maintaining energy homeostasis by responding to stress factors such as exercise, 
ischemia, redox imbalance changes in cellular pH and nutrient deprivation. All of 
these stressors result in the depletion of intracellular ATP levels, with the subsequent 
increase in the ratio of AMP:ATP resulting in the activation of AMPK (Yung, Ngan 
and Chan, 2016). AMPK is characterised by a catalytic α-subunit and regulatory β/γ 
subunits, and upon activation is phosphorylated at Thr-172 within the activation 
domain of the α-subunit by the kinases LKB1 and CaMKKβ (Yung, Ngan and Chan, 
2016). The role of AMPK in autophagy initiation is well established. Under conditions 
of glucose starvation, AMPK activates Ulk1, a component of the autophagy 
machinery. The activation of AMPK can also phosphorylate and activate TSC2 which 
in turn can suppress mTORC1 and activate autophagy (Jang et al., 2018). It is only 
recently that AMPK has been shown to contribute to autophagosome maturation and 
lysosomal fusion. Knockout of the AMPK subunit AMPK α1 under starvation 
impaired autophagosome formation, with LC3-puncta positively stained with LAMP1 
observed in few AMPK α1 knockout cells. Impairment of AMPK signalling also 
resulted in the repression of autophagic flux (Jang et al., 2018).      




1.3.4.3 TFEB (transcription factor EB)  
Transcription factor EB (TFEB) is a master regulator of autophagy, which is 
responsible for the transcription of genes involved in autophagy and lysosome 
biogenesis (Sha et al., 2017). After phosphorylation by mTOR, TFEB is inactive and 
remains in the cytosol. Conversely, inhibition of mTORC1 results in 
dephosphorylation of TFEB, which becomes active and translocates to the nucleus 
where it upregulates transcription of its target genes (Sha et al., 2017). A recent study 
has identified a role for the ubiquitin-proteasome pathway in the regulation of 
autophagy and lysosomal functions through its regulation of TFEB activity. A 
chaperone-dependent E3 ubiquitin ligase, STUB1 (STIP1 homology and U-Box 
containing protein 1), has been shown to preferentially target inactive phosphorylated 
TFEB for degradation by the ubiquitin-proteasome pathway. An accumulation of 
phosphorylated TFEB in STUB1-deficient cells results in decreased autophagy and 
mitochondrial biogenesis (Sha et al., 2017). Therefore, the ubiquitin-proteasome 
pathway is involved in the regulation of autophagy and lysosomal functions through 
its regulation of TFEB activity.  
 
1.3.4.4 P53 
The autophagy and p53 pathways are functionally linked, where autophagy suppresses 
p53 and in turn, p53 activates autophagy (White, 2016). It is believed that the 
activation of autophagy is part of the ‘protective function’ of p53 in response to 
various stresses such as DNA damage, metabolic and oxidative stress. The absence of 
p53 itself may also create stress, resulting in the activation of autophagy. The 
regulation of autophagy through nuclear transactivation occurs through several 
pathways. These include the pro-autophagic factors TSC2, PTEN and AMPK, with 
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further signalling then mediated via mTOR inhibition (Mrakovcic and Frohlich, 2018). 
A more direct method of autophagy activation by p53 is through the upregulation of 
DRAM (damage-related autophagy modulator), which represents a lysosomal protein 
that can interfere with various stages of autophagosome formation (Mrakovcic and 
Frohlich, 2018). In addition, the downregulation of BCL-2, BCL-xL and MCL-1 or 
upregulation of BAX, BAD, BNIP3 or PUMA by p53 releases Beclin 1 and initiates 
autophagy. The cellular location of p53 also plays a crucial role in autophagy, with 
p53 proteins located in the cytosol having an inhibitory effect on autophagy. The 
mechanism by which cytosolic p53 exerts an inhibitory effect on autophagy remains 
to be fully elucidated. FIP200 (ATG17) has been identified as a cytoplasmic binding 
partner of p53 which may aid in the negative regulation of autophagy (Morselli et al., 
2011). 
    
1.4 Selective Autophagy 
Originally thought to be a bulk degradative process, research into autophagy has 
identified highly selective processes, including but not limited to, mitophagy, 
nucleophagy, xenophagy and aggrephagy. This selectivity is in part mediated by 
specific adaptor proteins – which selectively bind to cargo – and to LC3. 
 
1.4.1 Mitophagy  
Mitophagy is one of the best characterised types of selective autophagy. It serves to 
eliminate damaged mitochondria from the cell. Targeting of damaged mitochondria 
for elimination via autophagy involves two key genes, PINK1 and PARK2. When 
mitochondrial protein transport is disrupted, PINK1 is stabilised on the outer 
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mitochondrial membrane in a complex of TOM proteins. Stabilisation of PINK results 
in phosphorylation of pre-existing ubiquitin molecules on the mitochondrial surface, 
to which PARKIN (an E3 ligase) is recruited and tethered to the membrane where it 
is then phosphorylated by PINK1 (Youle and Narendra, 2011). The adaptor proteins 
NDP52 and OPTN were found to be required for mitophagy, binding the ubiquitinated 
cargo and linking them to the autophagosome for degradation (Heo et al., 2015). 
BNIP3 (BCL2 and adenovirus E1B 19 kDa-interacting protein 3) and BNIP3-like 
(BNIP3L), also referred to as NIX, have been reported to induce mitophagy in 
response to hypoxia. Screening for autophagy receptors revealed the ability of NIX to 
interact with LC3 and GABARAP via its LC3 interaction region (LIR) motif. 
Competition by BNIP3 or NIX for Bcl-2 binding may liberate Beclin 1 from inhibitory 
BCl-2 complexes, resulting in autophagy activation (Bellot et al., 2009). A third 
mechanism proposed for BNIP3 in autophagy activation is via mTOR inhibition. 




First described in yeast, nucleophagy describes the sequestration and degradation of 
nuclear material. Termed ‘piecemeal autophagy of the nucleus’ in yeast, small pieces 
of the nuclear envelope are engulfed via invaginations of the vacuolar membrane and 
degraded by luminal hydrolases (Roberts et al., 2003). Degradation of whole nuclei 
has also been reported in the fungus Aspergillus Oryzae (Rello-Varona et al., 2012). 
Previous studies have evidenced a role for autophagy in the maintenance of genomic 
integrity. Micronuclei, damaged DNA arising from the mis-segregation of 
chromosomes via a cell cycle perturbation, are tagged with p62 and subject to 
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degradation by autophagosomes (Rello-Varona et al., 2012). Interestingly, these 
micronuclei are positive for Ku70 and RAD51, markers of DNA repair, implying these 
micronuclei tried and failed to repair their DNA (Erenpreisa et al., 2002)(Erenpreisa 
et al., 2011). As demonstrated by Erenpreisa et al. (2011), micronuclei can re-join the 
main nucleus, where they can participate in DNA repair. Failure to repair appears to 
trigger their pinching away from the nucleus, where nucleophagy is activated. 
Autophagy has also been shown to degrade chromatin during cellular senescence. 
Cytoplasmic chromatin fragments arise during cell senescence, where chromatin 
pieces bud off from the nucleus, in a form of ‘terminal cell-cycle arrest’(Dou et al., 
2017). During oncogene induced cellular senescence, such as RAS activation, LC3 
binds to lamin binding domains present on chromatin (Dou et al., 2015). Lamin B1 
and associated histones shuttle from the nucleus to the cytoplasm for degradation via 
lysosomes. Attenuation of the interaction between LC3 and lamin B1, or indeed 
inhibition of autophagy, prevents lamin loss thus mitigating oncogene induced 
senescence (Dou et al., 2015). 
 
1.4.3 Aggrephagy 
Aggrephagy describes the elimination of ubiquitinated and aggregated proteins by 
macroautophagy. Protein aggregates form when misfolded proteins are not dealt with 
by chaperons and the ubiquitin-proteasome system (UPS). The ubiquitination of 
misfolded proteins is a key feature enabling the selection and degradation of protein 
aggregates via aggrephagy. Several receptors in mammalian cells, which possess LC3 
interaction regions (LIRs)  and a ubiquitin binding domain, facilitate the interaction 
between LC3 members and ubiquitinated substrates (Lamark and Johansen, 2012). 
The histone deacetylase HDAC6, p62 and dynein all play critical roles in aggresome 
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formation. HDAC6 can bind to polyubiquitinated misfolded proteins, along with 
dynein motors, allowing the transport of misfolded proteins to the aggresome 
(Kawaguchi et al., 2003). BCL-2-associaated athanogene 3 (BAG3), in conjunction 
with the chaperones HSP70 and HSPB8, and p62, targets aggregated proteins for 
autophagic degradation (Stürner and Behl, 2017). 
 
1.5 Other forms of autophagy 
1.5.1 Non-canonical autophagy  
It is now clear that variations on this macroautophagic pathway exist. The typical non-
canonical pathway described differs from traditional autophagy only in that it is 
independent of Beclin 1. A second type of non-canonical autophagy, termed Atg 5/ 7 
independent autophagy, relies on Beclin 1, but as the name infers, is independent of 
Atg5 and Atg7. Unlike the other forms of autophagy, this pathway does not require 
lipidation of LC3 on the mature autophagosome. Instead, Rab9-positive vesicles fuse 
with lysosomes to degrade intra-vesicular cargo. This type of autophagy was first 
described in ATG5 null MEFs, which could still form autophagosomes following 
treatment with etoposide, a DNA damaging agent (Arakawa et al., 2017). Another key 
feature which distinguishes Atg5/7-independent autophagy from the Beclin 1 
independent and conventional autophagy pathways is the origin of the autophagosome 
membrane components. While subject to some debate, the ER is generally accepted to 
be involved in the generation of autophagosomes. Double-FYVE-containing protein 
1, an ER localised protein, was found on the surface of pre-autophagosome structures 
termed “omegasomes” (Axe et al., 2008). Mitochondrial and plasma membranes have 
also been reported as origin material for autophagosome generation (Tooze and 
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Yoshimori, 2010). In contrast to the multiple sources of membrane material reported 
in conventional autophagy, the Atg5/7-independent pathway appears to derive its 
source material exclusively from the Golgi. This is supported with key observations 
made by Nishida et al. (2009), where autophagic vacuoles were almost always located 
proximal to the Golgi, while autophagosomes and autolysosomes displayed trans-
Golgi proteins. Golgi ministack formation was always found to precede 
autophagosome generation, and most importantly, the depletion of Golgi proteins 
inhibited this non-canonical pathway, but not conventional autophagy (Nishida et al., 
2009). The lipidation of LC3 on the mature autophagosome in conventional autophagy 
does not occur in this non-canonical pathway. The GTPase Rab9, which traffics 
proteins from late endosomes to the Golgi membrane, was demonstrated to be critical 
in the formation of isolation membranes. GFP-Rab9 was shown to be colocalised with 
autolysosomes in etoposide treated ATG5 deficient MEFs. siRNA knockdown of 
Rab9 decreased the number of autophagosomes and increased the number of isolation 
membranes, indicating a role for Rab9 in the elongation and closure of isolation 
membranes. In terms of the biological role of non-canonical autophagy, further studies 
are required. However, it has been shown to play a role in mitochondrial clearance 
during pluripotent stem cell differentiation, and like conventional autophagy, can be 
induced in response to DNA damage (Ma et al., 2015)(Nishida et al., 2009). We are 
the first to investigate a potential role for non-canonical autophagy in OC cells in 

























Figure 1.7: Schematic outlining the different macroautophagic pathways, which 
vary in the proteins involved but all culminate with lysosome degradation  (A) 
conventional macroautophagy, which utilises Beclin 1 and Atg5, with lipidated 
LC3 found on the mature autophagosome (B) the non-canonical autophagy 
pathway differs from canonical autophagy in that Beclin 1 is not required for 
initiation (C) the Atg5/7-independent pathway requires Beclin 1 for initiation, but 
unlike the previous pathways described, does not utilise Atg5 or Atg7 for 
conjugation. The Golgi is an exclusive membrane source for autophagosome 
generation which occurs when late endosomes fuse with isolation membranes 
(derived from the trans-Golgi cisternae). Rab9 is required to facilitate the extension 




1.5.2 LC3-associated phagocytosis  
As mentioned in section 1.5.1 above, various non-canonical functions for autophagy 
exist which are distinct in their mechanisms and functions. One such function is LC3-
associated phagocytosis (LAP), which is involved in immune regulation and disease. 
Unlike canonical autophagy, LAP is not dependent on the AMPK-mTORC1-ULK1 
pathway and does not respond to nutrient depletion or intra-cellular stress (Heckmann 
and Green, 2019). The hallmark of LAP is conjugation of LC3 to the phagosome 
membrane, and as such, the activation stimulus occurs from the cell exterior upon 
phagocytosis. Surface receptors including pattern recognition receptors (PRR), Toll-
like receptors (TLR) and immunoglobulin receptors (IgG) can activate LAP, however 
it remains unclear how these interactions lead to the recruitment of LAP regulators to 
the phagosome.  
LAP is unique in three aspects: it is characterised by a single membrane phagosome; 
the P13KC3 complex involved in LAP contains UVRAG and RUBCN which is unique 
and indispensable; and an intermediate stage requiring the production of ROS 
(reactive oxygen species) is necessary for LAP, prior to LC3 lipidation but subsequent 
to P13KC3 assembly. NOX2 is a protein complex which associates with the 
phagosome membrane whose activity is also required to recruit the LC3 conjugation 
machinery. Evidence is also emerging which suggests LAP differs in LC3 lipidation, 
with a rapid rate of LC3 lipidation observed after sealing of the phagosome membrane 
(Heckmann and Green, 2019).  
In terms of its physiological effects, LAP has been shown to play an important role in 
regulating the immune system. LAP is obligatory for the immunologically silent 
process of efferocytosis to occur, by preventing the secretion of pro-inflammatory 
cytokines. Efferocytosis describes the process whereby apoptotic cells are engulfed by 
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macrophages to prevent an autoimmune response. Phosphatidylserine (PtdSer) on the 
surface of dead cells interacts with TIM4 and triggers LAP (Martinez et al., 2011).  In 
the tumour microenvironment, LAP can prevent the mounting of an effective anti-
tumour immune response, via the secretion of anti-inflammatory cytokines. LAP 
activation in tumour associated macrophages (TAMs) polarizes them toward a pro-
tumour M2 phenotype, resulting in impaired T lymphocyte function and immune 
tolerance (Cunha et al., 2018). 
 
 1.6 Unconventional protein secretion  
1.6.1 Secretory autophagy 
The majority of secreted eukaryotic proteins are tagged with N-terminal peptides, 
permitting entry to the ER, where they follow a defined secretory pathway through the 
Golgi and are released via secretory vesicles at the plasma membrane [reviewed in 
(Cotzomi-Ortega et al., 2018)]. Unconventional secretion describes the extracellular 
secretion of proteins which lack signal peptides and thus are unable to enter the ER.  
Secretory autophagy can be classed as a form of unconventional secretion. Secretory 
autophagy describes the process by which the canonical autophagy pathway 
participates in the secretion of proteins via transporting them within an 
autophagosome to the plasma membrane, to multivesicular bodies (MVB) or secretory 
lysosomes for extracellular expulsion. The prototypical cargo for autophagic secretion 
is IL-1β. IL-1β was found to translocate to the lumen of a vesicle carrier, facilitated 
by heat shock protein HSP90, which later becomes a phagophore, then an 
autophagosome or fuses with them. Following generation of the double membrane 
autophagosome, IL-1β  localises between the inner and outer membranes (M. Zhang 
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et al., 2015). This can explain how IL-1β escapes autolysosomal degradation and can 
be transported to the plasma membrane, where the IL-1β containing autophagosome 
can fuse with the plasma membrane, or via an MVB first. Rab8a, which regulates 
polarized membrane trafficking and plasma membrane fusion of vesicular carriers, 
was reported to regulate the initiation of secretory autophagy and the release of IL-1 
β (Dupont et al., 2011).  
Disruption of degradative autophagy may divert autophagosomal organelles into the 
secretory autophagy pathway. This is supported by a study where pharmacological 
inhibition of autophagosome-lysosome fusion with Bafilomycin A1 could enhance α-
synuclein secretion, a constituent of protein aggregates known as Lewy bodies, while 
knockdown of Atg5 could attenuate secretion. Likewise, increased microtubule 
acetylation, caused by downregulation of HDAC6, resulted in decreased 
autophagosome lysosome fusion and increased α-synuclein secretion (Ejlerskov et al., 
2013).  
 
1.6.2 Exosome secretion 
Exosomes are nano-sized extracellular vesicles, less than 150nm in diameter, which 
originate from the endocytic pathway. During multivesicular body (MVB) formation, 
cells internalise macromolecules, membranes and fluids via invagination of the plasma 
membrane to form intraluminal vesicles (ILVs). The ESCRT machinery, consisting of 
four protein complexes ESCRT-o, -I, -II, -III and the AAA ATPase Vps4 complex, 
play an important role in formation of ILVs and sorting of cargo (Baixauli, López-
Otín and Mittelbrunn, 2014). For exosomes to be released, ILVs within MVBs must 
be transported to and fuse with the plasma membrane (Alenquer and Amorim, 2015). 
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Exosomes contain a mixture of both soluble and membrane bound proteins, DNA and 
microRNA. Uptake of cargo can occur in a bulk nonselective manner or selectively 
via ubiquitination of substrates (Smith, Jackson and Schorey, 2015).  
Tumour derived exosomes have been shown to play a significant role in facilitating 
cell to cell communication, immune regulation and metastatic spread. Exosomes 
derived from ovarian cancers contain a host of bioactive molecules which favour 
tumour progression and treatment resistance. Annexin A3 can be detected within 
exosomes derived from cisplatin resistant OC cell lines and in tumour samples from 
platinum resistant OC patients  (Yin et al., 2012) (Yan et al., 2010).  Human peritoneal 
mesothelial cells (HPMCs) treated with ovarian cancer-derived exosomes had a 
significantly enhanced invasion capacity, via exosomal transfer of CD44, enhancing 
the secretion of matrix-metalloprotinease-9 (MMP-9). Ovarian cancer derived 
exosomes have also been found to contain a range of miRNA which contribute to drug 
resistance. MiR-21, found in exosomes isolated from OC cancer associated adipocytes 
and fibroblasts, is transferred to the cancer cells where it can supress apoptosis and 
confer chemoresistance (Au Yeung et al., 2016). MicroRNA have also been 
implicated in mediating crosstalk between exosome release and autophagy, resulting 
in a phenomenon termed bystander autophagy. Bystander autophagy describes the 
activation of autophagy in distant cells which have not directly received treatment. 
Exosomes derived from irradiated brain tissue were found to contain high levels of 
miR-7. Following tail vein injection into mice, these exosomes travelled through the 
blood stream to the lung, where upon internalisation, could enhance the expression of 
autophagy markers LC3B and Beclin 1 via miR-7 inhibition of Bcl-2 (Cai et al., 2017). 
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1.7 Autophagy and Cancer 
When describing the complex dynamics between autophagy and tumour biology, the 
phrase ‘double edged word’ is frequently and aptly used. The role of autophagy in the 
cancer setting is dependent on a range of factors, including tumour type, stage and the 
genetic landscape. Autophagy has primarily evolved as a cytoprotective mechanism, 
to enable a cell to maintain homeostasis. As our knowledge of this process expands, it 
is evident that cancer cells can use this process to their advantage, meaning targeting 
autophagy could be clinically useful. 
 
1.7.1 Autophagy as a tumour suppressor 
Knockout of BECN1, which increased spontaneous tumour formation in mice, was 
the first indication of a tumour suppressive function of autophagy (Yue et al., 2003). 
A key tumour suppressive function of autophagy is its ability to remove reactive 
oxygen species (ROS). ROS act as key drivers of mutagenesis via activation of 
oncogenes and driving inflammation (Goetz and Luch, 2008). Additionally, 
mitochondria are key producers of ROS, so their elimination via mitophagy plays a 
crucial role in preventing oncogenesis. Conversely, a lack of autophagy can fuel 
malignant progression if ROS are not removed. Autophagic removal of protein 
aggregates also mediates an anti-tumour response, as accumulation of such aggregates 
can lead to increased ROS production, ER stress and activation of the DNA damage 
response (Mathew et al., 2009). Autophagy can promote apoptotic death of tumour 
cells via degradation of inhibitor of apoptosis (IAP) proteins (Xu et al., 2016). 
Supporting a tumour suppressive role for autophagy, deletion of proteins which 
positively regulate autophagy, including UVRAG and Bif-1, lead to increased cancer 
cell proliferation in breast, colon and prostate tumours (Morselli et al., 2009). 
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1.7.2 Autophagy in tumour progression  
Healthy cells use autophagy at basal levels to maintain cellular homeostasis, whereas 
malignant cells can elevate their autophagy levels. Particularly in the context of an 
oncogenic RAS mutation, cancer cells have been described as ‘autophagy addicted’ 
(Mancias and Kimmelman, 2011). Cancer cells typically have higher proliferation 
rates than their non-malignant counterparts, coupled with higher metabolic 
requirements. These requirements can be met by inducing high levels of autophagy, 
to produce ATP and other metabolic building blocks. Autophagy plays a diverse role 
in regulating cancer cell metabolism. Even in the presence of oxygen, sufficient to 
support oxidative phosphorylation, cancer cells favour the metabolism of glucose to 
lactate, a phenomenon dubbed the Warburg effect. Pyruvate kinase M2 (PKM2) is a 
key enzyme in the glycolytic pathway, preventing the accumulation of glycolytic 
intermediates. Inhibition of PKM2 results in an accumulation of glycolytic 
intermediates. Cancer cells utilise chaperone mediated autophagy to degrade PKM2, 
leading to an increase in glycolytic intermediates which can be used in biosynthetic 
pathways to support tumour growth (Lv et al., 2011). Conversely, the utilisation of 
autophagy to supress glycolysis can also be beneficial to cancer cells. Under acute 
stress conditions, cancer cells will slow down their proliferation rate in order to 
survive. The degradation of hexokinase-2 (HK2) by autophagy downregulates 
glycolysis, thus slowing down proliferation (Jiao et al., 2018).  
One of the hallmarks of cancer is its ability to evade the immune response, a hallmark 
which autophagy has been implicated in. Granzyme B, a serine protease used by 
natural killer (NK) cells to lyse their target, has been shown to be degraded via 
autophagy (Viry et al., 2014). Interestingly, autophagy has also been linked to the 
regulation of immune checkpoints, prominent targets for immunotherapies. Activation 
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of autophagy via mTOR inhibition was found to decrease the expression of PD-L1 in 
lung cancer cells, while mTOR activation resulted in increased PD-L1 expression 
(Lastwika et al., 2016). In a feed-forward loop PD-L1 can activate mTOR, which in 
turn upregulates PD-L1 expression. Of note, this feed-forward loop proceeded via 
mTORC1 and not mTORC2. In line with this, melanoma and ovarian cancer cells with 
low autophagy flux were found to have higher expression of PD-L1 compared to cells 
which displayed high autophagy flux (Clark et al., 2016). 
Autophagy has also been linked to tumour invasion and metastasis. One study reported 
that ULK2, which promotes autophagy by phosphorylating the initiation complex, 
downregulates E-cadherin, promoting cell motility (Kim et al., 2016). During 
metastasis, cells that travel to distant organs must be able to resist cell death which 
occurs due to the loss of contact with the extracellular matrix (ECM), termed anoikis. 
Autophagy has been shown to contribute to anoikis resistance and lung colonization 
in hepatocellular carcinoma cells (HCC) both in-vitro and in-vivo. Attenuation of 
autophagy via miR-30a overexpression could significantly reduce lung metastasis (Fu 
et al., 2018). 
 
1.7.3 Modulating autophagy for cancer treatment  
Given that autophagy generally plays a protective role in established tumours, 
inhibitors of autophagy are being trialled in patients. The anti-malarial drug 
hydroxychloroquine (HCQ), which prevents lysosomal turnover of autophagic 
substrates, is the most extensively trialled autophagic modulator.  Several trials are 
underway in pancreatic cancer, combining HCQ with chemotherapies such as 
gemcitabine and abraxane (NCT01128296, NCT01506973).  Promising results have 
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been obtained in breast and lung cancer patients with brain metastases, whereby the 
addition of HCQ lead to a one year increase in progression free survival in 83% of 
patients trialled, compared to 53% in the placebo group (Rojas-Puentes et al., 2013). 
In contrast, inducers of autophagy have been trialled to a lesser extent. Temsirolimus, 
an mTOR inhibitor, significantly improved progression free survival compared to 
standard of care chemotherapy regimens in patients with mantle cell lymphoma (Hess 
et al., 2009). A novel aspect of this study aimed to evaluate the chemosensitising 
ability of the autophagy modulating drug lithium, FDA approved for bipolar disorder. 
Given that both inhibiting and promoting autophagy can be beneficial, a one size fits 
all approach will not work. If autophagy modulation is to be successfully implemented 
into clinical regimens, the autophagy status of each cancer must be carefully assessed. 
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Table 1.4: Table summarising autophagy modulators in clinical trials for cancer 
therapy.  





















Advanced or metastatic 
breast cancer  
CQ + taxane II NCT01446016   
Oligometastatic prostate 
cancer 
HCQ II  NCT04011410   
Multiple Myeloma  Carfilzomib + HCQ I NCT04163107   
Platinum resistant 
epithelial ovarian cancer  
Itraconazole + HCQ I/II NCT03081702   
Advanced HCC Sorafenib + HCQ II NCT03037437 





1.7.4 Autophagy in ovarian cancer 
The role for autophagy in OC is diverse and can play both tumour suppressive and 
tumour promoting roles, depending on disease stage. Studies suggest that autophagy 
is generally suppressed in OC, which likely facilitates tumourigenesis. A recent study 
published by Delaney et al. (2017) has provided a genetic rationale for the study of 
autophagy in OC. Haploinsufficiency network analysis was used to identify pathways 
which are most disrupted by somatic copy number alterations (SCNAs), the most 
prevalent genetic alteration in OC. Of all KEGG (Kyoto Encyclopedia of Genes and 
Genomes) pathways analysed, autophagy was found to be the most severely disrupted. 
Monoallelic deletions in BECN1 and/or LC3 were found in 94% of the TCGA tumours 
analysed. In addition, autophagy genes such as Atg10, GAPARAPL2 and ULK2 were 
commonly lost in OV (Delaney et al., 2017). Despite this, numerous studies have 
shown that autophagy is readily inducible in OC cells in response to treatment. 
Autophagy induction, either by thioredoxin domain containing 17 (TXNDC17), ERK 
signalling or YAP activation promoted cisplatin resistance in various OC cell lines 
(S.-F. Zhang et al., 2015)(Wang and Wu, 2014)(Xiao et al., 2016). A role for 
autophagy in promoting OC cancer stem cell survival is also described in section 
1.1.8.2.2. Thus, autophagy appears to take on a tumour supportive role in the 
established tumour where it confers a significant survival advantage.  
Metastasis is a key process in tumour progression, as it allows cancer cells to 
disseminate from the site of origin. The most common route of metastasis in OC is via 
peritoneal seeding, and autophagy has been shown to aid in this process. A study by 
Kuo et al. (2019) revealed that autophagy plays a key role in selecting metastatic cells 
which can thrive in the peritoneum. OC cells were injected into mice, peritoneal 
metastases were harvested, cultured and implanted into new hosts. The selection 
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process was repeated three times to generate sublines. The metastases derived sublines 
were found to not only be enriched for autophagy genes but were more capable of 
inducing autophagy in response to stress (i.e. serum starvation or cisplatin treatment) 
than the parental cell lines. Inhibition of autophagy via ATG5 knockdown could also 
significantly impede the growth of the metastases derived sublines (Kuo et al., 2019). 
This study suggests that upregulation of autophagy confers a survival advantage to 
metastatic cells, meaning targeting autophagy may be clinically useful to tackle 
peritoneal metastases in OC. 
Analysis of the expression of autophagy markers may also be useful as a prognostic 
tool in OC. Expression of ATG9A, a key protein in autophagosome biogenesis, was 
analysed in tissue samples taken from 160 ovarian adenocarcinoma patients. High 
ATG9A expression correlated with higher clinical stage and relapsed disease (Dai, 
Zhang and Chen, 2014). A recent study developed a novel scoring system which could 
accurately predict the outcome for advanced OV patients after chemotherapy, using a 
panel of 43 ATG genes. The authors developed a training dataset using TCGA data to 
allow analysis of overall survival and recurrence-free survival (RFS). While the ATG 
score could not predict primary chemoresponse, following first line treatment, a higher 
ATG score was associated with shorter RFS (68.3% v 47.2%) (Niu et al., 2019). A 
higher ATG score was also correlated with poor overall survival, regardless of residual 
diseases status, a key clinical feature when predicting patient outcomes following 
treatment. Similarly, a paper was recently published which analysed the relationship 
between autophagy-related gene expression and clinical outcome of patients with 
ovarian serous cystadenocarcinoma. The group generated an autophagy-related risk 
signature containing eight genes related to autophagy: BLOC1S1, IL24, NRG4, 
PDK4, PEX3, PRKG1, SIRT2, and WDR45L. This autophagy-related risk signature 
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was found to be an independent prognostic indicator for serous ovarian cancer (An et 
al., 2018). 
Targeting autophagy is an attractive target for the clinical management of OC, to 
tackle chemoresistance and metastasis, and as a prognostic biomarker. However, given 
the complex role of autophagy in regulating multiple facets of tumour biology, a better 
understanding of the molecular pathways regulating autophagy in OC is required. This 
study aimed to assess, for the first time, the presence of more than one autophagy 
pathway in OC cells. By answering these questions, it is aimed to develop a therapeutic 




1.8 Thesis hypothesis and aims 
Hypothesis: Autophagy is used by ovarian cancer cells to facilitate recovery and 
regrowth following treatment with clinically relevant chemotherapy drugs. 
Aims: 
• 1 (A): To evaluate the sensitivity of a panel of ovarian cancer cell lines to 
paclitaxel and carboplatin  
• 1 (B) To characterize the ability of ovarian cancer cell lines to undergo 
apoptosis and induce autophagy 
• 2 (A): To assess the effect of chloroquine and lithium on the chemosensitivity 
of ovarian cancer cells  
• 2 (B): To evaluate the effect of brefeldin A on basal and drug induced 
autophagy 
• 3: To assess the importance of autophagy in the ability of ovarian cancer cells 
to recover from paclitaxel treatment  
• 4: To elucidate whether OC cells can recover their DNA content following 
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Chapter Two: Evaluation of the 
response of a panel of ovarian 






Ovarian cancer is the seventh most commonly diagnosed cancer among women 
worldwide. Most women have an excellent response to first line chemotherapy 
however disease recurrence is a major clinical challenge. In order to gain an insight 
into the mechanisms driving resistance, we investigated the response of a panel of 
ovarian cancer cell lines to two clinically relevant drugs, paclitaxel and carboplatin. 
Induction of apoptosis was evident only in response to paclitaxel, and to varying levels 
amongst the cell line panel. The murine ID8-luc2 cell line expressed the lowest active 
caspase-3 levels (3%), with the human OVCAR-3 cell line expressing the highest 
(40%). Importantly this activity was significantly reduced in all cell lines tested 
following recovery of surviving clones from a single round of treatment.  
We have also investigated expression of key autophagy proteins (Beclin 1, Atg5/12, 
and LC3I/II) and the capacity of all cell lines to undergo autophagy in the presence or 
absence of drugs. Each of the cell lines expressed the key autophagy proteins, although 
to varying levels, and importantly, protein expression did not correlate with the cells 
ability to undergo autophagy. Two subgroups of cells could be distinguished from this 
study, based on their drug sensitivity and their apoptotic and autophagic competency. 
The OVCAR-3 and -4 cells were most sensitive to both drugs, displayed the highest 
levels of apoptosis and low autophagy induction levels. By comparison, the OVCAR-
5 and -8 cell lines were more drug resistant, with low levels of apoptosis and high 
autophagy induction. 
The findings from this chapter have clinically significant implications, suggesting that 
apoptosis can be diminished following re-challenge with paclitaxel. As ovarian cancer 
patients typically receive multiple rounds of chemotherapy, this signifies autophagy 
as a clinically relevant target when conventional therapies are failing to induce cell 
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death. The use of a cell line panel in this study enabled the characterisation of cells 
with differing drug sensitivities, which may be linked to their apoptotic/autophagic 
competency. Such characterisation is important for the development of effective 
chemosensitising strategies in the face of considerable heterogeneity which exists 






2.2 Introduction  
Ovarian cancer remains the leading cause of death from gynaecological malignancies 
among women worldwide. Due to the benign nature of the disease symptoms, 
diagnoses are often made at a late stage resulting in poor survival outcomes for 
women. The standard of care for the clinical management of ovarian cancer has 
remained largely unchanged, with surgery and a dual taxane/platinum chemotherapy 
regimen utilised. Patients will typically receive an intravenous paclitaxel/carboplatin 
infusion every three weeks for up to 6 cycles (Boyd and Muggia, 2018). Disease 
recurrence is the major clinical challenge faced in the treatment of OC. The 
implementation of PARP inhibitors such as Olaparib, which are indicated as a 
maintenance monotherapy for women with complete or partial response to platinum 
chemotherapy, have improved progression free survival (O’Cearbhaill, 2018). Despite 
this, there is a need to further elucidate the molecular mechanisms driving resistance 
in order to improve patient outcomes. 
An area which has gained interest as a potential therapeutic target to overcome 
resistance is autophagy. Autophagy is an evolutionary conserved catabolic process, 
enabling the degradation and recycling of intracellular components. While autophagy 
primarily functions to promote healthy cell survival and homeostasis, it can also be 
utilised by cancer cells to confer a survival advantage. Cancer cells can use autophagy 
to thrive in the harsh tumour microenvironment and to withstand chemotherapeutic 
insult. Studies have reported that autophagy can contribute to both cisplatin and 
paclitaxel resistance (Kulshrestha et al., 2019); (Wang and Wu, 2014); (S.-F. Zhang 
et al., 2015).  
Ovarian cancers comprise a group of five pathologically and histologically distinct 
malignancies, as discussed in depth in section 1.1.3 of Chapter one. Serous cancers 
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are the most common, with high grade serous tumours accounting for over 70% of 
ovarian cancer deaths (Kim et al., 2018). A panel of four human cell lines (OVCAR-
3, -4, -5, -8) and one murine (ID8-luc2) cell line, all of which represent the serous 
subtype, were assessed for their response to paclitaxel and carboplatin. 
 A recent haploinsufficiency study identified autophagy as the most severely disrupted 
pathway among ovarian cancer cohorts, with monoallelic deletions in key autophagy 
genes including BECN1 and LC3 also reported in the OVCAR-3 cell line (Delaney et 
al. 2017). Levels of apoptosis competency have also been reported to vary widely 
among ovarian cancer cell lines. Therefore, in this study, we assessed a panel of OC 









2.3 Materials and Methods  
2.3.1 Cell culture and Reagents 
Established human ovarian cancer cell lines OVCAR-3, OVCAR-4, OVCAR-5 and 
OVCAR-8 were obtained directly from the NCI Frederick Cancer DCTC Tumor/Cell 
Line Repository. Murine ID8-luc2 cells were obtained from the Mayo Clinic. All 
human OVCAR cell lines were maintained in RPMI-1640 media. Due to a slow rate 
of growth in media supplemented with 10% (v/v) foetal calf serum (FCS), OVCAR-3 
and OVCAR-4 cultures were supplemented with 20% (v/v) (FCS). OVCAR-5 and 
OVCAR-8 cultures were supplemented with 10% (v/v) foetal calf serum. Murine ID8-
luc2 cells were cultured using Dulbecco’s Modified Eagles Medium (DMEM) 
containing 10% (v/v) foetal calf serum. All cultures were supplemented with 1% 
penicillin/streptomycin (Gibco Life Technologies, Cat # 15070-063). Cells were 
grown in T75cm2 flasks (Sarstedt) and maintained at 37°C, 5% CO2. The OVCAR-3 
cell line was established by Hamilton and colleagues in 1983, from the malignant 
ascites of an ovarian adenocarcinoma patient treated with cisplatin, adriamycin and 
cyclophosphamide (Hamilton et al., 1983). The OVCAR-4 cell line was also derived 
from the metastatic ascites of a HGSOC cisplatin refractory patient (Hamilton, Young 
and Ozols, 1984). The OVCAR-5 cell line was derived from ascites of a treatment 
naïve patient, while the OVCAR-8 cell line originated from the tumour tissue of a high 
dose carboplatin refractory patient (Hamilton, Young and Ozols, 1984). These cell 
lines were selected after a review of the literature was conducted, as they most likely 
represent the high grade serous subtype of OC. Microscopic analysis of  OVCAR-3,-
4, -5 and -8 derived xenografts revealed histology consistent with that of HGSOC 
tumours (Mitra et al., 2015). A study published in 2013 also ranked the OVCAR-3, -
4 and -8 cell lines as likely HGSOC, based on the fraction of their genome altered and 
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the number of copy number alterations, which were consistent with TCGA patient data 
(Domcke et al., 2013). All four OVCAR cell lines were also identified as high grade 
serous by (Anglesio et al., 2013). A number of functional characteristics, including 
migration, invasion and cisplatin sensitivity, of the OVCAR-4, -5 and -8 cell lines was 
conducted by (Haley et al., 2016). OVCAR-3 cells have been reported to have 
monoallelic deletions of BECN1 and LC3, with the OVCAR-5 and -8 cell lines having 
allelic gains in these genes (Delaney et al., 2017). Little is known about the status of 
these genes in the OVCAR-4 and ID8-luc2 cell lines. Each of the OVCAR cell lines 
is BRCA1/2 wildtype, however the OVCAR-8 cell line has hypermethylation of 
BRCA1. The OVCAR-8 cell line also has a hyperdiploid karyotype. The murine ID8 
cell line was derived from spontaneously transformed mouse surface epithelial cells 
(MOSE) by (Roby et al., 2000). They were included in the study in anticipation of 
future in vivo studies, as these cells form tumours within the peritoneal cavity of mice 
resembling stage III or IV cancers in women. 
 
2.3.2 Drug treatments  
Paclitaxel (Cat # T7402) and carboplatin (Cat # C2538) were both purchased from 
Sigma Aldrich. Paclitaxel was reconstituted in dimethyl sulfoxide (DMSO) to give 
58.55mM stock. Aliquots were prepared and stored at -200C. Working concentrations 
of paclitaxel were prepared fresh in media on the day of treatment. Carboplatin was 
reconstituted in water to give a 26.93mM stock, aliquoted and stored in the dark at 
room temperature. Working concentrations were prepared in media on the day of 
treatment. Cells received a 48 hour treatment with both paclitaxel and carboplatin 
unless otherwise stated. A working stock of chloroquine (CQ) was prepared in media 
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(1mM) on the day of treatment and added to the cells at the desired concentration of 
10µM, 2 hours prior to any other drug treatment. 
For clonogenic recovery assays, cells were treated for 24 or 48 hours with paclitaxel 
or carboplatin and subsequently reseeded for colony regrowth. For caspase-3 assays, 
cells also received a 24 or 48 hour treatment with paclitaxel or carboplatin, after which 
cells were probed and assessed by flow cytometry.  
For autophagy assays, cells were treated with paclitaxel or carboplatin +/-CQ (10µM) 
for 24 or 48 hours. Media containing drugs was then removed and replaced with new 
drug free media. Cells were allowed to recover for 24 hours and prepared for western 
blot, Cyto-ID autophagy assay or immunofluorescence. A 24 hour recovery period 
was added in an effort to mimic the clinical scenario, whereby the patient receives a 
treatment free interval.  




























Figure 2.1. Schematic illustrating the process of generating OVCAR clones. 
Step one of the process involves treating the OVCAR cell line (either 3, 4 or 5) 
with paclitaxel for 48 hours, along with untreated cells. Caspase activity was 
assessed after 48 hours. Cells were then seeded into six well plates in triplicate and 
allowed to recover for 10-14 days in drug-free media. Each well of the triplicate 
represents a different clone. Step two (B) After the recovery period, viable cells 
from each clone (Ov3R1, Ov3R2, Ov3R3) were re-challenged with paclitaxel for 
48 hours or remained untreated (UntOv3R). Cells were re-seeded and allowed to 
recover in drug-free media for 10-14 days. This represents the rounds of standard 
treatment as described in section 2.2. Step two (A) In addition to the clones, 
OVCAR cells were seeded and received either no treatment or paclitaxel for 48 




2.3.3 Colony formation assay 
Colony formation (clonogenic) assays were used to determine the ability of single cells 
to recover from a drug treatment and re-establish colonies. Following treatment with 
paclitaxel or carboplatin, the cells were trypsinised using 500µl Trypsin EDTA (Sigma 
Aldrich, Cat # T4049) and viable cells counted using the automated cell counter, 
NucleoCounter NC-100 (Chemometec). For the OVCAR-5, OVCAR-8 and ID8-luc2 
cell lines, 1,500 viable cells were re-seeded into their respective wells on a six-well 
plate (Nunc™ Thermo Scientific, Cat # 140685) (in triplicate). For the OVCAR-3 and 
OVCAR-4 cell lines, 2,500 cells were re-seeded in the same manner as these cell lines 
were much slower to replicate. Cells were allowed to recover for 10-14 days in drug-
free medium, until control cells reached a minimum confluency of 70%, and then 
prepared for staining. Media was aspirated, and cells were washed once with PBS 
before fixing in methanol for 5 minutes. Cells were then stained with Pro-diff solution 
C (Braidwood Laboratories E310) for 5 minutes. Plates were rinsed with water to 
remove excess stain and allowed to air-dry overnight. Plates were scanned and 
quantified using the Odyssey IR imaging system (Li-Cor, Cambridge, United 
Kingdom). For each cell line, we have looked for concentrations of both drugs that 
would reduce colony regrowth by over 50%. 
 
 2.3.4 Evaluation of morphology 
Treated cells were cytospun and allowed to air dry for 5 minutes. Cells were then fixed 
using methanol and stained using May Grunwald Giemsa (DiaPath). Cells were 
identified as apoptotic based on the presence of two or more of the following 
morphological features: cell shrinkage, chromatin condensation or DNA 
fragmentation into ‘apoptotic bodies’. Images were acquired using a DP70 digital 
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microscope camera and Olympus DP-Soft 823 version 3.2 software (Mason 
Technologies Dublin, Ireland).  
 
2.3.5 Evaluation of caspase-3 activity by flow cytometry 
Treated cells were trypsinised using 500µl Trypsin EDTA (Sigma Aldrich, Cat # 
T4049) and neutralised with 1ml of media, saving the supernatant. Cells were 
subsequently fixed in 4% paraformaldehyde (PFA) for 45 minutes at 40C, washed in 
a permeabilisation buffer (0.1% Triton X-100, 0.1% sodium azide, 10 mM HEPES, 4 
% FCS, 150 mM NaCl) and incubated with anti-active caspase-3 antibody (BD 
Biosciences, Cat # 559565) for 1 hour at 4℃. Cells were detected using an Alexa flour 
488 secondary antibody (Life Technologies, Cat # A11034). Analysis was performed 
using the BD LSR II flow cytometer and BD FACS Diva software. 
 
2.3.6 Western Blotting  
Total cellular protein was extracted by trypsinisation of cells followed by lysing in 10-
25µl  modified RIPA buffer (50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.25% sodium 
deoxycholate, 1% Igepal, 1 mM EDTA, 1x Pefabloc, 1x protease inhibitor cocktail, 1 
mM Na3VO4, 1 mM NaF), depending on pellet size. Samples (75 μg) were separated 
on NuPAGE 4–12% Bis-Tris gels (Invitrogen Life Technologies, Cat # NP0322) and 
electrophoretically transferred onto a PVDF membrane using the iBlot gel transfer 
system (Invitrogen IB1001). Membranes were blocked for one hour at room 
temperature using Odyssey blocking buffer (Li-Cor, Cat # 927-40100), and incubated 
overnight at 4℃ using: anti-LC3 (Cat # MBL-PD014), anti- ATG5 (Novus, Cat # 
NB110-53818), anti-Beclin-1 (Novus, Cat # NB500-249). Anti-β-actin (loading 
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control) (Sigma, Cat # A5441) was incubated at room temperature, rocking, for one 
hour.  IR-Dye conjugated secondary antibodies (Rockland) were utilised for protein 
detection. Membranes were analysed using the Odyssey Infra-red imaging system (Li-
Cor, Cambridge, United Kingdom).  
 
2.3.7 Cyto-ID Autophagy Detection kit  
Treated cells were trypsinised using 500µl of Trypsin EDTA (Sigma Aldrich, Cat # 
T4049) and stained using the Cyto-ID autophagy detection kit (Enzo Life Sciences, 
Cat # ENZ-51031-K200) according to the manufacturer’s instructions. Cyto-ID is a 
cationic amphiphilic tracer dye which selectively accumulates within autophagic 
vesicles. An increase in autophagic vacuole accumulation will result in an increase in 
fluorescence in the 488-2 channel. Samples were run on the BD LSRII flow cytometer 
with FACS Diva acquisition and analysis software. FlowJo data analysis software was 
used for gating and generating overlay histograms. Data is presented as Mean 
Fluorescence Intensity (MFI). 
 
2.3.8 Immunofluorescence  
Prior to treatment, cells were seeded directly onto coverslips in the well of a six well 
plate (Nunc™ Thermo Scientific, Cat # 140685). Following treatment (previously 
described), cells were washed with PBS, fixed (4 % PFA/PBS), washed 3 times with 
PBS and permeabilised in 100% cold methanol for 10 minutes at -20℃. Cells were 
again washed 3 times with PBS and blocked for 30 minutes at room temperature (5% 
BSA/PBS). Cells were probed with anti-LC3 (Abgent, Cat # APG8B) in 1% BSA/PBS 
overnight at 4℃ and detected with an Alexa Flour 594 goat anti-rabbit secondary 
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antibody (Life Technologies, Cat # A11037). Cells were incubated with Nuclear ID 
stain (1µl per 2ml PBS) for 30 minutes at room temperature, before the slides were 
mounted using Pro-Long Gold anti-fade without Dapi (Invitrogen, Cat # P36970). 
Images were acquired using a DP70 digital microscope camera and Olympus DP-
Soft823 version 3.2 software (Mason Technologies Dublin, Ireland). 
 
2.3.9 Statistical Analysis 
All data is expressed as mean ± the standard error of the mean (SEM), which represents 
the standard deviation of the distribution of the sample around the mean. Significance 
was determined by independent or paired student t-tests, which determines the 
difference between the means of two groups. The p-value was considered statistically 
significant where *p < 0.05, ** p < 0.01, *** p < 0.001. Statistical analysis was carried 
out and graphed using GraphPad Prism 5 software (GraphPad Software Inc., CA, 












2.4.1 Working concentrations of paclitaxel and carboplatin were established for 
a panel of human and one murine ovarian cancer cell line 
The sensitivity of ovarian cancer cell lines to paclitaxel and carboplatin was 
established using clonogenic assays. The clonogenic assay was selected as it allows 
the survival and proliferative capacity of a cell following treatment to be assessed. 
This was important for future experiments in the thesis which aimed to determine how 
OC cells recovered after drug treatment.  To investigate cellular response to treatment, 
we have looked for concentrations that clearly have cytotoxic activity, reducing 
recovery by over 50% following withdrawal of the drug.    
The ID8-luc2 cell line was treated for 24 hours with paclitaxel. Recovery was 
significantly impeded in a dose dependent manner at concentrations ranging from 2.5 
(***p = 0.0006) – 50 µM [Figure 2.2A]. 48 hour treatments with carboplatin 
significantly impeded clonogenic regrowth at concentrations of 30 µM (**p = 0.001) 
and 40 µM [Figure 2.2B]. 
A panel of human ovarian cancer cell lines were also treated with both paclitaxel and 
carboplatin to assess their recovery over a range of concentrations. In all cell lines, 
dose dependent responses were evident following treatment with paclitaxel. Following 
48 hour treatments, paclitaxel impeded cell recovery in the OVCAR-3 and -4 cell lines 
with significant loss of viability at 2 and 1.5nM (*p =0.003, ***p =0.0001, 
respectively) [Figure 2.3A and B, respectively]. In both the OVCAR-5 and -8 cell 
lines, higher concentrations of 5nM paclitaxel were required to significantly inhibit 
cell growth (**p = 0.002, **p = 0.001 respectively) [Figure 2.3C and D, respectively].   
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The OVCAR-3 and -4 cell lines were also more sensitive to carboplatin, with 
significantly reduced recovery evident at 0.5µM and 1µM (**p = 0.004; **p = 0.004, 
respectively) [Figure 2.4A and B, respectively]. In both the OVCAR-5 and -8 cell lines 
higher carboplatin doses of 7.5µM and 2.5µM were required to inhibit cell recovery 
(**p = 0.0037; ***p = 0.0005, respectively) [Figure 2.4C and D, respectively]. Based 
on the dose response ranges graphed in figures 2.2 to 2.4, effective concentrations of 




































Figure 2.2. The effects of paclitaxel and carboplatin treatments on the recovery of the 
mouse ovarian carcinoma cell line. ID8-luc2 cells were treated with a range of (A) paclitaxel 
concentrations, for 24 hours or (B) carboplatin concentrations for 48 hours. Cells were re-
seeded (1500 cells per well) and allowed to recover in drug free media for 10-14 days. Stained 
colonies were scanned, and integrated intensity values were quantified. Data is presented 
graphically as % control (where control = 100%) (n=3). We have looked for concentrations 
that would reduce recovery by at least 50%. Statistical analysis was performed using a paired 






















Figure 2.3. The effects of paclitaxel treatments on the recovery of the human ovarian 
cancer cell lines OVCAR-3, -4, -5, -8.  A panel of human ovarian cancer cell lines were 
treated with a range of paclitaxel concentrations (nM) for 48 hours. (A) OVCAR-3 and (B) 
OVCAR-4 cells were seeded (2500 cells per well) and allowed to recover for 10-14 days. (C) 
OVCAR-5 and (D) OVCAR-8 cells were re-seeded (1500 cells per well) in drug free media 
and allowed 10-14 days to recover. All colonies were fixed, stained, and quantified using the 
Odyssey Infrared Imaging System (Li-Cor). Data is presented as % control (where control = 
100%) (n=3). We have looked for concentrations that would reduce recovery by at least 50%. 
Statistical analysis was performed using a paired students t-test and values are deemed 
























Figure 2.4. The effects of carboplatin treatments on the recovery of the human ovarian 
cancer cell lines OVCAR-3, -4, -5, -8.  Following treatments with carboplatin (µM) for 48 
hours, (A) OVCAR-3 and (B) OVCAR-4 cells were re-seeded (2500 cells per well) and 
allowed to recover for 10-14 days. (C) OVCAR-5 and (D) OVCAR-8 cells were re-seeded 
(1500 cells per well) and allowed 10-14 days to recover. All colonies were fixed, stained and 
integrated intensity values obtained. Data is presented as % control (where control = 100%) 
(n=3). We have looked for concentrations that would reduce recovery by at least 50%. 
Statistical analysis was performed using a paired students t-test. Values are significant where 











We could also separate the human cell lines into two distinct subgroups with 
differential sensitivity to both drugs. The OVCAR-5 and -8 cell lines were 
significantly more resistant to both drugs compared to the OVCAR-3 and -4 cell lines, 
requiring on average 3 fold higher concentrations of paclitaxel, and 7 fold higher 









ID8-luc2 2.5uM 40uM 
OVCAR-3 2nM, 2.5nM 0.5uM, 0.6uM 
OVCAR-4 1.5nM, 2nM 1uM, 1.5uM 
OVCAR-5 5nM, 7.5nM 7.5uM, 10uM 
OVCAR-8 5nM, 7.5nM 2.5uM, 5uM 
Table 2.1. The concentrations of paclitaxel and carboplatin derived from the dose 
ranges in figures 2.2 to 2.4, which reduced clonogenic recovery by at least 50%, 
are listed. These concentrations were used for subsequent experiments.   
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2.4.2 Assessment of apoptosis induction in ovarian cancer cell lines following 
treatment with paclitaxel and carboplatin   
The literature is conflicted regarding the apoptosis competency of ovarian cancer cell 
lines. Apoptotic cell death is the desired outcome following treatment with 
chemotherapeutic drugs. It was therefore important to establish if the panel of ovarian 
cancer cell lines were competent at inducing apoptosis in response to treatment with 
paclitaxel and carboplatin.  
Morphology was assessed for apoptotic features including cell shrinkage, nuclear 
fragmentation and membrane blebbing. Active caspase-3 was also quantified using 
flow cytometry. Caspase-3 is a protease which is cleaved from its pro-caspase form 
into its active form during the execution stage of apoptosis and is a standard indicator 
of apoptosis. 
The ID8-luc2 cell line was treated with paclitaxel (2.5µM) and carboplatin (40µM) 
for 24 and 48 hours, respectively. No morphological features of apoptosis were evident 
in treated cells [Figure 2.5A (i) and 4B (i) respectively], however mitotic catastrophe 
was apparent with paclitaxel, consistent with its activity as a microtubule inhibitor 
[Figure 2.5A (i), right panel]. Chromosome condensation (and potential mitotic 
catastrophe) was also evident in carboplatin treated cells (denoted with red arrows) 
[Figure 2.5B (i)]. A small increase in caspase-3 activity was observed following 
2.5µM paclitaxel treatment (**p= 0.003), while no significant activation was observed 
following treatment with carboplatin (40µM) [Figure 2.5A (ii) and 2.5B (ii)].  
Morphological features of apoptosis were evident in both the OVCAR-3 and -4 cell 
lines following 48 hour treatments with 2nM paclitaxel (black arrows, Figure 2.6A (ii) 
and B (ii), respectively). Following treatment with 0.5µM and 2µM carboplatin 
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respectively, there was no morphological evidence of apoptosis in either the OVCAR-
3 or -4 cell lines, however limited necrotic features including loss of plasma membrane 
integrity were observed (denoted with green arrows) [Figure 2.6A (iii) and B (iii), 
respectively]. Consistent with the morphological evidence, both OVCAR-3 and -4 cell 
lines, treated with paclitaxel (2 and 2.5nM) and (1 and 1.5nM) respectively, displayed 
activation of active caspase-3. OVCAR-3 cells had the highest levels of active-
caspase-3 at 43 % [Figure 2.6A (iv)] with the OVCAR-4 cell line showing 22 % 
[Figure 2.6B (iv)]. Carboplatin treatment did not activate caspase-3 in either OVCAR-
3 or -4 cell lines [Figure 2.6A (iv) and Figure 2.6B (iv), respectively].  
The OVCAR-5 and -8 cell lines were similarly evaluated after 48 hour treatments with 
both drugs. Following 5 and 7.5nM paclitaxel treatment respectively, morphological 
features of apoptosis were evident in both the OVCAR-5 and -8 cell lines [black 
arrows], Figure 2.7A (ii) and 2.7B (ii), respectively]. Following treatments with 10 
and 5µM carboplatin, in the OVCAR-5 and -8 cell lines respectively, apoptotic 
features were not observed, however other abnormal features were, such as 
chromosome condensation (highlighted with red arrows), and loss of plasma 
membrane integrity consistent with necrosis (denoted with green arrows) [Figure 2.7A 
(iii) and 2.7B (iii), respectively]. Consistent with the morphological evidence, active 
caspase-3 expression was detected in the OVCAR-5 and -8 cell lines following 7.5nM 
paclitaxel treatment at 11 % and 8 % respectively [Figure 2.7A (iv) and 2.7B (iv)].  
In summary, the most sensitive cell lines (OVCAR-3 and -4) displayed the highest 
induction of apoptosis following paclitaxel treatment and perhaps unsurprisingly, the 
most resistant pair (OVCAR-5 and -8) exhibited the least apoptosis induction. In 
contrast, treatment with carboplatin did not show any evidence of apoptosis induction 
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in any of the OC cell lines tested.  These data highlight both a cell line dependent and 






















Figure 2.5. Features of apoptosis were assessed in the ID8-luc2 cell line following 
treatment with Paclitaxel and carboplatin (A)(i) ID8-luc2 cells were treated for 24 hours 
with paclitaxel (2.5 µM) and morphological features of apoptosis were assessed (not 
evident) (Magnification 400X) (A)(ii) To corroborate morphological data, active caspase-
3 levels were assessed following paclitaxel treatment using flow cytometry (n=3). (B)(i) 
Morphological features of apoptosis were assessed in untreated cells (left panel) and 40 
µM carboplatin treated cells (right panel). Cells with condensed chromosomes are 
highlighted with red arrows (Magnification 400X). (B)(ii) Active caspase-3 levels were 
assessed following carboplatin treatment using flow cytometry. All percentages of active 
caspse-3 are dispalyed as ± SEM (n=3). Paired students t-test were used, and values are 



























































Figure 2.6. Apoptotic features were assessed in the OVCAR-3 and -4 cell lines 
following 48 hour treatments with paclitaxel and carboplatin. (A) Morphological 
features of OVCAR-3 cells are shown following (ii) paclitaxel (2nM) and (iii) carboplatin 
(0.5µM) treatment (magnification 400X). (iv) Analysis of active caspase 3 following 
treatment with both paclitaxel and carboplatin (n=3). (B) Morphological features of 
apoptosis were assessed in OVCAR-4 cells following (ii) paclitaxel treatment (2nM) and 
(iii) carboplatin treatment (2µM). Cells marked with black arrows display apoptotic 
features, cells with chromosome condensation are marked with red arrows, while cells with 
necrotic morphology are highlighted with green arrows (magnification 400X). (iv) Active 
caspase-3 analysis was conducted using flow cytometry to substantiate morphological 
data. Values are graphed ± SEM (n=3). Paired students t-test were used, and values are 








    
 





















  Figure 2.7. Apoptotic features were assessed in the OVCAR-5 and -8 cell lines 
following 48 hour treatments with paclitaxel and carboplatin. (A) Morphological 
features of OVCAR-5 cells are shown in (i) untreated cells and following (ii) paclitaxel 
(5nM) and (iii) carboplatin treatment (10µM) (magnification 400X). (iv) Analysis of active 
caspase-3 following treatment with both paclitaxel and carboplatin (n=3). (B) 
Morphological features of apoptosis were assessed in OVCAR-8 cells following (ii) 
paclitaxel treatment (7.5nM) and (iii) carboplatin treatment (5µM). Cells marked with 
black arrows display apoptotic morphology, cells with chromosome condensation are 
marked with red arrows, while cells with necrotic morphology are highlighted with green 
arrows (magnification 400X). (iv) Active caspase-3 analysis was conducted using flow 
cytometry (n=3). Paired students t-test were used, and values are deemed significant where 
*p< 0.05, **p< 0.01, ***p <0.001.  
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2.4.3 Apoptosis is decreased, and recovery is increased, in ovarian cancer cells 
following a single round of paclitaxel treatment  
Ovarian cancer patients often undergo successive rounds of chemotherapy, and 
resistance to treatment is commonly acquired. In order to mimic these clinical effects 
in-vitro, the three cell lines displaying the highest levels of active caspse-3 (OVCAR-
3, -4, -5) were recovered from one round of paclitaxel treatment and then re-
challenged, after which caspase-3 levels and clonogenic recovery were assessed. The 
OVCAR clones were generated as described in Figure 2.1.  
In the OVCAR-3 cell line, all the recovered clones (Ov3R1, R2, R3) were more 
resistant to paclitaxel treatment, with significantly more cells recovering from the 
Ov3R3 clone compared to OV3 cells, which received one paclitaxel treatment (***p 
= 0.0002) [Figure 2.8A (i)]. The recovered clones also displayed significantly less 
active caspase-3 activity compared to OVCAR-3 cells receiving just one treatment 
(OV3) (Ov3R2 *p = 0.011, Ov3R3 *p = 0.024) [Figure 2.8A (ii)].  
In the OVCAR-4 cell line, one out of three of the recovered clones had a significant 
increase in re-growth, as shown by the clonogenic assay, when compared to cells 
receiving one round of paclitaxel treatment (OV4) (Ov4R2 *p = 0.0279) [Figure 2.8B 
(i)]. Interestingly, two out of three clones also displayed a significant decrease in active 
caspase-3 activity, compared to cells receiving one round of paclitaxel treatment 
(Ov4R1 *p = 0.0351; Ov4R2 *p = 0.0155) [Figure 2.8B (ii)].    
In the OVCAR-5 cell line, the recovered clones were all significantly more resistant 
to paclitaxel treatment compared to cells receiving one round of treatment, as indicated 
by increased re-growth of all clones in the clonogenic assay (Ov5R1 **p = 0.006, 
Ov5R2 ***p = 0.0001, Ov5R3 ***p = 0.0002) [Figure 2.8C (i)]. Two out of three 
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clones which were re-challenged with paclitaxel displayed a significant reduction in 
active caspase-3 activity compared to those which received just one treatment (OV5) 
(Ov5R2 **p = 0.002, Ov5R3 **p = 0.005) [Figure 2.8C (ii)]. 
These data indicate that treatment with paclitaxel results in a reduction of OC cell 
apoptotic competency, in at least two out of three clones from each cell line. Clones 























































Figure 2.8. (A) (i) OVCAR-3, (B) (i) OVCAR-4 and (C) (i) OVCAR-5 cells were 
treated for 48 hours with 2, 1.5 and 5 nM paclitaxel, respectively. OVCAR-3 and 
-4 cells were then re-seeded (2500 cells per well), while OVCAR-5 cells were 
seeded (1500 cells per well) in drug-free media and allowed to recover for 10-14 
days. Recovered clones for each cell line (labelled R1, R2 and R3) were generated 
by re-seeding and treating with paclitaxel at their respective concentrations for a 
second time. Cells were also seeded which received only one paclitaxel treatment 
(labelled OV3, OV4 and OV5, respectively). Recovery was assessed using 
clonogenic assays, integrated intensities were quantified, and data is presented as 
% control (where control = 100%) (n=3). (ii) Active caspase-3 activity was 
assessed by flow cytometry in all cell lines (n=3). Data is displayed as % caspase 
activity ± SEM. Statistical analysis was performed using an unpaired student’s t-




2.4.4 Ovarian cancer cells express key autophagy proteins 
Basal expression of three key autophagy proteins (Beclin 1, Atg5/12, and LC3) were 
assessed in untreated cells using western blotting.  
Beclin 1, a key component of the PI3K complex involved in autophagosome 
formation, was detected in all the cell lines, producing a band 52kDa in size [Figure 
2.9A (i)(ii)]. To allow LC3 lipidation during autophagosome maturation, Atg5 and 12 
conjugation is necessary, producing a conjugate 55 kDa in size. Expression of the 
conjugate was detected in each of the cell lines [Figure 2.9B (i)(ii)]. The OVCAR-5 
and -8 cell lines had the lowest expression of the conjugate, when compared to the 
OVCAR-3, -4 and ID8-luc2 cell lines. During autophagosome maturation, LC3I is 
lipidated to form LC3II and inserts into the outer membrane of the mature 
autophagosome. Expression of LC3II is considered one of the most reliable indicators 
of autophagy induction. As evident in Figure 2.9C (i)(ii), LC3I (16-18 kDa) and LC3II 






























Figure 2.9. Western Blot analysis of the basal expression of key autophagy proteins. 
The expressions of (A)(i) Beclin 1, (B)(i) Atg5/12 and (C)(i) LC3II were quantified in a 
panel of ovarian cancer cell lines using the Li-Cor odyssey scanner and normalised to β-










2.4.5 Basal autophagy is present in human ovarian cancer cell lines  
Having established that the panel of OC cell lines express key autophagy proteins, we 
tested the ability of the cell lines to undergo basal autophagy. This was evaluated by 
blocking autophagosome turnover with the lysomotropic agent chloroquine and 
assessing the amount of autophagosomes that accumulate after 24 or 48 hours. If the 
cell is undergoing autophagy, vesicles will accumulate due to lack of turnover. 
To assess the levels of autophagic vesicles two assays were employed, the Cyto-ID 
autophagy detection kit and immunofluorescent imaging for LC3. Treatment with CQ 
(24 or 48 hours) caused a significant increase in vesicle accumulation in each of the 
cell lines (Figure 2.10 (i), blue overlays), ((A) ID8-luc2  *** p =  0.0007, (B) OVCAR-
3 ** p = 0.001, (C) OVCAR-4 * p = 0.049, (D) OVCAR-5 ** p = 0.004, (E) OVCAR-
8 *** p = 0.0009). The OVCAR-8 cell line displayed the highest accumulation of 
autophagosomes (4 fold increase), with a corresponding increase in red punctate LC3 
staining [Figure 2.10E (i) and (ii)]. The OVCAR-5 cell line displayed a 2.3 fold 
increase in vesicle accumulation and increased LC3 staining [Figure 2.10D (i) and 
(ii)]. The murine ID8-luc2 displayed a 2 fold increase in vesicle accumulation, which 
appeared inconsistent with LC3 immunostaining, which was minimally affected 
[Figure 2.10A (i) and (ii)]. The OVCAR-3 cells also displayed a 2 fold increase in 
vesicle accumulation, with the OVCAR-4 cells displaying the lowest accumulation 
(1.4 fold increase), consistent with the corresponding LC3 immunofluorescent 
expression [Figure 2.10B and C (i)(ii), respectively]. These results, along with the data 
from section 2.4.4 above, suggest that basal autophagy is not impeded by lack of 
gene/protein expression. It is notable that the OVCAR-8 cells displayed the lowest 
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Figure 2.10. Assessment of basal autophagy in ovarian cancer cell lines. (i) The Cyto-
ID autophagy detection kit was used to measure autophagic vesicle accumulation in either 
untreated (Control) or CQ (10µM) treated cells. Representative histogram overlays are 
displayed in the left-hand panels, with the corresponding mean fluorescent intensities 
graphed within for (A) ID8-luc2 (B) OVCAR-3 (C) OVCAR-4 (D) OVCAR-5 and (E) 
OVCAR-8 cells (n=3). (ii) The expression of LC3 was assessed following treatment with 
chloroquine in (A) ID8-luc2 cells (24 hours) and (B) OVCAR-3 (C) OVCAR-4 (D) 
OVCAR-5 and (E) OVCAR-8 cell lines (48 hours). Cells were probed with anti-LC3 
antibody at 1:1000 dilution and imaged using a DP70 digital microscope camera 
(magnification 400X). Control cells are displayed in the left-hand panels, while CQ treated 
cells are on the right. Statistical analysis was performed using a paired t-test, with 





































2.4.6 Assessment of induction of autophagic flux following drug treatment  
We then assessed whether autophagy is induced following treatment with paclitaxel 
and carboplatin. The entire autophagy process, from cargo sequestration to 
degradation is termed ‘flux’. Vesicle accumulation and indeed LC3II accumulation 
may be interpreted as either a block in the turnover of autophagosomes or an induction 
of the pathway. To distinguish between autophagy induction and accumulation due to 
blocking autophagosome turnover, cells were co-treated with CQ. ID8-luc2 cells were 
treated with paclitaxel alone or in combination with CQ (10µM) and allowed to 
recover in drug free media for 24 hours before autophagy induction was assessed. As 
shown in Figure 2.11A (i), treatment with paclitaxel alone (red overlay) resulted in 
vesicle accumulation, but the addition of CQ (green overlay) resulted in a further 
increase in vesicle accumulation, beyond that seen with CQ (turquoise overlay) or 
paclitaxel alone. This indicates an induction of autophagic flux. This was confirmed 
using western blot analysis of LC3II [Figure 2.11A (ii)]. The addition of CQ to 
paclitaxel (lanes 6-8) resulted in greater LC3II expression when compared to CQ alone 
(lane 2). 
Autophagy induction was also evident following carboplatin treatment in the ID8-luc2 
cells. Cyto-ID autophagy analysis revealed a significant increase in vesicle 
accumulation in cells treated with a combination of carboplatin and CQ (green 
overlay) when compared to either carboplatin (red overlay) or CQ alone (turquoise 
overlay) [Figure 2.11B (i)]. Western blot analysis of LC3II showed a greater 
accumulation of protein in carboplatin plus CQ treated cells (lane 4) compared to CQ 
alone (lane 2) [Figure 2.11 B (ii)]. These data are indicative of autophagy induction in 
the ID8-luc2 cells in response to both paclitaxel and carboplatin.  
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Vesicle accumulation was similarly assessed in all human OVCAR cell lines. As 
shown in Figure 2.12, the addition of CQ to (A) paclitaxel or (B) carboplatin (green 
overlays) in OVCAR-3 cells did not enhance vesicle accumulation beyond that with 
CQ alone (turquoise overlays), suggesting no autophagy flux in response to either 
drug. Western blot analysis revealed marginal increases in LC3II accumulation in 
response to paclitaxel and carboplatin following the addition of CQ [Figure 2.12C].  
In the OVCAR-4 cell line the addition of CQ to paclitaxel or carboplatin (green 
overlays) failed to show any vesicle accumulation beyond what is induced by CQ 
(turquoise overlays) (Figure 2.13A and B, respectively). However, western blot 
analysis did reveal enhanced accumulation of LC3II when CQ was added to 
carboplatin (lane 9) [Figure 2.13C]. 
In the OVCAR-5 cell line enhanced accumulation of autophagic vesicles was detected 
following the addition of CQ to both paclitaxel and carboplatin (Figure 2.14A and B, 
green overlays) when compared to CQ (turquoise overlays) or drug (red overlays) 
alone. LC3II accumulation was increased following the addition of CQ to paclitaxel 
(lanes 4 and 6) and carboplatin (lane 10) [Figure 2.14C]. Taken together, these data 
suggest that autophagy is induced in the OVCAR-5 cell line in response to both 
paclitaxel and carboplatin. 
In the OVCAR-8 cell line, the addition of CQ to both paclitaxel and carboplatin caused 
a significant increase in autophagic vesicle accumulation (green overlay) beyond that 
with CQ (turquoise overlays) or drug (red overlays) alone [Figure 2.15A and B].  
Western blot analysis confirmed an increase in LC3II following paclitaxel and CQ 
treatment (lanes 4 and 6), however, flux was not evident in carboplatin treated cells 
by western blot (lanes 8 and 10) [Figure 2.15C]. The Cyto-ID autophagy assay may 
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be detecting autophagosomes which are not tagged with LC3, resulting in increased 



























































































































Figure 2.11. Assessment of autophagy in the ID8-luc2 cell line after treatment with 
paclitaxel and carboplatin +/- CQ, followed by a 24 hour recover period. Cells were 
treated with paclitaxel (1, 2.5 or 5µM) +/- CQ (10µM) or carboplatin +/- CQ (40µM) for 
24 and 48 hours respectively and allowed to recover in drug free media for a further 24 
hours. Cyto-ID analysis by flow cytometry was utilised to assess autophagy induction after 
a 24 hour recovery period following (A)(i) paclitaxel or (B)(i) carboplatin treatment. A 
representative histogram overlay is presented to the left, while corresponding mean 
fluorescent intensities are graphed to the right (n=3). LC3II protein expression was 
measured via western blotting after the recovery period following (A)(ii) paclitaxel or 
(B)(ii) carboplatin treatment. Bands were quantified and normalised to β-actin, with the 
corresponding normalised integrated intensity values graphed to the right (n=1). 
Differences between means were analysed using a paired t-test, with significance defined 
























Figure 2.12. Assessment of autophagy in the OVCAR-3 cell line after treatment with 
paclitaxel and carboplatin +/-CQ, followed by a 24 hour recover period. (A) 
Following a 48 hour treatment with paclitaxel +/- CQ (10µM), or (B) carboplatin +/- CQ, 
cells were allowed 24 hours in drug free media to recover. Cyto-ID autophagy detection 
kit was used to assess autophagic vesicle accumulation. A representative histogram 
overlay is shown to the left, with corresponding mean fluorescent intensities graphed to 
the right (n=3). (C) Following the same treatment conditions, cells were probed for LC3II 
to assess autophagy induction. Blots were quantified and normalised to β-actin. 





























Figure 2.13. Assessment of autophagy in the OVCAR-4 cell line after treatment with 
paclitaxel and carboplatin +/- CQ, followed by a 24 hour recover period. Following a 
48 hour treatment with (A) paclitaxel +/- CQ (10µM) or (B) carboplatin +/- CQ, cells were 
allowed 24 hours in drug free media to recover. Cyto-ID autophagy detection kit was used 
to assess vesicle accumulation. Representative histogram overlays are presented to the left, 
alongside corresponding mean fluorescent intensity values to the right (n=3). (C) 
Following the same treatment condition, western blot analysis was performed to assess 
LC3II accumulation. Blots were scanned and quantified using the Odyssey Li-Cor Infrared 
scanning system and normalised to β-actin. Normalised integrated intensity values are 


























Figure 2.14. Assessment of autophagy in the OVCAR-5 cell line 24 hours after 
withdrawal of paclitaxel and carboplatin +/- CQ. Cyto-ID analysis by flow cytometry 
was utilised to assess autophagic vesicle accumulation following a 24 hour recovery 
following (A) paclitaxel +/- CQ (10µM) or (B) carboplatin +/- CQ treatment. 
Representative histogram overlays are presented to the left with their corresponding mean 
fluorescent intensity values presented to the right (n=3). (C) Western blot analysis of LC3II 
following withdrawal of paclitaxel and carboplatin was assessed. Blots were scanned and 
quantified using the Odyssey Li-Cor Infrared scanner. Integrated intensities are graphed as 

























































































Figure 2.15. OVCAR-8 cells were assessed for autophagy induction following a 24 hour 
recovery from paclitaxel and carboplatin treatment +/- CQ. Cyto-ID autophagy assay was 
used to assess autophagosome accumulation following a 24 hour recovery period from 
treatment with (A) paclitaxel +/- CQ (10µM) and (B) carboplatin +/- CQ. Histogram overlays 
are shown to the left, with corresponding mean fluorescent intensities graphed to the right 
(n=3) (C) Western blot analysis of LC3II was performed to further assess autophagy induction 
(n=3). Data is presented as LC3II normalised to β-actin. Differences in means were determined 




Taking the results from this study together, we can separate the cell lines based on 
their drug sensitivity, autophagy and apoptotic levels. The cell lines which had the 
lowest levels of basal and drug induced autophagy (OVCAR-3 and OVCAR-4), also 
displayed the highest levels of apoptosis, and were most sensitive to both drugs. In 
comparison, the cells with the highest levels of basal and drug induced autophagy 
(OVCAR-5 and OVCAR-8), displayed the lowest levels of apoptosis and were more 

















Evidence regarding the apoptotic and autophagic competency of OC cells in the 
literature is conflicted. This study has characterised a panel of OC cell lines in terms 
of their apoptotic and autophagic response to two clinically relevant 
chemotherapeutics, paclitaxel, and carboplatin.  
The panel of cell lines could be divided into two distinct subgroups. The ID8-luc2, 
OVCAR-5 and -8 cell lines were the most resistant to both drugs, while the OVCAR-
3 and -4 cell lines were the most sensitive. Furthermore, the most resistant cell lines 
were found to have the lowest active caspase-3 levels, while the most sensitive cells 
displayed the highest levels of active caspase-3. Despite seeing a visible reduction in 
clonogenic recovery in the ID8-luc2 cell line following treatment with paclitaxel and 
carboplatin, paclitaxel induced a small increase in caspase-3 cleavage (3%), while 
carboplatin did not induce any caspase-3 cleavage. It is possible that these cells have 
lost apoptosis, however, caspase-3 activation has previously been reported in the ID8 
cell line (Said and Motamed, 2005). Morphological analysis of ID8-luc2 cells treated 
with paclitaxel revealed features of mitotic catastrophe, such as G2/M arrest and 
micronucleation. It is possible that ID8 cells undergo caspase-independent mitotic 
death (CIMD), previously reported to occur in colon cancer cells following paclitaxel 
treatment (Niikura et al., 2007). Caspase-3 activation was not evident in any of our 
OC cells in response to carboplatin treatment. This suggests that the cytotoxic effects 
of carboplatin observed in the panel of OC cell lines is non-apoptotic. In contrast to 
our data, a study by Abed et al. (2016) reported increased caspase-3 activation in 
OVCAR-3, -4 and -8 cells following carboplatin treatment. This study however, used 
a significantly higher concentration of carboplatin, 66µM (Abed, Abdullah and 
Richardson, 2016). A postulated mechanism of action for carboplatin’s induction of 
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apoptosis is via ROS generation, reported only to occur at high concentrations (> 
50µM) in cardiomyocytes and human laryngeal carcinoma cells (Cheng et al., 2008) 
(Brozovic et al., 2013). Platinum salts, such as carboplatin, elicit their cytotoxic 
mechanisms via two methods: direct covalent bonding of the salt to the DNA resulting 
in adducts, or via the generation of ROS which form DNA adducts (Nunes and Serpa, 
2018). Supporting this observation, high levels of glutathione, a ROS scavenger, have 
been implicated in resistance to carboplatin. Thus, it is possible, that the low 
concentrations of carboplatin used in our study are insufficient for ROS generation 
and apoptosis induction, although we have not assessed this. In agreement with our 
findings, a recent study showed that carboplatin treatment in OVCAR-3 cells lead to 
Akt phosphorylation and XIAP stabilisation, resulting in the inhibition of caspase-3 
and -7 activation and lack of apoptosis induction (Zhang et al., 2018). Limited necrotic 
morphology was evident in OVCAR-3, -4 and -5 cells following carboplatin 
treatment. Supporting this observation, a recent study reported the induction of 
necroptosis in a carboplatin resistant OC cell line EFO-21, whereas apoptosis was 
induced in carboplatin sensitive OC cells IGROV-1 and A2780S (Thibault et al., 
2018). Necroptosis may be induced in our cells in response to carboplatin, however, 
this would need to be confirmed with specific markers, such as activation of RIPK3. 
Cancer cells use multiple pathways to evade drug induced death, including the 
upregulation of drug efflux pumps such as P-glycoprotein, leading to drug resistance. 
While each of the OVCAR cell lines have wild type BRCA, the promoter region of 
BRCA1 is hypermethylated in the OVCAR-8 cell line. A patient with extensive 
BRCA1 methylation was found to have lost this methylation during disease relapse 
after combination carboplatin treatment (Patch et al., 2015). Epigenetic alterations to 
BRCA genes after treatment may also contribute to resistance.  
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Further investigation into the cell death pathways underlying response to carboplatin 
in OC cells is necessary. 
We have demonstrated for the first time that apoptosis is reduced in OC cells following 
a re-challenge with paclitaxel, and that these cells are more resistant. This could have 
significant implications for the clinical management of OC, given that OC patients 
undergo multiple rounds of chemotherapy. Our results were obtained following a 
single paclitaxel treatment; however, it implies that apoptosis is likely abrogated 
following multiple treatments. Thus, targeting this pathway may be ineffective in the 
long term, which is consistent with the attainment of resistance in most patients. 
We have confirmed that the panel of OC cell lines express key autophagy proteins 
Beclin 1, Atg5/12 and LC3, and importantly, we have shown that the cell lines express 
varying levels of each protein. Furthermore, we have demonstrated that high protein 
expression levels are not predictive of a cells tendency to undergo autophagy. While 
the OVCAR-8 cells displayed the lowest expression of Beclin 1 and Atg5/12, they had 
the highest induction of basal autophagy. In OC, autophagy was found to be the most 
severely disrupted pathway by coincident gene deletions (Delaney et al., 2017). 
Despite this, each cell line in our panel was found to express key autophagy proteins 
and autophagy was readily inducible. In agreement with our findings, a previous study 
revealed that while a monoallelic deletion in BECN1 was found in OVCAR-8 cells, 
protein expression remained stable (Correa et al., 2015). Studies to date have focused 
on the prognostic value of autophagy biomarkers, as opposed to a ‘predictive’ 
biomarker, to stratify patients who will respond to a given treatment. A combination 
of autophagy markers, including LC3 and Beclin 1, have previously been used to 
determine autophagy activation, and infer clinicopathologic features relating to 
autophagy (Masuda et al., 2016) (Wolpin et al., 2014). However, our results suggest 
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that caution is warranted when selecting potential autophagy biomarkers based on 
their expression levels.   
Mirroring the caspase-3 data, the cell lines which previously displayed the lowest 
active caspse-3 levels (ID8-luc2, OVCAR-5 and -8) displayed the highest levels of 
autophagy flux in response to paclitaxel and carboplatin. The OVCAR-3 and -4 cell 
lines, which displayed the highest active caspase-3 levels, had the lowest levels of 
drug induced autophagy. Crosstalk between autophagy and apoptosis has been widely 
reported, with the consensus being that autophagy and apoptosis are mutually 
inhibitory. Autophagy can exert an inhibitory effect on apoptosis via the selective 
degradation of apoptotic proteins, such as caspase-8 (Hou et al., 2010). If a cell reaches 
a point of no return, apoptosis is activated, which can lead to the suppression of 
autophagy. Caspases can degrade several autophagic proteins including Atg5 and 
Beclin 1 (You et al., 2013). Caspase cleaved autophagy proteins can then acquire a 
pro-death role. The cleavage of Beclin 1 by caspase-3, -6 or -9 leads to the generation 
of a carboxy-terminal fragment downstream of its BH3 domain, which can bind to the 
mitochondria to mediate cytochrome c release via MOMP (Wirawan et al., 2010). 
Upon cleavage by caspase-3, ATG4D also acquires a pro-apoptotic role and is targeted 
to the mitochondria (Betin and Lane, 2009). A number of studies have shown that 
inhibiting autophagy can potentiate apoptosis (Kim et al., 2015) (Zhu et al., 2018) 
(Lohitesh et al., 2018). A study published this year found that inhibition of autophagy 
via microRNA targeting of LC3B, promoted apoptosis and increased the 
chemosensitivity of OC cells (Tang et al., 2019). Another study described the 
interaction of p53 and RAS signalling networks in mediating OC cisplatin resistance 
via modulation of both apoptosis and autophagy. P53 induction, along with the 
introduction of ERK active RAS mutants inhibited apoptosis and promoted autophagy 
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in OC cells, conferring cisplatin resistance, while AKT active RAS mutants had less 
autophagy, more apoptosis and were sensitive to cisplatin (Zhang et al., 2019). In these 
studies, autophagy played a cytoprotective role, suggesting that inhibition of 
autophagy may be a useful strategy in sensitising cells to treatment. Expression of key 
proteins which regulate autophagy may also account for the different levels of 
autophagy observed. In agreement with our observations, the OVCAR-3 cells, which 
displayed low autophagic flux in this study, have been reported to express high levels 
of mTOR, which supresses autophagy (Zhou et al., 2018).  
In summary, this study has shown that a panel of OC cells differ significantly in their 
response to chemotherapy. To our knowledge, this is the first study to assess a panel 
of OC cell lines in terms of their apoptotic and autophagic response to 
chemotherapeutic drugs. By using of a panel of OC cell lines, generated from different 
patient types, it is more representative of the heterogeneity which exists among 
patients in the clinic. This data also supports a personalised medicine approach and 
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Chapter Three: Evaluation of 
pharmacological modulators of 
autophagy: chloroquine, lithium 
and brefeldin A, on a panel of 










Five year survival rates for ovarian cancer remain poor and have not significantly 
improved in the last decade. The backbone of OC treatment remains cytoreductive 
surgery and a platinum/taxane chemotherapy doublet. Resistance to chemotherapy is 
a significant clinical hurdle which has yet to be overcome when treating OC. To 
improve patient outcomes, it is vital to elucidate novel treatment strategies to 
overcome chemoresistance. Autophagy has been implicated in OC chemoresistance 
and has gained interest as a therapeutic target. In this chapter, we aimed to assess the 
effect of autophagy modulators on the chemosensitivity of our panel of cell lines. 
Chloroquine was found to significantly reduce clonogenic recovery following drug 
treatment in the OVCAR-5 and -8 cell lines. In contrast, it exerted a protective effect 
in the OVCAR-3 and -4 cells. Lithium is a mood stabilising drug routinely used to 
treat bi-polar disorder; however, our group has previously shown it is an effective 
chemosensitising agent in both oesophageal and colon cancer. Similar to the effects of 
CQ, lithium could significantly sensitise OVCAR-5 and -8 cells to paclitaxel and 
carboplatin, but it did not sensitise OVCAR-3 cells. In addition, brefeldin A was used 
to block non-canonical Atg5/Atg7-independent autophagosome generation. The 
addition of brefeldin A to paclitaxel could significantly reduce autophagosome 
accumulation in ID8-luc2, OVCAR-5 and OVCAR-8 cells. While this data highlights 
autophagy as an attractive therapeutic target to overcome chemoresistance, it’s 







The standard of care for OC patients involves cytoreductive surgery combined with 
platinum and taxane chemotherapy. The combination of paclitaxel and carboplatin 
comprises the backbone of treatment for OC patients which is effective, well-tolerated 
and less toxic than other combination therapies.  Although patients treated with first 
line paclitaxel-carboplatin achieve a good clinical response, disease recurrence rates 
are 25 % for those with early stage disease and 80 % for those with advanced disease 
(Pokhriyal et al., 2019). Autophagy has been shown to play a role in chemoresistance 
in OC, with autophagy induction acting as a protective mechanism against cisplatin 
and paclitaxel (Zhan et al., 2016). Thus, autophagy inhibition has emerged as an 
attractive therapeutic target to combat resistance in OC. During the development of 
novel therapies, it can take upwards of 10 years before a potential drug will reach 
phase I clinical trials. As such, repurposing of drugs, that are already approved, has 
become an area of interest, particularly for cancer treatment.  
Chloroquine is one of only two autophagy modulating drugs which are FDA-approved 
for cancer treatment. Chloroquine and its analogues have well characterised toxicity 
profiles, due to their decades old use as anti-malarial agents, making them an attractive 
drug to target autophagy in the cancer setting. Chloroquine, which is a weak base, 
accumulates within acidic vesicles, such as lysosomes, where it raises intravesicular 
pH and impedes the function of lysosomal enzymes. This in turn impairs the fusion 
and digestion of autophagic vacuoles (Mauthe et al., 2018).  
Lithium is a mood stabilising drug, FDA approved for the treatment of bipolar 
disorder, with a track record of safety. The rationale for repurposing lithium as an 
anticancer agent came from a retrospective study of psychiatric patients receiving 
lithium, who displayed a significantly reduced incidence of cancer compared to their 
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non-lithium treated counterparts (Cohen et al., 1998). More recent studies conducted 
have corroborated these findings (Martinsson et al., 2016) (Huang et al., 2016) 
(Pottegard et al., 2016). A study published in 2019 using a systems biology approach 
highlighted the potential influence of lithium on cancer. Using STRING and KEGG 
pathway analysis, the study found mutual enrichment of STRING-derived 
interactomes of lithium sensitive enzymes with KEGG cancer related signaling 
pathways (Ge and Jakobsson, 2019). Experimental evidence also provides a rationale 
for using lithium to sensitise cancer cells to chemotherapy. A study by our group has 
shown that the addition of lithium to standard chemotherapeutic agents enhanced their 
cytotoxicity in oesophageal and colorectal cancer cells (O’Donovan et al., 2015). 
Another study reported the chemosensitising effect of lithium in colorectal cancer and 
ovarian cancer cells (Li et al., 2014). Therefore, in this study, we aimed to assess if 
lithium could sensitise OC cells to treatment. Although the way in which lithium exerts 
its cytotoxic effects remains controversial, a key pathway influenced by lithium is 
autophagy. Lithium has been reported to both induce and inhibit autophagy. Previous 
work published by our group has provided evidence to show an autophagy inhibitory 
effect of lithium, via lysosomal dysfunction (O’Donovan et al., 2015). Thus, we also 
aimed to assess the effects of lithium on autophagy in our OC cells.  
The Atg5/Atg7-independent autophagy pathway is a recently described alternative 
autophagy pathway, which can occur in the absence of Atg5 and Atg7 but requires 
Beclin 1. Autophagosomes formed during this pathway are thought to originate in the 
Golgi, as opposed to the ER during canonical autophagy. Brefeldin A, a known Golgi 
inhibitor, has previously been reported to inhibit this non-canonical pathway, but not 
canonical autophagy. In this study, we have used brefeldin A to assess the presence of 
Atg5/Atg7-independent autophagy, both basally and in response to treatment. A 
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schematic illustrating the expected effect on autophagosome accumulation via use of 
brefeldin A is depicted in Figure 3.1 below.  
 
 
3.3 Materials and Methods  
3.3.1 Cell culture and Reagents 
Established human ovarian cancer cell lines OVCAR-3, OVCAR-4, OVCAR-5 and 
OVCAR-8 were obtained directly from the NCI Frederick Cancer DCTC Tumor/Cell 
Line Repository. Murine ID8-luc2 cells were obtained from Mayo Clinic. All human 
OVCAR cell lines were maintained in RPMI 1640 media. OVCAR-3 and OVCAR-4 
cultures were supplemented with 20% (v/v) foetal calf serum, whilst OVCAR-5 and 
OVCAR-8 cultures were supplemented with 10% (v/v) foetal calf serum. Murine ID8-
luc2 cells were cultured using Dulbecco’s Modified Eagles Medium containing 10% 
(v/v) foetal calf serum.  All cultures were supplemented with 1% 
penicillin/streptomycin (Gibco Life Technologies 15070-063). Cells were grown in 
























3.3.2 Drug treatments 
Paclitaxel (Cat # T7402), Carboplatin (Cat # C2538), Chloroquine (Cat # C6628), 
Lithium Chloride (Cat # L9650) and Brefeldin A (Cat # B6542) were purchased from 
Sigma Aldrich. Paclitaxel was reconstituted in DMSO to give 58.55mM stock. 
Aliquots were prepared and stored at -20℃. Carboplatin was reconstituted in water to 
Figure 3.1. Schematic illustration of the anticipated effects of brefeldin A on 
autophagosome accumulation. In untreated cells, autophagosomes detected using 
the Cyto-ID autophagy assay may derive from both the canonical pathway and the 
Atg5/Atg7-independent pathway. The addition of CQ should block lysosomal 
fusion and lead to an accumulation of autophagosomes derived from both 
pathways. If basal Atg5/Atg7-independent autophagosomes are being generated, 
the addition of brefeldin A should prevent non-canonical autophagosome 
accumulation. Similarly, if chemotherapeutic treatment induces the generation of 
Atg5/Atg7-independent derived autophagosomes, the addition of brefeldin A 




give a 26.93mM stock, aliquoted and stored in the dark at room temperature. 
Chloroquine was reconstituted in water and stored at -20℃ in aliquots. Brefeldin A 
was reconstituted in 1ml of ethanol and stored at -20℃. Working concentrations of 
each drug were prepared in media on the day of treatment. Lithium chloride was 
weighed and resuspended in media to create a working stock (1mM) on the day of 
treatment.  
For the clonogenic recovery studies assessing CQ, cells were treated with paclitaxel 
or carboplatin +/- CQ (10 µM) for 24 or 48 hours. CQ was added 2 hours prior to any 
other drug treatment and remained for the duration of treatment. Cells were 
subsequently re-seeded for colonies growth. For clonogenic recovery studies assessing 
lithium, cells were treated with paclitaxel or carboplatin +/- lithium (10 or 20mM) for 
48 hours. Cells were then re-seeded for colonies growth.  
To assess the effect of lithium on autophagy, cells were treated with lithium (10 or 
20mM) +/-CQ (10µM) for 48 hours. Cells were then cytospun for morphological 
analysis, pelleted for western blots or stained with the Cyto-ID autophagy kit for flow 
cytometry analysis.  
To evaluate the effect of brefeldin A on autophagosome accumulation, cells received 
CQ (10µM) for 48 hours, with brefeldin A (10µg/ml) added for the final 24 hours of 
treatment. Alternatively, cells were treated with paclitaxel for 48 hours, with brefeldin 
A (10µg/ml) added for the final 24 hours of treatment. Cells were subsequently stained 




3.3.3 Colony formation assay 
Colony formation (clonogenic) assays were used to determine the ability of single cells 
to recover from a drug treatment and re-establish colonies. Following specified 
treatment, cells were trypsinised using 500µl of Trypsin EDTA (Sigma Aldrich, Cat # 
T4049) and viable cells counted using the NucleoCounter NC-100 (Chemometec). For 
the OVCAR-5, OVCAR-8 and ID8-luc2 cell lines 1,500 viable cells were re-seeded 
into a well of a six-well plate (Nunc™ Thermo Scientific, Cat # 140685). For the 
OVCAR-3 and OVCAR-4 cell lines, 2,500 cells were re-seeded in the same manner. 
Cells were allowed to adhere and grow for between 10 and 14 days, until control wells 
reached at least 70% confluency. Following the recovery period, media was aspirated, 
and wells were washed once with PBS. Cells were then fixed in 96% ethanol for 5 
minutes and stained with Pro-diff solution C (Braidwood Laboratories E310) for 5 
minutes. Following a rinse with water to remove excess stain, plates were allowed to 
air-dry overnight. Plates were then scanned and quantified using the Odyssey IR 
imaging system (Li-Cor, Cambridge, United Kingdom).  
 
3.3.4 Cyto-ID autophagy detection kit 
Treated cells were trypsinised using 500µl of Trypsin EDTA (Sigma Aldrich, Cat # 
T4049) and stained using the Cyto-ID autophagy detection kit (Enzo Life Sciences, 
Cat # ENZ-51031-K200) according to the manufacturer’s instructions. Cyto-ID is a 
cationic amphiphilic tracer dye which selectively accumulates within autophagic 
vesicles. An increase in autophagic vacuole accumulation will result in an increase in 
fluorescence in the 488-2 channel. Samples were run on the BD LSRII flow cytometer 
with FACS Diva acquisition and analysis software. FlowJo data analysis software was 
 
 161 
used for gating and generating overlay histograms. Data is presented as Mean 
Fluorescence Intensity (MFI). 
 
3.3.5 Western Blotting  
Total cellular protein was extracted by trypsinisation of cells followed by lysing in 10-
25µl of modified RIPA buffer (50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.25% 
sodium deoxycholate, 1% Igepal, 1 mM EDTA, 1x Pefabloc, 1x protease inhibitor 
cocktail, 1 mM Na3VO4, 1 mM NaF), depending on pellet size. Samples (75 μg) were 
separated on NuPAGE 4–12% Bis-Tris gels (Invitrogen Life Technologies, Cat # 
NP0322) and electrophoretically transferred onto a PVDF membrane using the iBlot 
gel transfer system (Invitrogen, Cat # IB1001). Membranes were blocked with 
Odyssey blocking buffer (Li-Cor, Cat # 927-40100) for 1 hour at room temperature, 
and incubated overnight at 4℃ using: anti- ATG5 (Novus, Cat # NB110-53818), anti-
Beclin 1 (Novus, Cat # NB500-249) and anti-Rab9 (Abgent, Cat # ab2810) antibodies. 
Anti-β-actin (loading control) (Sigma, Cat # A5441) was incubated at room 
temperature, rocking, for one hour. IR-Dye conjugated secondary antibodies 
(Rockland) were utilised for protein detection on the Odyssey Infra-red imaging 
system (Li-Cor, Cambridge, United Kingdom).  
 
3.3.6 Evaluation of morphology 
Treated cells were cytospun and allowed to air dry for 5 minutes. Cells were then fixed 
using methanol and stained using May Grunwald Giemsa (DiaPath). Cells which were 
apoptotic were identified based on the presence of two or more of the following 
morphological features: cell shrinkage, chromatin condensation or DNA 
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fragmentation into ‘apoptotic bodies’. Images were acquired using a DP70 digital 
microscope camera and Olympus DP-Soft 823 version 3.2 software (Mason 
Technologies Dublin, Ireland).  
 
3.3.7 Statistical Analysis 
All data is expressed as mean ± the standard error of the mean (SEM), which represents 
the standard deviation of the distribution of the sample around the mean. Significance 
was determined by independent or paired student t-tests, which determines the 
difference between the means of two groups. The p-value was considered statistically 
significant where *p < 0.05, ** p < 0.01, *** p < 0.001. Statistical analysis was carried 
out and graphed using GraphPad Prism 5 software (GraphPad Software Inc., CA, 









3.4 Results  
3.4.1 Inhibition of autophagy with CQ sensitises ID8-luc2 cells to paclitaxel and 
carboplatin  
In the previous chapter, autophagic flux, in response to paclitaxel and carboplatin was 
observed in the ID8-luc2 cell line. Clonogenic assays revealed that ID8-luc2 cells can 
recover and form colonies after paclitaxel and carboplatin treatment. The effect of 
chloroquine (CQ), which impedes autophagy, on chemosensitivity was therefore 
assessed in this cell line.  
ID8-luc2 cells were treated with paclitaxel (24 hours) and carboplatin (48 hours) alone 
or in the presence of CQ. Following treatment, 1500 viable cells were reseeded in 
triplicate and allowed to recover in drug-free medium for 10-14 days. The addition of 
CQ to paclitaxel and carboplatin significantly reduced clonogenic recovery in the ID8-
luc2 cell line following 1µM paclitaxel (*p = 0.018) and 40µM carboplatin (**p = 
0.004) treatment [Figure 3.2 A and B, respectively]. A reduction in clonogenic 
recovery was evident following the addition of CQ to 2.5 µM paclitaxel, although it 



























Figure 3.2. ID8-luc2 clonogenic recovery is significantly reduced following the addition 
of CQ to paclitaxel and carboplatin. (A) Cells were treated with 1µM and 2.5µM paclitaxel 
± CQ (10 µM) for 24 hours, re-seeded (1500 cells per well) and allowed to recover for 10-14 
days. (B) Cells were treated with 40 µM carboplatin ± CQ for 48 hours, re-seeded (1500 cells 
per well) and allowed to recover for 10-14 days. All colonies were stained and scanned using 
the Li-COR Infrared Odyssey Scanner. Integrated intensities were quantified, and data is 
graphed as % control (where control = 100%), (n=3). Statistical significance was defined 
where *p < 0.05, **p < 0.01.  
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3.4.2 Assessment of the effect of CQ on recovery of OVCAR-3 and OVCAR-4 
cells following treatment  
The addition of CQ to the OVCAR-3 cell line resulted in a significant protective effect 
following treatment with paclitaxel (*p = 0.010, **p = 0.001; respectively), and a 
moderate protective effect following treatment with carboplatin, which was not 
significant [Figure 3.3 A and B, respectively]. In contrast, the addition of CQ to the 
OVCAR-4 cell line significantly reduced clonogenic recovery following treatment 
with paclitaxel (*p = 0.028, *p = 0.017; respectively), while CQ protected OVCAR-4 


















Figure 3.3. Assessment of the effect of CQ on the clonogenic recovery of OVCAR-3 and 
OVCAR-4 cell lines following treatment with paclitaxel and carboplatin. OVCAR-3 and 
-4 cells were treated with paclitaxel or carboplatin ± CQ. Following treatment viable cells 
were re-seeded (2500 cells per well) and clonogenic recovery was assessed. OVCAR-3 cell 
recovery following (A) paclitaxel or (B) carboplatin plus or minus CQ (10µM). OVCAR-4 
cell recovery following (C) paclitaxel or (D) carboplatin treatment ± CQ. All colonies were 
fixed, stained and scanned using the Li-Cor Odyssey Infrared scanner. Integrated intensities 
were obtained and graphed as % control (where control = 100%) (n=3). Statistical significance 




3.4.3 Inhibition of autophagy with chloroquine sensitises OVCAR-5 and 
OVCAR-8 cells to paclitaxel and carboplatin 
In contrast to the OVCAR-3 and -4 cells, strong evidence for autophagy flux was 
observed by Cyto-ID or western blot in the OVCAR-5 and -8 cell lines in response to 
paclitaxel and carboplatin. The effect of CQ on recovery was therefore assessed in 
these cell lines.  
The addition of CQ to paclitaxel significantly sensitised both OVCAR-5 and OVCAR-
8 cells to paclitaxel treatment (*p = 0.045, *p = 0.022; *p = 0.01 respectively) [Figure 
3.4A and C]. In addition, the recovery of both the OVCAR-5 and OVCAR-8 cell lines 
was significantly reduced by the addition of CQ following treatment with 10 and 5µM 
carboplatin respectively [Figure 3.4B and D]. These data would encourage the use of 
chloroquine as a chemosensitising agent in cancer cells that respond to chemotherapy 
































Figure 3.4. Assessment of the effect of CQ on the clonogenic recovery of OVCAR-5 and 
OVCAR-8 cell lines following treatment with paclitaxel and carboplatin. Following 
treatment with carboplatin ± CQ (10µM), OVCAR-5 and -8 cells were re-seeded (1500 cells 
per well) and allowed to recover for 10-14 days. OVCAR-5 cell recovery following (A) 
paclitaxel and (B) carboplatin ± CQ. OVCAR-8 cell recovery following (C) paclitaxel and (D) 
carboplatin ± CQ. All colonies were fixed, stained and scanned using the Li-Cor Odyssey 
Infrared scanner. Data is presented graphically as % control (where control = 100%) (n=3). 




3.4.4 Lithium significantly enhances chemosensitivity in a panel of OC cell lines 
Lithium is a mood stabilising drug commonly used in the management of bipolar 
disorder. Previous work by our group has demonstrated the chemo-sensitising effect 
of lithium in oesophageal and colorectal cancer cells (O’Donovan et al., 2015). To test 
this in the panel of OC cell lines, cells were treated with lithium along with paclitaxel 
and carboplatin, and clonogenic recovery was assessed. 
Treatment with lithium significantly sensitised ID8-luc2 cells to 40µM carboplatin, 
with no visible colonies remaining (**p = 0.003) [Figure 3.5]. Lithium did not 
sensitise the murine ID8-luc2 cells to paclitaxel (data not shown). The addition of 
lithium to paclitaxel significantly reduced clonogenic recovery in three of the OVCAR 
cell lines tested. Reduced clonogenic recovery in the OVCAR cell lines following 
treatment with lithium and paclitaxel was greater than that of either drug alone, 
suggesting an additive effect. A notable reduction in clonogenic recovery was evident 
with the OVCAR-5 and -8 cell lines following lithium addition to paclitaxel [Figure 
3.6C and D, respectively]. The effect of lithium on paclitaxel sensitivity in the 
OVCAR-4 cell line remains to be determined. 
The addition of lithium to carboplatin had no effect on the OVCAR-3 cell line and a 
limited effect on the OVCAR-4 cell line [Figure 3.7A and B, respectively]. The 
OVCAR-5 and OVCAR-8 cell lines showed significant sensitisation at both 

























Figure 3.5. A significant reduction in recovery following treatment with lithium and 
carboplatin is evident in ID8-luc2 cells. To assess a potential synergistic effect between 
lithium and carboplatin, cells were treated with both drugs alone and in combination, and 
clonogenic recovery was assessed. ID8-luc2 cells were seeded (1500 cells per well) and 
allowed to recover. Integrated intensities were obtained and presented as % control (where 























Figure 3.6. Lithium significantly sensitises OVCAR-3, -5 and -8 cells to paclitaxel. 
Following treatment with lithium and paclitaxel for 48 hours, clonogenic recovery was 
assessed. (A) OVCAR-3 cells were re-seeded (2500 cells per well) after treatment and 
recovery was assessed. (B) OVCAR-5 cells and (C) OVCAR-8 cells were seeded (1500 cells 
per well) and allowed to recover. All colonies were fixed, stained and scanned using the Li-
Cor Odyssey Infrared scanner. Integrated intensities are graphed as % control (where control 









Figure 3.7. A significant reduction in recovery following combination treatment with 
lithium and carboplatin is evident in OVCAR-4, -5 and -8 cells. To assess a potential 
synergistic effect between lithium and carboplatin, cells were treated with both drugs alone 
and in combination, and clonogenic recovery was assessed. (A) OVCAR-3 and (B) OVCAR-
4 cells were re-seeded (2500 cells per well) after treatment and recovery was assessed. (C) 
OVCAR-5 cells and (D) OVCAR-8 cells were seeded (1500 cells per well) and allowed to 
recover. All colonies were fixed, stained and scanned using the Li-Cor Odyssey Infrared 
scanner. Integrated intensities are graphed as % control (where control = 100%) (n=3). 








3.4.5 Evaluation of the effects of lithium on autophagy  
Previous work by our group has demonstrated a role for lithium in modulating 
autophagy by inhibiting turnover (O’Donovan et al., 2015). The cell lines which 
displayed sensitivity to lithium (ID8-luc2, OVCAR-5 and -8), all displayed the highest 
levels of autophagic flux in chapter two. Therefore, we aimed to determine if there 
were any effects of lithium on autophagy in these cell lines, which may contribute to 
its chemosensitising effects.     
 
3.4.5.1 Evaluation of the effects of lithium on autophagy in ID8-luc2 cells 
In the ID8-luc2 cells, autophagy was assessed after 48 hour treatment. Morphology 
was assessed for the presence of vesicles (highlighted with black arrows). While 
vesicles were present in untreated cells (left hand panels), a greater accumulation of 
vesicles were present following 48 hour treatment with 20mM lithium (right hand 
panels) [Figure 3.8A]. To assess the effect of lithium on autophagic flux (described in 
chapter two, results section 2.4.6), cells were pre-treated with CQ alone and in 
combination with lithium. As shown in figure 3.8 (B), treatment with CQ alone for 48 
hours resulted in an increase in vesicle accumulation (turquoise overlays), as assessed 
by Cyto-ID. Treatment with lithium caused a significant increase in vesicle 
accumulation (red overlay), which was significantly enhanced by CQ (green overlay), 
suggesting induction of autophagic flux (***p =0.0001). To confirm autophagy 
induction, LC3II expression was measured using western blotting. In contrast to the 
Cyto-ID data, lithium alone caused a decrease in LC3II expression. The expression of 
LC3II following treatment with CQ and lithium could not be quantified and would 
need to be repeated [Fig 3.8C]. This data suggests that in the ID8-luc2 cell line, lithium 
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can induce autophagosome accumulation, however we cannot conclude if the 








































































Figure 3.8. Evaluation of the effects of lithium on autophagy in ID8-luc2 cells. 
Cells were treated with lithium chloride (lithium) (20mM) alone and in 
combination with CQ (10µM) for 48 hours. (A) Cells were stained using Pro-diff 
II to assess vesicle accumulation in untreated (left hand panels) and lithium treated 
cells (right hand panels) (magnification 400X). Vesicles are highlighted with black 
arrows. (B) Cyto-ID analysis was used to assess vesicle accumulation following 48 
hour treatment with lithium ± CQ. Mean fluorescent intensities are graphed ± SEM 
(n=3), to the right of the representative histogram overlays. (C) Western blot 
analysis of LC3I and LC3II following 48 hour treatment with lithium +/- CQ. Blots 
were scanned using the Odyssey Infrared Imaging system (Li-Cor) (n=1). Values 





3.4.5.2 Evaluation of the effects of lithium on autophagy in OVCAR-5 and -8 
cells 
OVCAR-5 cells received treatment with 10mM lithium. Morphological analysis of 
OVCAR-5 cells revealed enhanced cytoplasmic accumulation of vesicles following 
48 hour lithium treatment (right hand panels) compared to untreated cells (left hand 
panels) [Figure 3.9A]. Features of apoptosis (described in methods section 5.3.4 and 
indicated with green arrows) were evident 48 hours post lithium treatment. Cyto-ID 
analysis revealed enhanced vesicle accumulation following 48 hour lithium treatment 
(red overlay) (**p = 0.005) or CQ alone (turquoise overlay) [Figure 3.9B]. The 
combination of both further enhanced accumulation although it was not statistically 
significant (green overlay) [Figure 3.9 B]. Analysis of LC3II expression revealed a 
modest increase in expression following treatment with lithium at 48 hours, which was 
not enhanced by the addition of CQ [Fig 3.9C].  
In the OVCAR-8 cell line, vesicle accumulation (indicated with black arrows) was 
enhanced following a 48 hour treatment with lithium [Figure 3.10A]. Features of 
apoptosis (indicated with green arrows) were present 48 hours post lithium treatment 
(top right hand panel) [Figure 3.10A]. Cyto-ID analysis revealed a slight accumulation 
of autophagic vesicles after lithium treatment (red overlay), which was further 
increased, although not significantly, by CQ (green overlay), suggesting moderate flux 
[Figure 3.10B]. Western blot analysis of LC3II expression showed no increase in 
LC3II levels following 48 hour lithium treatment, with no increase in expression 
following the addition of CQ [Figure 3.10C]. Taken together, this data implies lithium 

























































Figure 3.9. Evaluation of the effects of lithium in OVCAR-5 cells. Cells were treated 
with lithium chloride (lithium) (10mM) alone and in combination with CQ (10µM) for 48 
hours. (A) Cells were stained using Pro-diff II to assess vesicle accumulation in untreated 
(left hand panels) and lithium treated cells (right hand panels) (magnification 400X). 
Vesicles are highlighted with black arrows. Cells displaying apoptotic features following 
lithium treatment are indicated with green arrows. (B) Cyto-ID analysis was used to assess 
vesicle accumulation following 48 hour treatment with lithium ± CQ. Mean fluorescent 
intensities are graphed ± SEM (n=3), beside the representative histogram overlays. (C) 
Western blot analysis of LC3I and LC3II following 48 hour treatment. Bands were 
quantified, normalised to β-actin and integrated intensities graphed (n=1). Values were 























































Figure 3.10. Evaluation of the effects of lithium in OVCAR-8 cells. Cells were treated 
with lithium (20mM) alone and in combination with CQ (10µM) for 48 hours. (A) Cells 
were stained using Pro-diff II to assess vesicle accumulation in untreated (left hand panels) 
and lithium treated cells (right hand panels) (magnification 400X). Vesicles are highlighted 
with black arrows. Cells displaying apoptotic features following lithium treatment are 
indicated with green arrows. (B) Cyto-ID analysis was used to assess vesicle accumulation 
following 48 hour treatment with lithium ± CQ. Mean fluorescent intensities are graphed 
± SEM, to the right of representative histogram overlays (n=3). (C) Western blot analysis 
of LC3I and LC3II following 48 hour treatment. Bands were quantified using the Odyssey 





3.4.6 Non-canonical autophagy may contribute to basal autophagy in OVCAR-5 
and OVCAR-8 cells  
The Atg5/Atg7 independent non-canonical autophagy pathway has recently been 
described, and has been shown to be induced following chemotherapy treatment 
(Arakawa et al., 2017). We therefore wanted to assess whether this non-canonical 
pathway was present in our cells. Autophagosomes generated during Atg5/Atg7 
independent non-canonical autophagy have been reported to originate from the Golgi 
apparatus and brefeldin A has been shown to inhibit this type of autophagy (illustrated 
in figure 3.1 of section 3.3) (Grose and Klionsky, 2016), (Nishida et al., 2009). To 
assess the accumulation of autophagosomes originating from the Golgi, brefeldin A 
was used. 
Basal accumulation of non-canonical derived autophagosomes was first assessed. 
Cells were treated with chloroquine for 48 hours ± brefeldin A (10µg/ml), with 
brefeldin A added for the final 24 hours of treatment. As evident in Figure 3.11A and 
B respectively, the addition of brefeldin A (red overlays) could significantly reduce 
basal autophagic vesicle levels in the OVCAR-5 (**p = 0.004) and OVCAR-8 (**p = 
0.002) cell lines. Brefeldin A could also significantly reduce CQ-dependent 
autophagic vesicle accumulation in the OVCAR-5 (**p = 0.008) and OVCAR-8 (*p 
= 0.025) cell lines, providing further evidence that non-canonical autophagy is 
contributing to overall accumulation. Non-canonical derived autophagosomes were 
similarly assessed in OVCAR-3 and -4 cells. Brefeldin A reduced autophagosome 
accumulation alone and when added with CQ in OVCAR-3 and -4 cells, although this 
reduction was significant in the OVCAR-4 cells only [Supplementary figure 1]. These 

























































Figure 3.11. Assessment of the presence of basal non-canonical autophagy in OVCAR-5 
and OVCAR-8 cells. The OVCAR-5 and -8 cells were treated for 48 hours with CQ (10µM), 
with brefeldin A (10µg/ml) added for the final 24 hours of treatment. Cyto-ID autophagy assay 
was used to assess autophagy levels in (A) OVCAR-5 and (B) OVCAR-8 cells. Representative 
histogram overlays are presented to the left, with mean fluorescent intensities graphed to the 




































3.4.7 Non-canonical autophagy may contribute to the response to paclitaxel in 
OVCAR-5 and OVCAR-8 cells 
We then assessed the effect of brefeldin A on paclitaxel dependent autophagosome 
accumulation. Following a 48 hour treatment with paclitaxel, OVCAR-5 and 
OVCAR-8 cells were placed in paclitaxel free media which contained brefeldin A 
(10µg/ml) for a further 24 hours. Autophagosome accumulation was assessed using 
the Cyto-ID autophagy assay. Treatment with brefeldin A significantly reduced 
paclitaxel induced vesicle accumulation in OVCAR-5 (**p = 0.003) and OVCAR-8 
(**p =0.005) cell lines [Figure 3.12A and B respectively]. Similar effects of brefeldin 
A on non-canonical autophagosome accumulation following paclitaxel treatment were 
observed in OVCAR-3 and -4 cells [Supplementary figure 2]. These data indicate that 































Figure 3.12. Evaluation of the presence of non-canonical autophagy following treatment 
with paclitaxel in OVCAR-5 and OVCAR-8 cells. The Cyto-ID autophagy detection kit was 
used to measure autophagosome accumulation after treatment with paclitaxel ± brefeldin A 
(10µg/ml). Representative histogram overlays are shown in the left-hand panels for (A) 
OVCAR-5 and (B) OVCAR-8 cells, with corresponding mean fluorescent intensities from 
triplicate samples graphed to the right (n=3). Asterisks indicate a significant difference 





































































Here we have evaluated the chemosensitising effects of autophagy modulators in our 
panel of OC cell lines. We have observed that CQ exerts a protective effect in two of 
our cell lines, OVCAR-3 and -4. The protective effect of CQ on the OVCAR-3 cell 
line observed in our study may be attributable to caspase inhibitory effects. CQ is 
widely used as an inhibitor of autophagic flux, however, autophagy-independent 
functions of CQ, such as apoptosis modulation, have been described. CQ has been 
reported to elicit both pro- and anti-apoptotic effects. It can enhance TRAIL mediated 
apoptosis via upregulation of death receptor 5 (DR5) (Park et al., 2016). CQ can act 
as a DNA intercalator, and has been reported to induce apoptosis via p53 activation, 
potentially by causing structural DNA perturbations which upregulate p53 signalling  
(Tan et al., 2012) (Kim et al., 2010). In contrast, CQ was also found to impede 
apoptosis by reducing caspase-3 levels in OVCAR-3 cells (Lang et al., 2015). The 
protective effect of CQ on the OVCAR-3 cell line observed in our study may therefore 
be attributable to such caspase inhibitory effects, and further work would be needed 
to confirm this. 
The addition of CQ to paclitaxel and carboplatin had a chemosensitising effect in both 
the OVCAR-5 and -8 cell lines, which displayed higher levels of autophagy. It is 
possible that the enhanced cytotoxicity is related to a higher dependency on autophagy. 
In agreement with our study, pre- treatment with CQ was found to increase paclitaxel 
sensitivity in lung cancer cells via inhibition of autophagy (Datta et al., 2019). 
Similarly, CQ could sensitise paclitaxel-resistant ovarian, lung and sarcoma cells to 
treatment via autophagy inhibition, and via inhibition of drug efflux transporters on 
the cell membrane (Gao, Xu and Qiu, 2015). Another study reported that 
cytoprotective autophagy was induced in OC cells via Akt/mTOR activation in 
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response to cisplatin. The addition of CQ led to an inhibition of autophagy and 
sensitised the cells to cisplatin (Zhu et al., 2017). Studies have also shown that CQ 
mediated autophagy inhibition can enhance apoptosis. This was reported in 
osteosarcoma cells, whereby the addition of chloroquine could enhance apoptosis by 
inhibiting autophagy (Ishibashi et al., 2019). Another study showed that apoptosis 
induced by cisplatin in gastric cancer cells could be enhanced via the addition of CQ, 
and this effect was due to the inhibition of autophagy (Jin et al., 2014). In our cell 
lines which demonstrated enhanced chemosensitivity following the addition of CQ, 
drug induced apoptosis levels were low with paclitaxel and absent with carboplatin, 
as discussed in chapter two. It is possible that CQ is increasing apoptosis in these cells 
or another cell death mechanism, mediating the enhanced toxicity observed. It will be 
important going forward to test the effect of CQ on apoptosis in all of the cell lines.  
CQ can also elicit its cytotoxic effects independently of caspase mediated apoptosis 
via lysosomal cell death (LCD). LCD is executed via lysosomal membrane 
permeabilisation (LMP). During LMP, lysosomal proteases, such as cathepsins, are 
released from the lysosome, where they can mediate both caspase-dependent and 
independent cell death mechanisms, including necrosis (Aits and Jäättelä, 2013).  Thus 
in apoptosis deficient cells, CQ may sensitise cells to treatment via activating other 
cell death pathways, as was reported by Circu et al in  non-small-cell lung cancer cells, 
which underwent cathepsin-mediated death (Circu et al., 2018). Another study 
reported lysosomal mediated death following CQ treatment in metastatic breast cancer 
cells, which was dependent on glucose (Gallagher et al., 2017). Alternative cell death 
induced by CQ may also be important for sensitising OC cells to chemotherapy, given 
that we have demonstrated diminished apoptosis in OC cells following re-challenge 
with paclitaxel in chapter two.  
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Multiple clinical trials are underway assessing the efficacy of CQ (and its derivative 
hydroxychloroquine) in combination with chemotherapies (Duffy et al., 2015). The 
HYDRA-1 study is a phase I/II trial investigating the tolerability and efficacy of 
combining hydroxychloroquine with Itraconazole for platinum resistant epithelial OC 
patients (NCT03081702). Given that we have shown a protective effect of CQ in the 
OVCAR-3 and OVCAR-4 cells in response to chemotherapeutic drugs, our results 
suggest that caution is warranted when using CQ to treat OC patients in the clinic. Its 
use could be detrimental to some patients rather than beneficial. Further studies are 
needed to elucidate the effect of CQ on OC cells to enable its effective implementation 
into current treatment strategies.  
Like CQ, we have shown that lithium can significantly sensitise three of our five cell 
lines OC cells to both paclitaxel and carboplatin (ID8-luc2, OVCAR-5 and -8). In 
contrast to our results, a study reported that lithium significantly increased resistance 
to cisplatin in OC cells (Cai et al., 2007). Similarly, the addition of lithium to two high 
grade serous OC cell lines did not elicit a chemosensitising effect (Novetsky et al., 
2013). However, the study by Novetsky et al. (2013) used 1mM lithium, 10 times less 
than that used in our study suggesting dose dependent effects of lithium, which has 
been reported in other studies. In breast cancer MCF-7 cells, it was found that at low 
lithium concentrations (1-10mM), cells were protected from apoptosis via reductions 
in caspase-2 and -7 and increases in anti-apoptotic proteins such as BAX (Suganthi et 
al., 2012). Similarly, another study using PC12 neural cells found that a higher 
concentration of lithium (9.6 mM) was found to decrease cell viability, while at a 
lower concentration (2.4mM) cell viability was not affected (Sahebgharani et al., 
2008).   Comparable to our study, lithium was  found to significantly inhibit the growth 
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of SKOV3 OC cells in vitro and in vivo, when SKOV3 cells were xenografted into 
mice (Cao, Lu and Feng, 2006).  
Our study revealed that in the OVCAR-3 cells there was no benefit to adding lithium 
to both drugs. We have previously characterised this cell lines as having low 
autophagy levels. By comparison, significant chemosensitisation was evident 
following the addition of lithium to both drugs in the OVCAR-5 and OVCAR-8 cell 
lines, which displayed high levels of autophagy. This suggests that lithium’s 
chemosensitising ability may be autophagy dependent. The role of lithium in 
modulating autophagy is conflicting, with studies reporting both inhibition and 
promotion of autophagy. Induction of autophagy via lithium has been reported to elicit 
a variety of neuroprotective functions primarily via the clearance of aggregate 
proteins. Lithium has been reported to induce autophagy by inhibiting inositol 
monophosphatase (IMPase), resulting in a decrease of free inositol and myo-inositol-
1,4,5-triphosphate (IP3). This inhibitory effect of IMPase by lithium increased the 
cellular clearance of mutant huntingtin fragments by induction of autophagy (Sarkar 
et al., 2005). Lithium has also been shown to exert autophagy inhibitory effects (Li et 
al., 2010). In our analysis, lithium treatment caused an increase in vesicles in the ID8-
luc2, OVCAR-5 and -8 cells, as evident by the Cyto-ID autophagy assay, while 
observational analysis of morphology also revealed enhanced vesicle accumulation. 
However, in the OVCAR-5 and -8 cell lines, the addition of CQ to lithium-treated cells 
did not significantly enhance the accumulation of autophagosomes, suggesting 
compromised flux. We hypothesised that if lithium impedes autophagic flux, it may 
explain why our cells which previously exhibited the greatest autophagy flux were the 
most sensitive to lithium. In line with this, our group has previously suggested that 
compromised flux, due to lysosomal dysfunction, may contribute to lithium’s 
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cytotoxic effects (O’Donovan et al., 2015).  In addition to compromised flux, lithium 
can also inhibit autophagy via inhibition of GSK-3β, leading to mTOR activation 
(Sarkar et al., 2008). 
Several studies also describe lithium’s modulating effects on apoptosis, with both pro 
and anti-apoptotic effects reported. In colon cancer cells, the addition of lithium to 
cisplatin increased caspse-3 activity and reduced cell viability (Bao et al., 2014). In 
contrast, lithium has also been reported to exert anti-apoptotic effects. Lithium was 
found to reverse propofol-induced caspase 3 activation, while a separate study 
reported diminished caspase 3 expression in a rat model of brain injury, which was 
attributed to upregulation of the anti-apoptotic protein XIAP (Straiko et al., 2009) (Li 
et al., 2010). In our study, morphological features of apoptosis were evident in 
OVCAR-5 and -8 cells following lithium treatment, which may be attributable to its 
cytotoxicity. Future work will aim to elucidate a mechanism of action for lithium. 
Apoptosis assays will be conducted, as well as western blotting and flow cytometry to 
assess the effect of lithium on lysosome function. Future work will also evaluate the 
chemosensitising ability of lithium in xenograft models and in vivo models. Given that 
we have shown significant chemosensitising effects of lithium, a drug known to be 
safe and well tolerated, it provides a plausible additional therapeutic option for OC 
patients.   
We have demonstrated that brefeldin A significantly reduces basal and paclitaxel-
induced autophagosome accumulation, suggesting that a non-canonical brefeldin A-
sensitive autophagy may be present in OC cells. To our knowledge this has not 
previously been reported.  During our study, we also performed clonogenic assays 
with the addition of brefeldin A to assess any chemosensitising effects in our cells. 
However, due to high toxicity of brefeldin A alone, any sensitising effects when 
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combined with chemotherapeutics could not be determined. Future studies will be 
repeated with lower doses, or reduced treatment times. Other studies however have 
reported the benefit of pharmacological modulation with brefeldin A to sensitise OC 
cancer cells. Brefeldin A has been reported to inhibit migration and invasion and to 
induce intrinsic apoptosis and caspase-8 activation in OVCAR-3 cells (Lee, Kim and 
Lee, 2013). In line with its potential as an anti-cancer agent, efforts are being made to 
develop brefeldin A analogues with enhanced pharmacological properties and anti-
proliferative activity (Paek, 2018). 
The results from this study may have important clinical ramifications. While these 
data highlight autophagy modulation as an attractive therapeutic target to overcome 
chemoresistance for some patients, it may not provide any benefit to others. Cell line 
dependent effects of CQ and lithium were observed, with chemosensitising effects 
evident only in the cell lines which displayed low apoptosis and high autophagy levels. 
This highlights the patient specific approach which must therefore be undertaken when 










3.6 References  
Aits, S. and Jäättelä, M. (2013) ‘Lysosomal cell death at a glance’, Journal of Cell Science, 
126(9), p. 1905-1912. 
Bao, H. et al. (2014) ‘Delayed administration of a single dose of lithium promotes recovery 
from AKI.’, Journal of the American Society of Nephrology: JASN, 25(3), pp. 488–500.  
Cai, G. et al. (2007) ‘Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers 
cisplatin resistance in ovarian cancer cells.’, International Journal of Oncology, 31(3), pp. 
657–662. 
Cao, Q., Lu, X. and Feng, Y.-J. (2006) ‘Glycogen synthase kinase-3β positively regulates the 
proliferation of human ovarian cancer cells’, Cell Research, 16(7), pp. 671–677.  
Circu, M. et al. (2018) ‘Modulating lysosomal function through lysosome membrane 
permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-
small-cell lung cancer cells, PLoS ONE, 12(9), pp.e0184922. 
Cohen, Y. et al. (1998) ‘Cancer morbidity in psychiatric patients: influence of lithium 
carbonate treatment.’, Medical Oncology, 15(1), pp. 32–36.  
Datta, S. et al. (2019) ‘Autophagy inhibition with chloroquine reverts paclitaxel resistance and 
attenuates metastatic potential in human nonsmall lung adenocarcinoma A549 cells via ROS 
mediated modulation of beta-catenin pathway.’, Apoptosis: An International Journal on 
Programmed Cell Death, 24(5–6), pp. 414–433.  
Duffy, A. et al. (2015) ‘Autophagy modulation: a target for cancer treatment development.’, 
Cancer Chemotherapy and Pharmacology, 75(3), pp. 439–447.  
Gallagher, L. E. et al. (2017) ‘Lysosomotropism depends on glucose: a chloroquine resistance 
mechanism’, Cell Death & Disease, 8(8), pp. e3014–e3014.  
Gao, M., Xu, Y. and Qiu, L. (2015) ‘Enhanced combination therapy effect on paclitaxel-
resistant carcinoma by chloroquine co-delivery via liposomes.’, International Journal of 
Nanomedicine, 10, pp. 6615–6632.  
Ge, W. and Jakobsson, E. (2019) ‘Systems Biology Understanding of the Effects of Lithium 
on Cancer’, Frontiers in Oncology, 9(296), p. 296.  
Huang, R.-Y. et al. (2016) ‘Use of lithium and cancer risk in patients with bipolar disorder: 
population-based cohort study.’, The British journal of psychiatry: The Journal of Mental 
Science, 209(5), pp. 393–399.  
 
 190 
Ishibashi, Y. et al. (2019) ‘Chloroquine Enhances Rapamycin-induced Apoptosis in MG63 
Cells.’, Anticancer Research, 39(2), pp. 649–654.  
Jin, Z. X. et al. (2014) ‘The Effect of Chloroquine on the Apoptosis Induced by Cisplatin in 
Human Gastric Cancer BGC823 Cells’, Advanced Materials Research, 926–930, pp. 1124–
1127.  
Kim, E. L. et al. (2010) ‘Chloroquine activates the p53 pathway and induces apoptosis in 
human glioma cells’, Neuro-Oncology, 12(4), pp. 389–400.  
Lang, F. et al. (2015) ‘Apoptotic Cell Death Induced by Resveratrol Is Partially Mediated by 
the Autophagy Pathway in Human Ovarian Cancer Cells’, PloS One, 10(6), pp. e0129196–
e0129196.  
Lee, S. A., Kim, Y. J. and Lee, C. S. (2013) ‘Brefeldin a induces apoptosis by activating the 
mitochondrial and death receptor pathways and inhibits focal adhesion kinase-mediated cell 
invasion.’, Basic & Clinical Pharmacology & Toxicology, 113(5), pp. 329–338. 
Li, H. et al. (2014) ‘Lithium chloride suppresses colorectal cancer cell survival and 
proliferation through ROS/GSK-3β/NF-κB signaling pathway’, Oxidative Medicine and 
Cellular Longevity, 2014, p. 241864. 
Li, Q. et al. (2010) ‘Lithium reduces apoptosis and autophagy after neonatal hypoxia-
ischemia.’, Cell death & disease, 1(7), p. e56. 
Martinsson, L. et al. (2016) ‘Lithium treatment and cancer incidence in bipolar disorder.’, 
Bipolar Disorders, 18(1), pp. 33–40.  
Mauthe, M. et al. (2018) ‘Chloroquine inhibits autophagic flux by decreasing autophagosome-
lysosome fusion’, Autophagy, 14(8), pp. 1435–1455.  
Novetsky, A. P. et al. (2013) ‘Lithium Chloride and Inhibition of Glycogen Synthase Kinase 
3β as a Potential Therapy for Serous Ovarian Cancer’, International Journal of Gynaecologic 
Cancer, 23(2), p. 361-366. 
O’Donovan, T. R. et al. (2015) ‘Lithium Modulates Autophagy in Esophageal and Colorectal 
Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo.’, PloS 
One, 10(8), p. e0134676. 




Park, E. J. et al. (2016) ‘Chloroquine enhances TRAIL-mediated apoptosis through up-
regulation of DR5 by stabilization of mRNA and protein in cancer cells.’, Scientific Reports, 
6, p. 22921.  
Pokhriyal, R. et al. (2019) ‘Chemotherapy Resistance in Advanced Ovarian Cancer Patients’, 
Biomarkers in Cancer’, 11, p. 1179-1198. 
Pottegard, A. et al. (2016) ‘Long-term use of lithium and risk of colorectal adenocarcinoma: 
a nationwide case-control study.’, British Journal of Cancer, 114(5), pp. 571–575.  
Sahebgharani, M. et al. (2008) ‘Lithium chloride protects PC12 pheochromocytoma cell line 
from morphine-induced apoptosis.’, Archives of Iranian Medicine, 11(6), pp. 639–648. 
Sarkar, S. et al. (2005) ‘Lithium induces autophagy by inhibiting inositol monophosphatase’, 
The Journal of Cell Biology, 170(7), pp. 1101–1111.  
Sarkar, S. et al. (2008) ‘A rational mechanism for combination treatment of Huntington’s 
disease using lithium and rapamycin.’, Human Molecular Genetics, 17(2), pp. 170–178.  
Straiko, M. M. W. et al. (2009) ‘Lithium protects against anaesthesia-induced developmental 
neuroapoptosis.’, Anaesthesiology, 110(4), pp. 862–868. 
Suganthi, M. et al. (2012) ‘Biphasic Dose-Dependent Effect of Lithium Chloride on Survival 
of Human Hormone-Dependent Breast Cancer Cells (MCF-7)’, Biological Trace Element 
Research, 150(1), pp. 477–486. 
Tan, H. K. et al. (2012) ‘Interference of intrinsic curvature of DNA by DNA-intercalating 
agents.’, Organic & Biomolecular Chemistry, 10(11), pp. 2227–2230.  
Zhan, L. et al. (2016) ‘Autophagy as an emerging therapy target for ovarian carcinoma’, 
Oncotarget, 7(50), pp. 83476–83487.  
Zhu, J. et al. (2017) ‘Low concentration of chloroquine enhanced efficacy of cisplatin in the 
treatment of human ovarian cancer dependent on autophagy’, American Journal of 




























Supplementary figure 1: Assessment of the presence of basal non-canonical autophagy 
in OVCAR-3 and OVCAR-4 cells. Cyto-ID autophagy assay was used to assess autophagy 
levels in (A) OVCAR-3 and (B) OVCAR-4 cells, following treatment with CQ (10µM) 
(turquoise overlays) for 48 hours, with brefeldin A (10µg/ml) (red overlays) added for the 
final 24 hours of treatment. Representative histogram overlays are presented to the left, with 
mean fluorescent intensities graphed to the right (n=3). The addition of brefeldin A to CQ 
(green overlay) significantly reduces autophagosome accumulation in OVCAR-4 cells. A 

























Supplementary figure 2: Evaluation of the presence of non-canonical autophagy 
following treatment with paclitaxel +/- brefeldin A in OVCAR-3 and OVCAR-4 cells. 
Brefeldin A significantly reduces autophagosome accumulation following treatment with 
paclitaxel in OVCAR-3 and OVCAR-4 cells. The Cyto-ID autophagy detection kit was used 
to measure autophagosome accumulation after treatment with paclitaxel (red overlays) ± 
brefeldin A (10µg/ml) (turquoise overlays) in (A) OVCAR-3 and (B) OVCAR-4 cells. 
Brefeldin A addition to paclitaxel (green overlays) significantly reduces autophagosome 
accumulation in both cell lines. Representative histogram overlays are shown in the left-hand 
panels with corresponding mean fluorescent intensities are graphed to the right (n=3). 
Asterisks indicate a significant difference between paclitaxel alone versus paclitaxel plus 







Chapter Four: Inhibition of 
autophagy reduces recovery and 
enhances chemo-sensitivity in 
ovarian cancer cells following 









Advances in targeted therapies have decreased the reliance on toxic chemotherapies 
in a number of cancers, such as breast and prostate cancer. The backbone of OC 
treatment, however, remains cytoreductive surgery and a platinum/taxane 
chemotherapy doublet. Resistance to chemotherapy is a significant clinical hurdle 
which has yet to be overcome when treating OC. To improve patient outcomes, it is 
vital to elucidate the molecular determinants which underpin chemoresistance. In 
chapters two and three, we observed high levels of autophagy in the ID8-luc2, 
OVCAR-5 and -8 cells, and recovery of these cells was significantly reduced by the 
autophagy inhibitor chloroquine. To further establish a role for autophagy in 
chemoresistance, siRNA knockdown of two key autophagy genes, BECN1 and ATG5, 
was performed in these cell lines. Knockdown of these genes could significantly 
reduce ID8-luc2 and OVCAR-8 cell recovery following paclitaxel treatment, and 
reduce OVCAR-5 cell recovery, despite optimal knockdown not being achieved. 
These data highlight a role for autophagy in recovery following treatment. The 
reduction of autophagosomes in chapter three following brefeldin A treatment 
suggested the presence of an additional brefeldin A-sensitive autophagy pathway, 
which may be the non-canonical Atg5/7-independent autophagy pathway. To further 
assess the contribution of this non-canonical pathway in response to treatment, siRNA 
knockdown of a gene involved in non-canonical autophagy, Rab9, was performed 
along with BECN1. Knockdown of Rab9 significantly impeded the recovery of 
OVCAR-8 cells following treatment with paclitaxel. Although not statistically 
significant, reduction in Rab9 expression could also reduce clonogenic recovery of 
OVCAR-5 cells following paclitaxel treatment. To our knowledge, this is the first 
study to demonstrate a potential role for non-canonical autophagy pathway in the 
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resistance of OC cells to paclitaxel.  This data provides a rationale for inhibiting 
autophagy to combat chemoresistance in OC. 
 
4.2 Introduction 
 Over 70% of women diagnosed with OC present with late stage disease which is 
difficult to treat. The backbone of OC treatment involves surgical debulking and 
intravenous administration of a carboplatin/paclitaxel doublet for 6 cycles, which was 
developed based on the results of the GOG 158 study (Ozols et al., 2003). Although 
most patients will achieve an excellent clinical response following first line treatment, 
disease relapse is a common occurrence. This is the most significant clinical challenge 
yet to be met in the treatment of OC. In those patients with advanced disease, relapse 
can occur within just 2 years of receiving initial treatment. Resistance to 
chemotherapies occurs generally via two mechanisms: (A) intrinsic chemo-resistance- 
whereby the cancer cells are inherently resistant or (B) acquired resistance- where the 
cancer cells utilise biological functions such as increased drug efflux, inhibition of 
apoptosis or autophagy (Pokhriyal et al., 2019). The excellent efficacy of first line 
treatment observed in patients, and the subsequent high rates of disease recurrence, 
warrants a better understanding of the mechanisms behind acquired resistance in order 
to tackle the high rates of recurrence.   
In chapter three, CQ could significantly sensitise ID8-luc2, OVCAR-5 and -8 cells to 
paclitaxel, suggesting a role for autophagy paclitaxel resistance. However, CQ is not 
specific to the autophagy pathway, and can mediate other processes important in drug 
response, including apoptosis. Therefore, to confirm a role for autophagy in response 
to treatment, siRNA knockdown of key autophagy genes, BECN1 and ATG5 was 
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performed. Beclin 1 is a Bcl-2-homology (BH)-3 domain only protein which plays an 
important role in localising autophagic proteins to a pre-autophagosomal structure 
(PAS). It is mainly localised within the cytoplasm in places such as the endoplasmic 
reticulum (ER), mitochondria and perinuclear membrane (Kang et al., 2011). Beclin 
1 can mediate every major step in autophagic pathways, from autophagosome 
formation to autophagosome maturation. Atg5 plays a key role in autophagosome 
formation. The conjugation of ATG5-ATG12-ATG16L1 allows phagophore 
membrane elongation and facilitates autophagosome-lysosome fusion by binding to 
TECPR1 (Zheng et al., 2019) (Ye, Zhou and Zhang, 2018).  
The Atg5/Atg7-independent autophagy pathway is a recently described alternative 
autophagy pathway, which can occur in the absence of Atg5 and Atg7 but requires 
Beclin 1. Autophagosomes formed during this pathway derive from the Golgi, as 
opposed to the ER during canonical autophagy, and LC3 is not required. Rab9 is 
required to facilitate membrane extension and closure by fusing isolation membranes 
with vesicles from the trans-Golgi and late endosomes. Physiological roles for 
Atg5/Atg7-independent autophagy include mitochondrial clearance in stem cells and 
clearance of erythrocytes (reviewed by (Shimizu, 2018). While the non-canonical 
Atg5/Atg7-independent autophagy pathway has been reported to be induced following 
treatment with etoposide, there is no known role for Atg5/Atg7-independent 
autophagy in chemoresistance (Arakawa et al., 2017). In chapter three, we have shown 
that brefeldin A can significantly reduce paclitaxel induced autophagosome 
accumulation. To assess a potential role for non-canonical autophagy in response to 




4.3 Materials and Methods  
4.3.1 Cell culture and Reagents 
Established human ovarian cancer cell lines OVCAR-5 and OVCAR-8 were obtained 
directly from the NCI Frederick Cancer DCTC Tumor/Cell Line Repository. Murine 
ID8-luc2 cells were obtained from Mayo Clinic. All human OVCAR cell lines were 
maintained in RPMI 1640 media. OVCAR-5 and OVCAR-8 cultures were 
supplemented with 10% (v/v) foetal calf serum. Murine ID8-luc2 cells were cultured 
using Dulbecco’s Modified Eagles Medium containing 10% (v/v) foetal calf serum.  
All cultures were supplemented with 1% penicillin/streptomycin (Gibco Life 
Technologies 15070-063). Cells were grown in T75cm2 flasks (Sarstedt) and 
maintained at 37°C, 5% CO2. 
 
4.3.2 siRNA transfection 
Cells were reverse transfected for 24 hours, prior to any drug treatment, with gene 
specific siRNAs and non-specific scramble controls using Lipofectamine 2000 
transfection reagent (Life technologies, Cat # 11668500) according to instructions 
from the manufacturer. Depending on the cell line, knockdown efficiency was 
validated at either 48 or 72 hours, to coincide with drug treatment duration. On-Target 
plus smartpool siRNA were purchased from Dharmacon for both mouse (Beclin-1: 
Cat # L-055895-00-0005, ATG5: Cat # L-064838-00-0005, Rab9: Cat # L-040861-
01-0005) and human cell lines (Beclin-1: Cat # L-010552-00-0005, ATG5: Cat # L-
004374-00-0005, Rab9A: Cat # L-004177-00-0005) . A Non-specific target control 




4.3.3 Drug treatments 
Paclitaxel (Cat # T7402) and carboplatin (Cat # C2538) were purchased from Sigma 
Aldrich. Paclitaxel was reconstituted in DMSO to give 58.55mM stock. Aliquots were 
prepared and stored at -20℃. Working concentrations of paclitaxel were prepared 
fresh in media on the day of treatment. Carboplatin was reconstituted in water to give 
a 26.93mM stock, aliquoted and stored in the dark at room temperature. Working 
concentrations were prepared in media on the day of treatment. ID8-luc2 cells received 
a 24 hour treatment with both paclitaxel and carboplatin, while the human OVCAR 
cell lines received a 48 hour treatment. Chemotherapeutic drugs were added 24 hours 
post transfection to all cell lines.  
 
4.3.4 Colony formation assay 
Colony formation (clonogenic) assays were used to determine the ability of single cells 
to recover from a drug treatment and re-establish colonies. Following specified 
treatments, cells were trypsinised using 500µl of Trypsin EDTA (Sigma Aldrich, Cat 
# T4049) and viable cells counted using the NucleoCounter NC-100 (Chemometec). 
For the OVCAR-5, OVCAR-8 and ID8-luc2 cell lines 1,500 viable cells were re-
seeded into a well of a six-well plate (Nunc™ Thermo Scientific, Cat # 140685). For 
the OVCAR-3 and OVCAR-4 cell lines, 2,500 cells were re-seeded in the same 
manner. Cells were allowed to adhere and grow for between 10 and 14 days, until 
control cells reached at least 70% confluency. Following the recovery period, media 
was aspirated, and wells were washed once with PBS. Cells were then fixed in 96% 
ethanol for 5 minutes and stained with Pro-diff solution C (Braidwood Laboratories 
E310) for 5 minutes. Plates were rinsed with water to remove excess stain and air-dried 
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overnight. Plates were scanned and quantified using the Odyssey IR imaging system 
(Li-Cor, Cambridge, United Kingdom).  
 
4.3.5 Western Blotting  
Total cellular protein was extracted by trypsinisation of cells followed by lysing in 10-
25µl of modified RIPA buffer (50 mM Tris HCl (pH 7.4), 150 mM NaCl, 0.25% 
sodium deoxycholate, 1% Igepal, 1 mM EDTA, 1x Pefabloc, 1x protease inhibitor 
cocktail, 1 mM Na3VO4, 1 mM NaF), depending on pellet size. Samples (75 μg) were 
separated on NuPAGE 4–12% Bis-Tris gels (Invitrogen Life Technologies, Cat # 
NP0322) and electrophoretically transferred onto a PVDF membrane using the iBlot 
gel transfer system (Invitrogen IB1001). Membranes were blocked with Odyssey 
blocking buffer (Li-Cor, Cat # 927-40100) for 1 hour at room temperature. Membranes 
were then incubated overnight at 4℃ using: anti- ATG5 (Novus, Cat # NB110-53818), 
anti-Beclin 1 (Novus, Cat # NB500-249) and anti-Rab9 (Abgent, Cat # ab2810) 
antibodies overnight at 4°C. Anti-β-actin (loading control) (Sigma, Cat # A5441) was 
incubated at room temperature, rocking, for one hour. IR-Dye conjugated secondary 
antibodies (Rockland) were utilised for protein detection on the Odyssey Infra-red 
imaging system (Li-Cor, Cambridge, United Kingdom).  
 
4.3.6 Statistical Analysis 
All data is expressed as mean ± the standard error of the mean (SEM), which represents 
the standard deviation of the distribution of the sample around the mean. Significance 
was determined by independent or paired student t-tests, which determines the 
difference between the means of two groups. The p-value was considered statistically 
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significant where *p < 0.05, ** p < 0.01, *** p < 0.001. Statistical analysis was carried 
out and graphed using GraphPad Prism 5 software (GraphPad Software Inc., CA, 

















4.4 Results  
4.4.1 Inhibition of autophagy demonstrates its role in chemoresistance in ID8-
luc2 cells  
In chapter two, autophagic flux, in response to paclitaxel and carboplatin was observed 
in the ID8-luc2 cell line. Clonogenic assays revealed recovery and colony regrowth of 
up to 50% in ID8-luc2 cells after paclitaxel and carboplatin treatment. To assess the 
involvement of autophagy in this recovery, key autophagy regulators BECN1 and 
ATG5 were knocked down and recovery was assessed. 
ID8-luc2 cells were transfected with 30nM of BECN1 and ATG5 siRNA either alone 
or in combination. Protein expression following knockdown of BECN1 alone was 
reduced to 58% (lane 2) and when combined with Atg5 was reduced to 33% (lane 4) 
compared to a scrambled control (lane 1) [Figure 4.1A]. Transfection of ID8-luc2 cells 
with an siRNA targeted to ATG5 reduced protein expression to 66% (lane 2), with a 
minimal reduction in Atg5/12 expression evident when combined with a BECN1 
siRNA (lane 3) [Figure 4.1B].  
Following reverse transfection with the targeted siRNAs for 24 hours, ID8-luc2 cells 
were treated with 2.5µM paclitaxel for 24 hours, re-seeded and clonogenic recovery 
assessed. Transfection with each siRNA alone resulted in small reductions in 
clonogenic recovery, which were not significant. However, a significant reduction in 
recovery was found following double knockdowns of BECN1 & ATG5 (*p = 0.027) 
[Figure 4.1C]. Although optimal knockdowns were not achieved, recovery was still 
significantly reduced, suggesting that autophagy does play a role in recovery following 






















Figure 4.1. Knockdown of BECN1 in combination with ATG5 significantly reduces ID8-
luc2 recovery following paclitaxel treatment. ID8-luc2 cells were transfected for 24 hours 
with 30nM siRNA. 24 hours post transfection, media was removed, and cells were treated 
with 2.5µM paclitaxel for a further 24 hours, before cells were reseeded for clonogenic 
recovery (48 hours post transfection). Western blot was used to assess (A) Beclin 1 and (B) 
Atg5/12 expression (48 hours post transfection). All blots were scanned, quantified and values 
normalised to β-actin. Integrated intensities are graphed ±SEM (n=2). (C) Following 
knockdown with specific siRNAs and 24 hour treatment with 2.5µM paclitaxel, ID8-luc2 cells 
were re-seeded and recovery assessed. All colonies were fixed, stained and scanned using the 
Li-Cor Odyssey Infrared scanner. Integrated intensities are graphed as % control (where 




4.4.2 Knockdown of key autophagy genes BECN1 and ATG5 sensitises 
OVCAR-5 and OVCAR-8 cells to paclitaxel 
We have demonstrated that autophagic flux is induced following paclitaxel treatment 
in OVCAR-5 and OVCAR-8 cells, and that these cells exhibited up to 50% colony 
regrowth. We have also shown the ability of CQ to significantly sensitise these cells 
to treatment, indicating a role for autophagy in recovery. To confirm this, two key 
autophagy regulators, BECN1 and ATG5, were transiently knocked down using 
siRNA. Cells were then treated for 48 hours with paclitaxel and recovery was assessed.  
The OVCAR-5 cell line was transfected with 20 nM of specific siRNA targeted to 
BECN1 and ATG5, either alone or combined as a double knockdown. Western blot 
analysis showed a reduction in Beclin 1 expression to 25% (lane 2) and to 37% (lane 
3) following single and double knockdown respectively, 72 hours post knockdown 
[Figure 4.2A]. ATG5 protein expression was reduced to 40% (lane 2), and to 60% 
(lane 3) following single and double knockdown respectively [Figure 4.2B].   
 Knockdown of ATG5 alone and in combination with BECN1 reduced recovery of 
OVCAR-5 cells following paclitaxel treatment, although it was not statistically 
significant [Figure 4.2C]. It is possible that a greater knockdown is required to impede 
autophagy. 
The OVCAR-8 cell line was transfected with 30nM of siRNA targeted to BECN1 and 
ATG5, either alone or in combination. Western blot analysis revealed a reduction in 
Beclin 1 expression to just 10% (lane 2), and 25% (lane 3) in the single and double 
knockdown cells respectively, 72 hours post transfection [Figure 4.3A]. Atg5 protein 
expression levels were reduced to just 14% in the single knockdown (lane 2) and 36% 
in the double knockdown cells (lane 3) [Figure 4.3B]. 
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Single or double knockdown of BECN1 and ATG5 resulted in a significant inhibition 
of OVCAR-8 cell recovery following treatment with paclitaxel (*p = 0.008, *p = 0.08, 
*p = 0.031, respectively) [Figure 4.3C]. Taken together, these data highlight a role for 
autophagy in the recovery of OVCAR-5 and OVCAR-8 cell lines following paclitaxel 
treatment. It is likely that sufficient knockdown is required in order to achieve an 
impediment in autophagy. Where this is achieved in the OVCAR-8 cells, the 




































Figure 4.2. ATG5 knockdown alone and combined with BECN1 reduces recovery of 
OVCAR-5 cells following paclitaxel treatment (A) Reduction in expression of Beclin 1 and 
(B) Atg5/12 was shown using western blotting 72 hours post transfection (n=2) (C) 24 hours 
after siRNA transfection, cells were treated with 5nM paclitaxel for a further 48 hours and 
cells were reseeded for colony regrowth (72 hours post transfection). Colonies were fixed, 
stained and scanned using the Li-Cor Odyssey Infrared scanner. Integrated intensities are 

























Figure 4.3. BECN1 and ATG5 knockdown significantly reduces OVCAR-8 cell recovery 
following paclitaxel treatment (A) Reduction in the expression of Beclin 1 and (B) Atg5/12 
was demonstrated using western blotting (n=2). (C) 24 hours after siRNA transfection, cells 
were treated with 5nM paclitaxel for 48 hours and reseeded for clonogenic recovery (72 hours 
post transfection). Colonies were fixed, stained and scanned using the Li-Cor Odyssey 
Infrared scanner. Integrated intensities are graphed as % control (where control = 100%) 




4.4.3 Knockdown of Rab9 and BECN1 sensitises OVCAR-5 and OVCAR-8 cells 
to paclitaxel 
In chapter three, the addition of brefeldin A could significantly reduce basal and drug 
induced autophagosomes, suggesting the presence of a non-canonical brefeldin A-
sensitive autophagy pathway, which may be Atg5/Atg7-independent autophagy. To 
further assess a role for this pathway in recovery from paclitaxel, Rab9 was knocked 
down alone and in combination with BECN1. Autophagosomes generated during the 
Atg5/Atg7-independent non-canonical pathway require Rab9 for extension and 
closure of phagophores (Nishida et al., 2009). Rab9 is GTPase with multiple functions 
in the endolysosomal system, including lysosome biogenesis and transport from the 
trans-Golgi network to late endosomes (Kucera, Bakke and Progida, 2016). BECN1 
is also involved in the initiation of this non-canonical pathway.  
OVCAR-5 cells were transfected for 24 hours with 20nM of BECN1, and 40nM of 
Rab9 siRNA. Beclin 1 expression was reduced to 56% following knockdown of 
BECN1 alone (lane 2) and to 61% when used in combination with Rab9 (lane 3) 
[Figure 4.4A]. The Rab9 knockdown was not as effective, with protein expression 
reduced to only 80% and 70% following single knockdown (lane 2) and double 
knockdown with BECN1 (lane 3) respectively [Figure 4.4B]. Despite not achieving 
optimal knockdown, the reductions in Beclin 1 and Rab9 protein expression did reduce 
the recovery of OVCAR-5 cells following paclitaxel treatment, although this did not 
reach significance [Figure 4.4C]. It remains possible that non canonical autophagy 
may contribute to response to paclitaxel, however more efficient knockdown of Rab9 
would be required to demonstrate this.  
OVCAR-8 cells were transfected for 24 hours with 30nM of BECN1 and Rab9 siRNA. 
Beclin 1 expression was reduced to 10% following single knockdown (lane 2), and 
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just 25% when part of a double knockdown with Rab9 (lane 3) [Figure 4.5A]. 
Following transfection with 30nM siRNA, Rab9 expression was reduced to 30% when 
knocked down alone (lane 2), and to 32% when combined with a BECN1 targeted 
siRNA (lane 3) [Figure 4.5B]. After 48 hour treatment with 5nM paclitaxel, 
knockdown of BECN1 and Rab9 significantly reduced clonogenic recovery (*p = 
0.022) [Figure 4.5C]. These data indicate that a non-canonical brefeldin A-sensitive 
autophagy pathway may also play a role in the recovery of OVCAR-8 cells following 
paclitaxel treatment. 
Collectively, these data suggest that both canonical and non-canonical pathways are 
likely to be involved in the recovery of OVCAR-5 and OVCAR-8 cells following 







Figure 4.4. Evaluation of the effect of BECN1 and Rab9 knockdown on OVCAR-5 cell 
recovery following paclitaxel treatment.  OVCAR-5 cells were transfected for 24 hours 
with targeted siRNA, treated for 48 hours with 7.5nM paclitaxel and clonogenic recovery was 
assessed. (A) Western blot analysis of Beclin 1 and (B) Rab9 72 hours after siRNA 
knockdown. All blots were scanned, quantified and values normalised to β-actin. Integrated 
intensities are graphed ±SEM (n=2). (C) Following knockdown with specific siRNAs and 48 
hour treatment with paclitaxel, OVCAR-5 cells were re-seeded (1500 cells/well) and recovery 
assessed. All colonies were fixed, stained and scanned using the Li-Cor Odyssey Infrared 

























Figure 4.5. Reducing the expression of Beclin 1 and Rab9 significantly impedes OVCAR-
8 recovery following paclitaxel treatment. OVCAR-8 cells were transfected for 24 hours 
with 30nM siRNA, treated for 48 hours with 5nM paclitaxel and clonogenic recovery was 
assessed. (A) Western Blot analysis of Beclin 1 and (B) Rab9 knockdown was confirmed 72 
hours post transfection. Blots were scanned, quantified and values normalised to β-actin. 
Integrated intensities are graphed ± SEM (n=2). (C) Following knockdown with specific 
siRNAs and 48 hour treatment with paclitaxel, OVCAR-8 cells were re-seeded (1500 
cells/well) and recovery assessed.  All colonies were fixed, stained and scanned using the Li-
Cor Odyssey Infrared scanner. Integrated intensities were obtained and are graphed as % 
control (with the control being 100%) ± SEM (n=2). Paired t-test was used to assess 







In this study, siRNA knockdown of key genes BECN1 and ATG5 significantly 
reduced clonogenic recovery in ID8-luc2 and OVCAR-8 cells. While not significant, 
reductions in Beclin 1 and Atg5 expression could also reduce OVCAR-5 cell recovery. 
The ID8-luc2 and the OVCAR-5 cell line were generally more difficult cell lines in 
which to achieve knockdown. Higher concentrations of siRNA, used for the OVCAR-
8 cells, were tested in OVCAR-5 cells, however no improvement, or reduced 
knockdown efficiency was obtained. Further optimisation of the transfection 
procedure in OVCAR-5 cells would be required, which was not feasible during this 
study. Alternatively, other strategies could be employed to reduce the expression of 
autophagy proteins. Lentiviral transfection of short hairpin RNA (shRNA) provides a 
more durable knockdown. CRISPRi technology, which allows gene silencing at the 
DNA level, can also provide a more robust knockdown with less off target effects. 
More robust and sustained knockdown of autophagy genes will also allow more 
accurate assessment of the role of autophagy in recovery. The half-life of siRNA can 
be anywhere from 3 to 6 days, meaning that the effects of the siRNA are likely reduced 
by the end of the clonogenic recovery. The knockdown achieved with OVCAR and 
ID8-luc2 cells indicates that autophagy plays a role in the recovery of OC cells 
following paclitaxel treatment. This finding is in line with several studies which also 
implicate autophagy in chemoresistance in OC cells. One study reported that 
knockdown of ATG5 in OV433 OC cells inhibited cell growth following cisplatin 
treatment (Wang et al 2014), while another study demonstrated that ATG5 knockdown 
could enhance the chemosensitivity of OC stem cells to carboplatin treatment (Pagotto 
et al 2017). Similarly, knockdown of BECN1 in A2780cp cisplatin resistant OC cells 
 
 213 
enhanced cisplatin mediated cell death (Bao et al 2015). Further studies with a 
platinum based drug in our cell lines would therefore be interesting. 
Knockdown of the non-canonical gene Rab9 with BECN1 reduced the recovery of 
OVCAR-5 and -8 cells following paclitaxel treatment, highlighting a potential role for 
brefeldin A-sensitive autophagy, such as the Atg5/Atg7-independent pathway, in 
response to treatment. Biological functions of Atg5/Atg7-independent autophagy have 
only begun to be elucidated. Roles in erythrocyte maturation, mitochondrial clearance 
during stem cell differentiation, and anti-inflammatory functions have all been 
reported (Honda et al., 2014) (Ma et al., 2015) (Ra et al., 2016). To date, only one 
other study has reported the presence of Atg5/Atg7-independent autophagy in 
response to a chemotherapeutic agent. Arakawa et al reported the accumulation of 
autophagic structures in Atg 5 deficient MEFs following treatment with etoposide, a 
DNA topoisomerase inhibitor (Arakawa et al., 2017). To our knowledge, ours is the 
first study to provide evidence that a non-canonical brefeldin A-sensitive autophagy 
pathway may contribute to paclitaxel resistance in OC cells. However, to confirm the 
presence of the Atg5/7-independent autophagy pathway, further experiments are 
required to assess autophagosome accumulation in Atg5/7 deficient cells. 
Immunofluorescence analysis of LAMP2, and its colocalisation with Rab9, following 
paclitaxel treatment in Atg5/7 deficient cells will also be performed. This data also 
highlights the possibility that more than one autophagy pathway may be present in OC 
cells and that this could also contribute to resistance to chemotherapy. This may have 
clinical significance when identifying therapeutic targets to tackle chemoresistance in 
OC. It is likely that targeting multiple pathways will be necessary. However, the full 
contribution and molecular regulation of this non-canonical pathway remains to be 
elucidated and warrants further investigation.   
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In summary, we have demonstrated a role for autophagy in response to paclitaxel in 
OC cells. Our data also supports a potential role for non-canonical Atg5/Atg7-
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1. Uncropped western blots 
Western blots showing how each relevant band (Beclin 1; ATG5/12 and Rab9) was 
identified. A molecular weight protein ladder was run alongside the samples in order 
to identify the proteins of interest based on their predicted size (kDa), which is stated 








































Uncropped western blots for OVCAR-8 cells. Western blots are shown for OVCAR-8 
cells probed for (A) Beclin 1 (B) ATG5/12 and (C) Rab9, following no treatment 
(untreated) or paclitaxel (5nM) treatment (pac). Cells were transfected for 24 hours with 









Chapter Five: Autophagy is 
involved in the recovery of DNA 










Ovarian cancer is the sixth most common cancer in women, with over 70% of women 
diagnosed with late stage disease. Paclitaxel is routinely used in the clinical 
management of OC. Despite its efficacy as a first line treatment, resistance and disease 
recurrence are common. Paclitaxel functions as a microtubule stabiliser, resulting in 
segregation errors and karyotype abnormalities which typically leads to apoptosis. 
Despite this, we have shown that OC cells can recover from paclitaxel treatment, and 
that autophagy contributes to this recovery. In this chapter, we aimed to assess the 
impact of paclitaxel on the cell cycle profile of ID8-luc2 and OVCAR-8 cells and 
assess if there may be a role for autophagy in the recovery of a normal DNA content. 
Treatment with paclitaxel resulted in a G2/M arrest and an accumulation of polyploid 
cells. Following 5 and 7 day recovery periods after paclitaxel treatment, ID8-luc2 and 
OVCAR-8 cells displayed a remarkable ability to recover their original cell cycle 
profile. The addition of CQ during the recovery period impeded ID8-luc2 cell cycle 
recovery, suggesting a role for autophagy. In addition, in OVCAR-8 cells, knockdown 
of BECN1 and ATG5 enhanced accumulation of polypoid cells, further supporting a 
role for autophagy in the recovery of a ‘normal’ DNA profile. We have shown that 
DNA fragments produced following paclitaxel treatment interact with autophagy 
markers LC3 and LAMP1 in ID8-luc2 and OVCAR-8 cells. Taken together, these data 
suggest that a selective type of autophagy, termed nucleophagy, may contribute to the 






The standard of care for OC treatment has remained unchanged over the last few 
decades, comprising of surgical debulking and chemotherapy. Although most patients 
will achieve an excellent clinical response following first line treatment, disease 
relapse occurs in the majority of women. This is the most significant clinical challenge 
yet to be met in the treatment of OC.  
Paclitaxel is a widely utilised taxane in the management of OC, which functions as a 
microtubule stabiliser. Paclitaxel causes segregation errors, resulting in striking 
nuclear fragmentation and the partition of genetic material into micronuclei (MN). 
MN typically originate from acentric chromosome or whole chromosome fragments 
which, after failing to be incorporated into the nucleus during telophase, become 
enclosed within a nuclear membrane (Fenech et al., 2011). Ovarian cancers have been 
reported to be predisposed to MN formation, facilitating genomic adaption following 
genotoxic insult, which may contribute to resistance and disease recurrence (Tang et 
al., 2018). Additionally, maintenance of genomic integrity is essential for cell survival 
and the presence of genomic abberations typically leads to cell death.  
Recently, studies have emerged linking autophagy to the maintenance of genome 
integrity. This was first evidenced in cancer cells deficient in the key autophagy gene 
Beclin 1, which displayed increased markers of DNA damage and aneuploidy 
(Karantza-Wadsworth et al., 2007). Since then studies have detailed the complex 
crosstalk between autophagy and DNA damage response (DDR) pathways, including 
homologous recombination (E. Y. Liu et al., 2015). In addition to its links to DDR 
responses, autophagic machinery has also been reported to selectively eliminate 
nuclear material, a process termed nucleophagy. Nucleophagy was first described in 
the budding yeast saccharomyces cerevisiae and termed piecemeal micro autophagy 
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of the nucleus (PMN) (Roberts et al., 2003). PMN occurs when small pieces of nucleus 
are extruded at nucleus-vacuole (NV) junctions into vacuolar membranes, which are 
then released into the vacuolar lumen and degraded by luminal hydrolases (Kvam and 
Goldfarb, 2007). In mammalian cells, mouse embryonic fibroblasts (MEFs) were 
found to contain autophagosomes positive for LC3 close to the nucleus. The 
autophagosomes were also positive for LAMP2, and colocalised with histone H1 and 
γH2AX, indicative of chromatin within the autophagosome (Park et al., 2009).  
Autophagy has also been shown to eliminate micronuclei. In a study by Rello-Varona 
et al. (2012), micronuclei colocalised with LC3 positive vesicles and stained positive 
for the autophagy adaptor protein p62. These co-localisations were lost upon 
knockdown of Atg5 or Atg7, supporting a role for autophagy in MN degradation 
(Rello-Varona et al., 2012).  
In this study, we have performed cell cycle analysis to assess the recovery of OC cell’s 
DNA profile following paclitaxel treatment. To assess a role for autophagy in recovery 
of the DNA profile, CQ was used to impede autophagy. To further evaluate a role for 
autophagy, siRNA knockdown of BECN1 and ATG5 was also performed. We have 
used confocal imaging to assess the localisation of autophagy markers with nuclear 






5.3 Materials and Methods 
5.3.1 Cell culture and Reagents 
OVCAR-8 were obtained directly from the American Type Culture Collection 
(ATCC) and maintained in RPMI 1640 media, supplemented with 10% (v/v) foetal 
calf serum. Murine ID8-luc2 cells were obtained from the Mayo Clinic and cultured 
in DMEM containing 10% (v/v) foetal calf serum. All cultures were maintained in 
T75cm2 flasks (Sarstedt) supplemented with 1% penicillin/streptomycin (Gibco Life 
Technologies, Cat # 15070-063) and maintained at 37°C, 5% CO2.  
 
5.3.2 Drug treatments 
Paclitaxel (Cat # T7402) and carboplatin (Cat # C2538) were both purchased from 
Sigma Aldrich. Paclitaxel was reconstituted in DMSO to give 58.55mM stock. 
Aliquots were prepared and stored at -200C. Working concentrations of Paclitaxel 
were prepared fresh in media on the day of treatment. Carboplatin was reconstituted 
in water to give a 26.93mM stock, aliquoted and stored in the dark at room 
temperature. Working concentrations were prepared in media on the day of treatment. 
CQ was prepared in media on the day of treatment (1mM) and added to the cells 2 
hours prior to any other drug treatment. 
For the cell cycle profile experiments, cells were treated with paclitaxel or carboplatin 
+/- CQ (10µM) for 24 or 48 hours. To assess cell cycle recovery, drugs were removed, 
and cells received new drug-free media, and were allowed to recover for up to 7 days. 
To assess the effect of CQ on cell cycle recovery, cells received media containing CQ 




For immunofluorescence experiments, cells were treated paclitaxel or carboplatin for 
24 or 48 hours, followed by a further 24 hour recovery period in drug free media.  




Prior to treatment, cells were seeded directly onto coverslips in the well of a six well 
plate (Nunc™ Thermo Scientific, Cat # 140685). Following treatment, cells were 
washed using PBS, fixed (4 % PFA/PBS), and washed 3 times with PBS and 
permeabilised in 100% cold methanol for 10 minutes at -20℃. Cells were washed 3 
times with PBS and blocked for 30 minutes at room temperature (5% BSA/PBS). Cells 
were probed with anti-LC3 (Abgent, Cat # APG8B) and anti-LAMP1 antibodies 
(Abcam, Cat # Ab25245) in 1% BSA/PBS overnight at 4℃ and detected by 
Alexa Flour 594 goat anti-rabbit and Alexa Flour 633 goat anti-rat secondary 
antibodies (Life Technologies, Cat # A11037 and A21094, respectively). Cells were 
incubated with Nuclear ID stain (1µl per 2ml PBS) for 30 minutes at room 
temperature, before the slides were mounted using Pro-Long Gold anti-fade without 
Dapi (Invitrogen, Cat # P36970). Images were acquired using the Olympus 
Fluoview1000 Confocal Laser Imaging System. 
 
5.3.4 siRNA transfection 
 Cells were reverse transfected for 24 hours using gene specific siRNAs and non-
specific scramble controls using Lipofectamine 2000 transfection reagent (Life 
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technologies, Cat # 11668500) according to instructions from the manufacturer. On-
Target plus smartpool siRNA were purchased from Dharmacon for both mouse 
(Beclin-1: Cat # L-055895-00-0005, ATG5: Cat # L-064838-00-0005) and human cell 
lines (Beclin-1: Cat # L-010552-00-0005, ATG5: Cat # L-004374-00-0005). A Non-
specific target control was also purchased from Dharmacon (Non-targeting siRNA #1: 
Cat # D-001810-01-20). 
 
5.3.5 Cell Cycle Analysis 
After designated treatment, 500,000 cells were pelleted and resuspended in 500µl 
PBS. Cells were fixed by adding 1,167µl of 100% ethanol dropwise while gently 
vortexing, to a final concentration of 70% and stored at -20℃ until the day of analysis. 
A minimum of 24 hours fixation at -20℃ was found to yield sharper peaks in the cell 
cycle profiles. On the day of analysis, cells were pelleted and washed with PBS. 
Propidium Iodide (20µg/ml) and Rnase A (200mg/ml) were prepared in PBS, added 
to the samples, and incubated at room temperature in the dark for 1 hour. PI is a DNA 
intercalator, which binds to DNA stoichiometrically. As cells residing in different 
phases of the cell cycle contain differing DNA contents, cells with higher contents 
(e.g. G2/M phase – 4N content, and aneuploid – >4N content) will have the highest 
fluorescence. As PI can also bind to RNA, Rnase A is added to remove RNA, allowing 
more accurate analysis. Data was acquired and analysed using the BD LSR II flow 





5.4 Results  
5.4.1 ID8-luc2 cells recover a typical DNA profile following paclitaxel and 
carboplatin treatment, and this is impeded by chloroquine 
Paclitaxel functions as a microtubule stabiliser, leading to aberrant segregation of 
chromosomes, G2/M arrest, formation of micronuclei and mitotic catastrophe. Despite 
this, we have shown that ID8-luc2 cells can recover and regrow following treatment. 
The effect of paclitaxel on the cell cycle profile of ID8-luc2 cells, which have a near 
tetraploid karyotype, following treatment and a subsequent recovery period in drug 
free media, was assessed by flow cytometry.  
The top panel of Figure 5.1 shows representative histograms of paclitaxel treated cells. 
Cells with ≥2N DNA content were gated and denoted as % (of parent population) 
within the histograms. Following 24 hour paclitaxel treatment (upper second panel) a 
G2/M arrest was evident. Increased accumulation of polyploid cells (with >4N DNA 
content) was also evident after treatment (upper middle panel) [Figure 5.1 (i)]. 5 days 
after withdrawal of drug, cells recovered their DNA profile, with the majority 
returning to the G0 phase with a decrease in cells with ≥2N DNA content (upper right 
panel) [Figure 5.1 (i)]. To assess the potential contribution of autophagy to this 
recovery, autophagy was inhibited using CQ (bottom panel outlined in red) [Figure 
5.1 (ii)]. Cells were treated with 2.5µM paclitaxel plus or minus CQ for 24 hours, 
reseeded and allowed to recover for up to 5 days in paclitaxel free media. To maintain 
the effect of CQ, it was supplemented into the media every 48 hours throughout the 
recovery period. Cells treated for 24 hours with paclitaxel in the presence of CQ still 
accumulated in the G2/M phase [lower middle panel, Figure 5.1 (ii)]. However, cells 
recovered for 5 days following paclitaxel treatment in the presence of CQ maintained 
G2/M accumulation [right lower panel, Figure 5.1 (ii)]. The addition of CQ also 
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impeded the clearance of cells with >4N DNA content after a 5 day recovery period. 
These data suggest that impeding autophagy does not interfere with the G2/M arrest, 
but it does impede the recovery of a pre-treatment DNA profile. 
Cell cycle was similarly assessed in ID8-luc2 cells following carboplatin treatment. 
The top panel of Figure 5.2 shows representative histograms of carboplatin treated 
cells. Control cells displayed higher accumulation in the G0 and G2/M phases, 
compared to those from Figure 5.1, which may be due to the longer growth time. 
Following 48 hour carboplatin treatment (top middle panel) a G2/M arrest was evident. 
Increased accumulation of polyploid cells (with >4N DNA content) was also evident 
after treatment (upper middle panel) [Figure 5.2 (i)]. 7 days after withdrawal of drug, 
cells can recover their DNA profile, with a reduction in cells with ≥2N DNA content 
evident (upper right panel) [Figure 5.2 (i)]. To assess the potential contribution of 
autophagy to this recovery, autophagy was inhibited using CQ (bottom panel outlined 
in red) [Figure 5.2 (ii)]. Cells were treated with 40µM carboplatin plus or minus CQ 
for 48 hours, reseeded and allowed to recover for up to 7 days in carboplatin free 
media. To maintain the effect of CQ, it was supplemented into the media throughout 
the recovery period. Cells treated for 48 hours with paclitaxel in the presence of CQ 
still accumulated in the G2/M phase (lower middle panel), while an increase in 
polyploid cells was also evident [Figure 5.2 (ii)]. However, following a 7 day recovery 
after paclitaxel treatment, in the presence of CQ, cells with ≥2N DNA content were 
minimally reduced and the clearance of polyploid cells was impeded (lower right 
panel) [Figure 5.2 (ii)]. This data suggests that impeding autophagy prevents the 



























Figure 5.1. Assessment of the cell cycle profile of ID8-luc2 cells following treatment with 
paclitaxel and CQ. (i) Cells were treated with paclitaxel (2.5µM) for 24 hours, and viable 
cells re-seeded and allowed to recover for 5 days. (ii) Cells were pre-treated with chloroquine 
(10µM) for 2 hours, prior to the addition of paclitaxel, for 24 hours. Viable cells were re-
seeded and allowed to recover for 5 days in the presence of chloroquine. Cells were stained 
with propidium iodide (20µg/ml) and analysed via flow cytometry (n=1). 
Figure 5.2. Evaluation of the cell cycle profile of ID8-luc2 cells following treatment with 
carboplatin and CQ. (i) Following treatment with carboplatin (40µM) for 48 hours, viable 
cells were re-seeded and allowed to recover for 7 days. (ii) Cells were pre-treated with 
chloroquine (10µM) for 2 hours, prior to the addition of carboplatin, for 48 hours. Viable cells 
were re-seeded and allowed to recover for 7 days in the presence of chloroquine. Cells were 
stained with propidium iodide (20µg/ml) and analysed via flow cytometry (n=1).  
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5.4.2 Nuclear material colocalises with LC3 and LAMP1 after paclitaxel 
treatment in ID8-luc2 cells 
Nucleophagy, a specific type of autophagy, is involved in the degradation of nuclear 
components. Removal of damaged nuclear material and micronuclei contributes to 
genome stability, which may enable cell recovery following treatment with 
chemotherapeutics. To assess the presence of nucleophagy, immunofluorescence 
analysis was performed following a 24 hour paclitaxel treatment and subsequent 24 
hour recovery in drug free media. The interaction between the autophagy marker LC3 
(green) and lysosomal marker LAMP1 (red) with DNA was assessed. Nuclei were 
visualised using the blue Nuclear-ID stain.   
In control cells (upper panel) the nuclei appeared intact, with little nuclear 
colocalisation between LC3 and LAMP1 [Figure 5.3]. In contrast, paclitaxel treated 
cells displayed marked nuclear fragmentation (lower panel). This fragmented nuclear 
material was colocalised with LC3, producing a cyan blue colour, highlighted with 
white arrows [lower middle left panel, Figure 5.3]. Fragmented nuclear material also 
colocalised with LAMP1, producing a magenta pink colour, also denoted with white 
arrows [lower middle right panel, Figure 5.3]. Yellow punctate foci, resulting from 
LC3 and LAMP1 colocalising, also associated with fragmented nuclear material, 
denoted with white arrows [lower right panel, Figure 5.3]. Taken together, these data 
suggest that autophagy may be involved in the elimination of micronuclei/DNA 

































































































































































































































































































































































































































































































































































































































5.4.3 OVCAR-8 cells can recover a typical DNA profile following paclitaxel 
treatment, which is not impeded by CQ  
We then assessed the effect of paclitaxel on the cell cycle profile of human OVCAR-
8 cells, which have a hyperdiploid karyotype. Following a 48 hour paclitaxel treatment 
(5nM) (top second panel), a G2/M arrest was evident, as was an accumulation of cells 
with >4N DNA content [Figure 5.4 (i)]. Following a 5 day recovery in drug free media, 
OVCAR-8 cells can recover a cell cycle profile similar to untreated cells, with the 
majority of cells returning to the G0 phase and cells with >4N DNA content were 
cleared [Figure 5.4 (i)]. To evaluate a role for autophagy in this recovery, autophagy 
was impeded using CQ. The addition of CQ to paclitaxel had a minimal effect on 
recovery. At 5 day recovery, a minimal increase in cells with >4N DNA content was 
present [Figure 5.4 (ii)]. More selective targeting of autophagy in OVCAR-8 cells may 
































Figure 5.4. Assessment of the cell cycle profile of OVCAR-8 cells following treatment 
with paclitaxel and CQ.  Following 48 hour treatments with (i) paclitaxel (5nM) (ii) plus CQ 
(10µM), cells were re-seeded and allowed to recover for 5 days. Cells were stained with 
propidium iodide (20µg/ml) and analysed via flow cytometry (n=1). Cells with ≥ 2N cells 
were gated, quantified and written as % (of parent population) within the histograms. 
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5.4.4 Nuclear material colocalises with LC3 and LAMP1 after paclitaxel 
treatment in OVCAR-8 cells  
To assess the presence of nucleophagy, cells were treated with paclitaxel for 48 hours, 
followed by a subsequent 24 hour recovery period in drug free media. Cells were then 
probed for LC3 and LAMP1. Nuclei were visualised using a blue Nuclear-ID stain. In 
control untreated cells, displayed in the top panels, nuclei appeared intact, with little 
nuclear colocalisation of LC3. In contrast, paclitaxel treated cells (lower panels) 
displayed nuclear fragmentation, and these fragments were closely associated with 
LC3 (denoted with yellow arrows) [Figure 5.5]. In control cells probed with LAMP1, 
nuclei were intact, with LAMP1 primarily cytoplasmic (top panels) [Figure 5.6]. 
Following paclitaxel treatment, fragmentation of the nucleus was evident, highlighted 
with yellow arrows (lower left hand panel). Fragmented nuclear material colocalised 
with LAMP1, producing a magenta colour, as highlighted with yellow arrows (lower 
right hand panel) [Figure 5.6]. Due to weaker staining of LAMP1 in the OVCAR-8 
cells, colocalisation between LC3 and LAMP1 could not be visualised. 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.5 Knockdown of key autophagy genes in OVCAR-8 cells impedes the 
recovery of the parental cell cycle profile 
While the molecular regulators of nucleophagy are yet to be elucidated, key autophagy 
genes including BECN1 and members of the Atg family of proteins have been 
implicated in genome maintenance. Atg proteins, including Atg5 and Atg7 are present 
in the nucleus, while loss of Beclin 1 and Atg5 in breast epithelial cells promoted DNA 
damage and aneuploidy (Karantza-Wadsworth et al., 2007). To elucidate a role for 
autophagy in the recovery of a typical cell cycle profile following treatment, siRNA 
knockdown of autophagy genes BECN1 and ATG5 was performed. Cells were 
transfected for 24 hours, after which transfection media was removed, and cells were 
treated with paclitaxel for 48 hours. After treatment, cells were allowed to recover in 
drug free media for up to 5 days.  
Knockdown was confirmed via western blot at 72 hours. Transfection with an siRNA 
targeted to BECN1 reduced protein levels to 36%, while an ATG5 targeted siRNA 
reduced protein expression to 37% [Figure 5.7A (i) and (ii), respectively].  
Following 48 hour paclitaxel treatment, knockdown of BECN1 and ATG5 alone or in 
combination had little impact on the cell cycle profile of OVCAR-8 cells [Figure 
5.7B].  Cell cycle profile was also examined 5 days after withdrawal of paclitaxel. 
ATG5 knockdown had no impact on the recovery of the DNA profile. BECN1 alone 
and in combination with ATG5 reduced the clearance of polyploid cells (>4N DNA 
content) compared to a scrambled control [Figure 5.7C]. Several replicates of this 
experiment would be required to determine if these differences are significant. These 
data imply that autophagy may be contributing to the recovery of DNA content in 
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Figure 5.7. Recovery of OVCAR-8 cell cycle profile following knockdown of autophagy 
genes. To assess the contribution of autophagy to the recovery of a typical cell cycle profile 
cells received 48 hour paclitaxel treatment (5nM), autophagy genes were knocked down and 
flow cytometry analysis was performed. (A) western blot analysis was used to confirm 
knockdown of (i) BECN1 and (ii) ATG5, 72 hours post transfection. Blots were scanned and 
quantified using the Li-Cor Odyssey Infrared scanner. Bands were normalised to β-actin 
(n=1). Representative histograms of transfected cells following (B) 48 hour treatment and (C) 
5 day recovery in paclitaxel free media (n=1). Cells with ≥ 2N DNA content were gated, 




5.5 Discussion  
In this study, we have shown that ovarian cancer cells can recover their DNA content 
profile following paclitaxel treatment and that CQ can impede this recovery. 
Treatment of ID8-luc2 and OVCAR-8 cells with paclitaxel causes a G2/M arrest and 
the accumulation of polyploid cells (>4N DNA content). Following a 5 and 7 day 
recovery in drug free media, the cells can recover their cell cycle profile and a 
reduction in polyploid cells is evident. Strikingly, the addition of CQ impeded the 
clearance of polyploid cells in ID8-luc2 cells. BECN1 and ATG5 knockdown in 
OVCAR-8 cells resulted in a modest increase in polyploid cells 5 days after 
withdrawal of paclitaxel. Transient knockdown with siRNA is typically lost after 3-5 
days, which may account for the modest increase in polyploid cells we observed. 
Stable knockdown, for example using short hairpin RNA (shRNA), would provide a 
more robust analysis of the impact of autophagy on cell cycle recovery. Additionally, 
one study has reported that autophagic degradation of micronuclei occurred in 
approximately 2-5% of the cancer cell population (Rello-Varona et al., 2012). 
Therefore, it is important to elucidate the full contribution of nucleophagy in OC, and 
these preliminary results suggest further investigation is warranted. Similar to our 
findings, ATG5 knockdown in mouse mammary carcinoma (MMC) cells caused an 
increase in polyploid cells by flow cytometry analysis following adriamycin treatment, 
when compared to their autophagy competent counterparts (Aqbi et al., 2018). 
In this study, paclitaxel treatment in OVCAR-8 cells caused the formation of 
micronuclei, which were tagged with LC3 and LAMP1.  Paclitaxel has previously 
been shown to induce the formation of micronuclei (MN). An interesting theory has 
emerged to explain the link between autophagy and MN elimination. Erenpreisa et al. 
(2012) suggest that following a futile attempt at DNA repair, micronuclei are 
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eliminated via autophagy. This idea was first supported by the discovery of Rad51 
positive MN in fibroblasts (Haaf et al., 1999). MN can remain attached to the nucleus 
via extension of nuclear envelope membranes comprised of heterochromatin layers, 
termed envelope limited chromatin sheets (ELCS) (Erenpreisa et al., 2012). ECLS 
allow the MN to link to new nuclear envelope sites, where their DNA can be repaired, 
and the MN can then be reincorporated into the nucleus. The authors then suggest that 
failure of repair would lead to MN budding from the nucleus and subsequent 
autophagic degradation (Erenpreisa et al., 2012). Thus, autophagic degradation of MN 
serves to minimise aneuploidy arising from DNA damage, improving the overall 
fitness of the cell. While nucleophagy has not been well characterised in tumour cells, 
the evidence to date suggests that DNA damaging agents like cisplatin, used in the 
clinical management of OC, cleave lamins and disrupts the nuclear membrane, thereby 
activating nucleophagy. Li et al. (2019) reported that DNA damage as a result of 
doxorubicin treatment causes accumulation of UBC9 in the nucleus, resulting in 
SUMOylation of lamin A/C. Lamin A/C interacts with the autophagy protein LC3, 
leading to nucleophagy activation and degradation of nuclear components, including 
lamin A/C and leaked nuclear DNA (Li et al., 2019). Another study reported that 
arginine reduced the lamin proteins A/C, thereby causing DNA leakage and autophagy 
mediated degradation of damaged nuclear DNA (Changou et al., 2014).  Analogous 
to our observations, Li et al. (2019) also reported colocalisation of LC3 and LAMP1 
with fragmented DNA material following treatment with doxorubicin. While we have 
shown that LC3 associates with fragmented nuclear material in OVCAR-8 cells, 
further experiments, such as assessing the co-localisation of LC3 with nuclear 
envelope proteins, including lamin A/C and B1, would be required to further support 
a role for autophagy in nuclear degradation (Baron et al., 2017).  
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Here we provide novel evidence to suggest that nucleophagy may play a role in 
maintaining genomic integrity in response to paclitaxel treatment in OC cells. 
However, the full contribution of nucleophagy in treatment response in OC cells 
warrants further investigation with more robust knockdown of autophagy genes. This 
data sheds light on the diverse role of autophagy in response to treatment in OC, 
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6.1 Key findings from thesis work 
Chapter 2 
▪ OC cells exhibit differential drug sensitivities, with the most drug resistant 
cells (ID8-luc2, OVCAR-5 and -8) displaying low levels of caspase-3-
dependent apoptosis and high levels of autophagy. In contrast, the most drug 
sensitive cell lines (OVCAR-3 and -4) display high levels of caspase-3-
dependent apoptosis and low autophagy levels.  
▪ Caspase-3-dependent apoptosis is significantly reduced, and recovery is 
significantly increased in OC cells (OVCAR-3, -4 and -5) following re-
challenge with paclitaxel. This provides a novel insight into a potential 
mechanism of drug resistance in OC cells. 
▪ Expression of autophagy proteins does not correlate with the ability of OC cells 
to undergo autophagy. This finding may be clinically relevant in the selection 
of biomarkers for use with autophagy modulating drugs.   
Chapter 3 
▪ CQ sensitises OC cells with high autophagy levels (ID8-luc2, OVCAR-5 and 
-8) to chemotherapy, but provides no benefit or exerts a protective effect in 
cells with low autophagy levels (OVCAR-3 and -4). 
▪ Lithium can significantly sensitise ID8-luc2, OVCAR-5 and -8 cells to 
treatment, but provides no benefit to OVCAR-3 and -4 cells. Further studies 
are required to elucidate a mechanism. 
▪ Brefeldin A-sensitive autophagy can be present at basal levels and in response 





▪ Knockdown of key autophagy genes can significantly sensitise OC cells to 
paclitaxel treatment, identifying a role for autophagy in paclitaxel resistance. 
▪ Non-canonical autophagy may also contribute to paclitaxel resistance in OC 
cells. 
Chapter 5 
▪ OC cells can recover a pre-treatment DNA profile following recovery after 
paclitaxel treatment, which is impeded by inhibiting autophagy with CQ. 
▪ Fragmented nuclear material induced by paclitaxel treatment colocalises with 
LC3 and LAMP1, suggesting a role for autophagic degradation of nuclear 
material.   
▪ Knockdown of autophagy genes BECN1 and ATG5 marginally impeded the 
recovery of OC cell’s DNA profile following paclitaxel treatment. Further 
research will be required in order to determine the role of autophagy in the 








6.2 General Discussion 
Ovarian cancer is the number one cause of death from gynaecological malignancies. 
The benign nature of disease symptoms leads to a late stage diagnosis in most women, 
resulting in poor survival rates. The standard of care remains cytoreductive surgery 
combined with a taxane/platinum chemotherapy doublet. Carboplatin/paclitaxel is the 
preferred combination, given its lower toxicity profile. The introduction of targeted 
therapies, particularly PARP inhibitors such as Olaparib, have improved progression 
free survival of patients that have failed all prior lines of treatment. Despite this, the 
five year survival rate currently stands at 32.9%. Most women exhibit an excellent 
response to first line chemotherapy, however 80% of women will experience disease 
recurrence. Treatment resistance is the single biggest challenge which has yet to be 
met in the clinical management of OC. Our lack of understanding regarding the 
mechanisms driving chemoresistance was the impetus behind this project.   
We have identified important differences in apoptosis and autophagy induction in 
response to chemotherapy in our panel of OC cell lines, which could be divided into 
two subgroups, as illustrated in Figure 1. Following paclitaxel treatment, OVCAR-3 
and -4 cells displayed high levels of caspase-3 activation while ID8-luc2, OVCAR-5 
and -8 cells induced low levels. None of our cell lines activated caspase-3 in response 
to carboplatin. Significant induction of autophagy was observed in three of our five 
cell lines (ID8-luc2, OVCAR-5 and -8), following treatment with paclitaxel and 
carboplatin.  
Repopulation of OC cells following first line chemotherapy is a recognised, but poorly 
understood phenomenon. To balance therapeutic efficacy with unwanted toxic side 
effects, chemotherapy is administered in six cycles, at three week intervals, consisting 
of a taxane followed by a platinum agent. As a result of these intermittent periods 
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without treatment, and during the time from completion of first line therapy to disease 
relapse, OC cells can repopulate (Telleria, 2013). To mimic the clinical regimens, we 
treated OC cells with paclitaxel and allowed them to recover for 7 days in drug free 
media, before re-challenging with paclitaxel. Importantly, we found caspase-3 levels 
to be significantly reduced and clonogenic recovery significantly increased following 
a single treatment. Although we have not investigated a mechanism for this reduction 
in apoptosis, it provides an important insight into one of the ways OC cells may escape 
chemotherapy treatment. It would also support a rationale for targeting autophagy 
when tumours are no longer apoptosis competent to help prevent disease recurrence. 
As described Chapter 2 section 2.5, autophagy and apoptosis are closely linked. A 
better understanding of the dynamics of autophagy and apoptosis in OC may enable 




















Figure 6.1. Diagram of apoptosis and autophagy induction in OC cells in 
response to treatment. Following paclitaxel treatment, ID8-luc2, OVCAR-5 and -8 
cells induce low levels of apoptosis and high levels of autophagy. In contrast, 




We assessed the effect of autophagy modulators CQ and lithium on the 
chemosensitivity of our cell lines. Interestingly, we found that CQ and lithium could 
significantly sensitise the cells which displayed high levels of autophagy (ID8-luc2, 
OVCAR-5 and -8). Importantly, CQ exerted no effect or a protective effect in 
OVCAR-3 and -4 cells, while lithium treatment also elicited no chemosensitising 
effect in OVCAR-3 cells. Such differences are likely to reflect the inherent 
heterogeneity which exists among patients in the clinic, highlighting the need for the 
development of biomarkers. As we have shown with our panel of cell lines, assessing 
basal expression levels of autophagy proteins does not accurately reflect the 
autophagic capacity of a cell. Markers including LC3, Beclin 1 and Atg family 
members have all been suggested as biomarkers (Bortnik and Gorski, 2017). However, 
in our OC cell lines this would not be predictive of the ability of OC cells to undergo 
autophagy. The development of biomarkers to identify patients who are likely to 
respond to autophagy modulation will be key to the success of any new agents. By 
elucidating the molecular mechanisms, and the contribution of different autophagy 
pathways to response to treatment will aid in the identification of such biomarkers. 
We have identified a brefeldin A-sensitive autophagy pathway in OC cells, at basal 
levels and in response to paclitaxel treatment. Brefeldin A, which blocks protein 
transport from the Golgi, has previously been shown to inhibit non-canonical 
autophagy (including the Atg5/Atg7-independent pathway), but not canonical 
autophagy. We observed a reduction in autophagic vesicle accumulation when cells 
were treated with brefeldin A, suggesting a contribution of Golgi-derived 




In Chapter four, we identified a role for autophagy in the regulation of 
chemosensitivity. Knockdown of key autophagy regulators BECN1 and ATG5 
significantly reduced recovery in ID8-luc2 and OVCAR-8 cells following paclitaxel 
treatment. In addition, we have shown that a non-canonical, brefeldin A-sensitive 
autophagy pathway may also contribute to chemoresistance in OC cells. The reduction 
in paclitaxel induced autophagosome accumulation following brefeldin A treatment in 
Chapter three indicated that this brefeldin A-sensitive pathway may be engaged in 
response to treatment. Increased sensitivity to paclitaxel following knockdown of 
Rab9 indicated that this pathway may be the Atg5/Atg7-independent pathway and may 
play a role in chemoresistance. We postulate that both canonical and non-canonical 
pathways may be active and contribute to resistance. This is in line with previous 
studies which have reported the co-operation of both pathways. One study found that 
the canonical and non-canonical autophagy pathways work together to maintain gut 
homeostasis. In response to lipopolysaccharide (LPS) stimulation, Atg5/Atg7-
independent autophagy is activated and functions alongside canonical autophagy to 
eliminate the pathogenic bacteria shigella (Ra et al., 2016). Similarly, mitochondrial 
degradation in erythrocytes is primarily mediated by non-canonical autophagy, and 
partly via canonical autophagy (Shimizu, 2018). While Atg5/Atg7-independent 
autophagy has been reported to be induced in response to the chemotherapeutic agent 
etoposide, we are the first to propose a role for this pathway in OC chemoresistance. 
Going forward, further experiments are required to elucidate an exact mechanism. 
Rab9, a GTPase which has functions in other pathways, is the only specific marker of 
the Atg5/Atg7-independent pathway identified to date, and its inhibition may be 
eliciting other non-autophagy related effects. To confirm the presence of the 
Atg5/Atg7-independent pathway, additional experiments in cells deficient in Atg5/7 
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are also necessary. This novel and exciting data characterises autophagy as a regulator 
of chemosensitivity in OC cells. We propose that the introduction of autophagy 
inhibitors into future treatment regimens will improve the responses of OC tumours 
that induce autophagy following treatment. 
Preliminary data from Chapter five suggests the possibility that a selective form of 
autophagy, termed nucleophagy, is involved in eliminating nuclear material following 
paclitaxel treatment. We have demonstrated for the first time, that OC cells can recover 
their original DNA content following paclitaxel treatment, and that autophagy is likely 
to be important for this recovery. The addition of CQ to ID8-luc2 cells, and siRNA 
knockdown of BECN1 and ATG5 in OVCAR-8 cells, both impeded the clearance of 
polyploid cells. We have also found that fragmented nuclear material induced by 
paclitaxel associates with LC3 and LAMP1, further suggesting that autophagy may be 
involved in the elimination of nuclear material in OC cells. Like macroautophagy, 
nucleophagy induction can be described as a ‘double edged sword’. In certain models, 
nucleophagy has been shown to induce cell death by degrading whole chromosomes 
in mitotic cells under oxidative stress (Sit et al., 1996). In contrast, nucleophagy has 
also been reported to limit aneuploidy as a result of genotoxic insult. Aneuploidy 
exerts a toll on the cell’s overall fitness, demanding higher metabolic requirements for 
proliferation. Thus, it is plausible to assume that tumour cells will endeavour to 
minimise such stress to promote cell survival and proliferation. To counteract the 
protective role of nucleophagy, chemotherapeutics which induce this process, such as 
cisplatin, could be combined with specific inhibitors of nucleophagy. In order to 
effectively target this pathway, it will be important to further investigate the molecular 
regulation of nucleophagy in OC cells. Interestingly, in a mouse model of 
neurodegeneration, a stall in canonical autophagy lead to the induction of non-
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canonical autophagy, postulated to be Atg5/Atg7-independent autophagy, which 
mediated lamin degradation (Baron et al., 2017). This data further supports the 
rationale that targeting more than one autophagy pathway is likely to be required for 
more effective treatment in OC patients.    
Inhibition of autophagy may also provide another important benefit in OC. Ovarian 
cancer stem-like cells, which can be isolated from cell lines, patient derived tumours 
and ascites, are resistant to chemotherapy and can repopulate tumours in animal 
models, making them a significant target in overcoming disease recurrence (Zhang et 
al., 2008) (Szotek et al., 2006). Autophagy has emerged as a key pathway regulating 
the self-renewal capabilities and chemoresistance of these cells. Ovarian cancer stem 
cells, enriched from SKOV3 cells, were reported to have enhanced autophagic flux 
compared to the general population of OC cells. Impairment of autophagy, either by 
CQ or knockdown of ATG5, significantly enhanced the sensitivity of the cancer stem 
cells to paclitaxel and impeded the stem cells sphere forming ability (Peng et al., 
2017). Another study reported autophagy as essential for the self-renewal of ovarian 
cancer spheroid cells, via forming a positive feedback loop via NRF2 to activate an 
antioxidant response. Treatment with bafilomycin A1, impaired the OC spheroid self-
renewal and inhibited tumour formation in vivo (Wang et al., 2018). As such, targeting 
autophagy could negate the inherent chemoresistance of CSC’s.  
PARP inhibitors, such as Olaparib and Niraparib, are currently used as maintenance 
therapies for OC patients. While originally thought to be beneficial only in BRCA 
mutated patients, recent studies have supported their use in women without BRCA 
mutation but with mutations in other DNA repair pathways. In women who have failed 
all prior lines of treatment, PARP inhibitors can significantly improve progression free 
survival. However, as with other therapies, resistance to PARP inhibitors is inevitable. 
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An exciting study in published in 2019 has implicated a role for autophagy in 
resistance to PARP inhibitors in pre-clinical models of ovarian cancer. The group 
assessed the impact on autophagy of four PARP inhibitors, olaparib, niraparib, 
rucaparib and talazoparib in 8 ovarian cancer cell lines. The PARP inhibitors increased 
autophagy in each of the cell lines. The addition of CQ or targeted siRNA against 
ATG5 and ATG7 significantly enhanced the efficacy of the PARP inhibitors, 
confirming a role for autophagy in resistance to PARP inhibition (Santiago-O;Farrill 
et al., 2019). Mechanistically, Olaparib decreases PARP activity, leading to an 
accumulation of DNA damage and γ-H2AX. Olaparib treatment also caused an 
increase in ROS accumulation and phosphorylation of ATM, while decreasing AKT 
and mTOR phosphorylation. Additionally, an increase in PTEN, a negative regulator 
of Akt, was also observed following Olaparib treatment. Given that PTEN inhibition 
decreases LC3 conversion, the authors suggest that PTEN may be an important 
regulator of olaparib-induced autophagy in OC cells. A similar study reported that the 
PARP inhibitor talazoparib activates autophagy in patient derived paediatric chronic 
myeloid leukaemia (CML) cells (Liu et al., 2019). Knockdown of ATG5 significantly 
enhanced the efficacy of talazoparib, further highlighting a role for autophagy in 
PARP inhibitor resistance. These results highlight another exciting benefit of 
autophagy inhibition to improve OC patient outcomes.  
Autophagy modulation in the cancer setting has been trialled over the last number of 
years, via the use of chloroquine and its derivative hydroxychloroquine (HCQ), the 
only FDA approved autophagy modulators. The role of autophagy in cancer is highly 
context dependent, with trials ongoing which both inhibit and attenuate autophagy. 
Based on the literature, it appears that drug induced autophagy in OC is protective, 
meaning that inhibiting autophagy would be beneficial.  Currently, one clinical trial 
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involving autophagy modulation for OC is active (NCT03081702). If the cell line data 
is representative, it is possible that the addition of CQ would limit the efficacy of 
treatment and might only be beneficial in a limited number of patients. To date, there 
are no targeted autophagy inhibitors available. Additionally, one study reported 
inconsistent autophagy modulation by CQ, as determined by measuring LC3-II levels 
in peripheral lymphocytes (Wolpin et al., 2014). As a result, more effective and less 
toxic CQ derivatives are also being tested, such as Lys05, a bisaminoquinoline CQ 
derivative. Lys05 more effectively accumulates within lysosomes and is a more potent 
inhibitor of autophagy. Lys05 administration in xenograft models of colon cancer and 
melanoma resulted in sustained autophagy inhibition using much lower doses than 
required with HCQ (Amaravadi and Winkler, 2012).  
CQ and HCQ are the only autophagy modulators currently approved for clinical use. 
There is a clear need for the introduction of novel autophagy modulators which may 
be more effective and less toxic. Consequently, we have evaluated lithium. We have 
shown the efficacy of lithium as a chemosensitising agent in three of our cell lines 
(ID8-luc2, OVCAR-5 and -8). What remains to be elucidated are lithium’s effects on 
autophagy in OC and how this chemosensitises the cells. Given that patients exhibit 
excellent initial responses to chemotherapy, resistance is likely to be acquired over 
multiple cycles. It could be envisioned that lithium could be administered concurrently 
with chemotherapy and during the three week intervals between chemotherapy cycles. 
Bi-polar patients receive lithium treatment for many years without adverse side 
effects, thus following the completion of treatment, OC patients may remain on low 
dose lithium treatment as a maintenance therapy (Berghöfer et al., 2013). Multiple 
classes of chemotherapeutic drugs, including platinum agents and taxanes, count 
peripheral neuropathy as the main dose limiting toxicity. Taxanes such as paclitaxel, 
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have previously been shown to bind to neuronal calcium sensor 1 (NCS1) causing 
aberrant calcium signalling leading to neuropathy. Lithium has been shown to interfere 
with the interaction between paclitaxel, NCS1 and the inositol 1,4,5-triphosphate 
receptor (Mo et al., 2012). A small retrospective study revealed that patients being 
treated with lithium while receiving chemotherapy had a reduced risk of developing 
chemotherapy induced peripheral neuropathy (CIPN) (Wadia et al., 2017). Thus, the 
concurrent administration of lithium with chemotherapy could be used to greatly 
improve OC patient’s quality of life whilst also tackling chemoresistance.  
Although autophagy inhibitory drugs such as CQ are routinely used in malaria 
patients, chronic autophagy inhibition should be performed with caution, given the 
important role of autophagy in maintaining normal cell physiology. Lysosomal 
destruction by HCQ may interfere with other important functions such as cell 
signalling, secretion and metabolism. CQ has also been reported to influence the 
tumour microenvironment. While CQ has been shown to promote anti-tumour 
immunity, via polarising macrophages to an anti-tumour M1 phenotype, it has also 
been shown to have immune supressing functions, such as preventing the release of 
HGMB1 and inflammatory cytokines (Chen et al., 2018) (M. Yang et al., 2013) (van 
den Borne et al., 1997). The inhibition of nucleophagy, combined with the off target 
DNA damaging effects of chemotherapeutics, could also lead to unwanted death of 
non-cancerous cells. Thus, understanding the full contribution of autophagy pathways 
to normal and cancer cell biology, along with elucidating the molecular regulators, 
should provide an improved response with reduced side effects.  
In the future, the development of specific autophagy inhibitors for clinical use is 
needed. Several autophagy inhibitors are being tested in the laboratory but have yet to 
be translated for clinical use. Start-up companies have been established with the 
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specific aim of identifying and developing targeted autophagy inhibitors. Current 
efforts have focused on VPS34 inhibition, to inhibit autophagosome biogenesis. 
Unpublished data from one company found that in addition to its autophagy effects, 
VPS34 could boost inflammation in the tumour microenvironment (Dolgin, 2019). 
The protein kinase ULK1 is also being developed as a therapeutic target. Verteporfin 
is another autophagy inhibitor which may be useful. Verteporfin is reported to interfere 
with phagophore expansion and cargo sequestration preventing the formation of 
autophagosomes (Donohue et al., 2011). Recently, verteporfin has been shown to 
inhibit OC cell proliferation, and significantly reduce tumour growth in an OVCAR-
8 xenograft model, although the effects were not attributed to autophagy inhibition 
(Feng et al., 2016). Another important question which needs to be addressed is when 
to administer autophagy inhibitors in the clinic. Hypothetically, autophagy inhibitors 
could be implemented at several different stages, as described in Figure 2. In addition, 
a given drug should have an accompanying biomarker to aid in the selection of patients 
who will benefit from the treatment. The development of such biomarkers will be 




























Figure 6.2. Timeline illustrating the potential implementation of autophagy 
inhibitors in the clinic. 1. As with current clinical trials using chloroquine, autophagy 
inhibitors may be administered concurrently with chemotherapy to enhance their efficacy. 
2. Ovarian cancer patients receive chemotherapy in cycles, with treatment free intervals 
in-between. Autophagy inhibitors may be administered during these treatment free 
intervals to prevent cancer cell recovery. 3. Alternatively, inhibitors could be administered 
after disease relapse to re-sensitise ovarian cancer cells to second line treatment. However, 
the successful implementation of autophagy inhibitors will depend on the identification of 
biomarkers that can identify patients who will respond. Our data suggests that autophagy 
modulators may only be beneficial to patient tumours that induce autophagy in response 
to chemotherapy.  
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In conclusion, this research has identified a novel insight into one of the ways OC cells 
may become resistant to treatment, with evidence of reduced apoptosis competency 
and enhanced clonogenic recovery in OC cells following re-challenge with paclitaxel. 
We have also highlighted the significant chemosensitising ability of the autophagy 
modulators CQ and lithium in three of our cell lines with high autophagic flux. 
Importantly, we have demonstrated a role for canonical and non-canonical autophagy 
in paclitaxel resistance. Moreover, we have shown, for the first time, the ability of OC 
cells to recover their DNA content following treatment and highlighted a potential role 
for nucleophagy in this recovery. This thesis has shed light on the diverse roles played 
by autophagy in response to chemotherapy in OC cells, making it an exciting 
therapeutic target. It is hoped that autophagy inhibitors may be developed and 
incorporated into clinical regimens to prevent disease recurrence, to ultimately 
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Appendix 2: National Cancer 
Control Programme GP Ovarian 










2. National Cancer Control Programme (NCCP) Ovarian cancer referral 
guidelines 
The benign nature of ovarian cancer symptoms makes it extremely difficult for general 
practitioners (GPs) to accurately refer women for further investigation. The NCCP 
ovarian cancer referral guideline was developed in collaboration with the Irish college 
of general practitioners and a range of clinical speciality groups to facilitate the earlier 
detection of ovarian cancer. The guide highlights worrisome symptoms and provides 

































































3. Cell Line Information 
Established human ovarian cancer cell lines OVCAR-3, -4, -5 and -8 were obtained 
from the NCI-Frederick Cancer DCTC Tumor/Cell Line Repository (United States of 
America). Murine ID8 cells were obtained from the Mayo Clinic (United States of 
America), and were transfected in house with luciferase, to generate ID8-luc2 cells. 
Cell culture and culturing conditions were performed as recommended by the cell line 
repository. 
Each cell line was passaged for no longer than six weeks. It is good practice to test for 
mycoplasma every six months. Mycoplasma contamination is currently assessed in 














3.1 ID8-luc2 cell line 
Cell line: ID8-luc2   
Species: Mouse 
Characteristics: ID8 are a mouse surface ovarian 
epithelium (MOSE) spontaneously 
transformed cell line physiologically 
and biologically resembling human 
epithelial ovarian cancer.  
Growth medium: DMEM + 10% FBS+ 2 mM L-
Glutamine   
Mode of growth: Adherent 
Method of harvest: Trypsin / EDTA 
 
Source: Dr. K. Roby 
Reference: Roby K.F., Taylor C.C., Sweetwood 
J.P., Cheng Y., Pace J.L., Tawfik O., 
Persons D.L., Smith P.G., Terranova 
P.F. Development of a syngeneic mouse 
model for events related to ovarian 





3.2 OVCAR-3 cell line 
Designation: OVCAR-3 
Species: Human 
Histologic type:  Adenocarcinoma 
Growth medium: RPMI 1640 + 10% FBS+ 2 mM L-
Glutamine   
Mode of growth: Adherent 




P+1 5 Days T75 P+1 3 Days T25 
P+2 1:2, 5, 10 P+3 1:5, 10, 20 
Assay phase split ratios/ 
Flask Inoculation densities 
1:5, 10, 20 
1:10, 20 
 
Approx. recovery/adaptation time & 
# passages: 
 
12 Days - 2 Weeks, 3-4 Passages 
 
Source: Dr. T. Hamilton 
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Reference: Hamilton, T., Young, R., McKoy, W., 
Grotzinger, K., Green, J., Chu, E., 
Whang-Peng, J., Rogan, A., Green, W., 
Ozols, R; Characterization of a Human 
Ovarian Carcinoma Cell line 
(NIH:OVCAR-3) with Androgen and 










Histologic type:  Adenocarcinoma 
Growth medium: RPMI 1640 + 10% FBS + 2 mM L-
Glutamine   
Mode of growth: Adherent 
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Method of harvest: Trypsin / EDTA - Trypsin 5-10 Minutes 
Recovery phase 
Split ratios 
P+1 4-6 Days T75 P+1 2-3 Days T25 
P+2 1:2, 5, 10 P+3 1:5, 10, 20 
Assay phase split ratios/ 
Flask Inoculation densities 
1:5, 10, 20 
1:5, 10 to 1:10, 20 
Approx. recovery/adaptation time & 
# passages: 
 
2-3 Weeks, 3-4 Passages 
Source: Dr. T. Hamilton 
Reference: Hamilton, T., Young, R., Ozols, R.; 
Experimental Model Systems of Ovarian 
Cancer: Applications to the Design and 
Evaluation of New treatment 










3.4 OVCAR-5 cell line 
 
Designation: OVCAR-5 
Species: Human  
Histologic type:  Carcinoma 
Growth medium: RPMI 1640 + 10% FBS + 2 mM L-
Glutamine   
Mode of growth: Adherent 
Method of harvest: Trypsin/EDTA 
Recovery phase 
Split ratios 
P+1 5 Days T75 P+1 3 Days T25 
P+2 1:2, 5, 10 P+3 1:5, 10, 20 
Assay phase split ratios/ 
Flask Inoculation densities 
1:10, 20, 40 
1:10,20 to 1:20, 40 Later 
Approx. recovery/adaptation time & 
# passages: 
 
2 Weeks, 3–4 Passages 
Source: Dr. T. Hamilton 
Reference: Hamilton, T., Young, R., Ozols, R.; 
Experimental Model Systems of 
Ovarian Cancer: Applications to the 
Design and Evaluation of New 
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Histologic type:  Adenocarcinoma 
Growth medium: RPMI 1640 + 10% FBS + 2 mM L-
Glutamine   
Mode of growth: Adherent 





P+1 3-4 Days T75, P+1 1-2 Days T25 
P+2 1:2, 5, 10 P+3 1:5, 10, 20 
Assay phase split ratios/ 1:20, 40, 80 
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Flask Inoculation densities: 1:40, 80 
Approx. recovery/adaptation time & 
# passages: 
 
2 Weeks, 3-4 Passages 
Source: Dr. T. Hamilton 
Reference: Hamilton, T., Young, R., Ozols, R.; 
Experimental Model Systems of 
Ovarian Cancer: Applications to the 
Design and Evaluation of New 


























4.1 Manuscripts currently in preparation for submission: 
Manuscript 1: Ovarian cancer cells that recover from treatment with a 
chemotherapeutic agent show decreased levels of apoptosis when re-challenged with 
the same agent.  
Manuscript 2: Inhibition of autophagy can sensitise apoptosis incompetent cells 
ovarian cancer cells to chemotherapy: Caution with inhibitors is warranted for 
apoptosis competent cancers.  
Manuscript 3: Autophagy is associated with the recovery of DNA content following 
paclitaxel treatment.  
 
4.2 Poster and Oral presentations 
Irish Association for Cancer Research (IACR) (2017, 2018) – poster 
presentations. ‘Investigating a role for autophagy in ovarian cancer chemoresistance’, 
Jennifer Quinn, Tracey R. O’Donovan, Sharon L. McKenna. 
New Horizons conference (2017, 2018) – poster presentations. ‘Investigating a role 
for autophagy in ovarian cancer chemoresistance’, Jennifer Quinn, Tracey R. 
O’Donovan, Sharon L. McKenna. 
Young cancer researchers networking (YCRN) (June 2018) – oral presentation. 
‘Investigating a role for autophagy in ovarian cancer chemoresistance’. Jennifer 
Quinn, Tracey R. O’Donovan, Sharon L. McKenna. 
Breaking through conference (September 2019) – poster presentation. ‘Induction 
of autophagy following treatment with chemotherapeutic agents, promotes recovery 
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and chemoresistance in ovarian cancer cells’, Jennifer Quinn, Tracey R. O’Donovan, 
Sharon L. McKenna. 
Irish Association for Cancer Research (IACR) (2020) – Oral presentation. 
‘Induction of autophagy following treatment with chemotherapeutic agents promotes 
recovery and chemoresistance in ovarian cancer cells’, Jennifer Quinn, Tracey R. 
O’Donovan, Sharon L. McKenna. (Awarded a best oral presentation prize). 
 
 
 
